Submit Data |  Help |  Video Tutorials |  News |  Publications |  FTP Download |  REST API |  Citing RGD |  Contact   

CHEBI ONTOLOGY - ANNOTATIONS

The Chemical Entities of Biological Interest (ChEBI) ontology is downloaded weekly from EMBL-EBI at http://www.ebi.ac.uk/chebi/. The data is made available under the Creative Commons License (CC BY 3.0, http://creativecommons.org/licenses/by/3.0/). For more information see: Degtyarenko et al. (2008) ChEBI: a database and ontology for chemical entities of biological interest. Nucleic Acids Res. 36, D344–D350.

Term:boron group element atom
go back to main search page
Accession:CHEBI:33317 term browser browse the term
Synonyms:exact_synonym: group 13 elements
 related_synonym: Element der Borgruppe;   boron group element;   boron group elements;   group III elements


show annotations for term's descendants           Sort by:
 
2-aminoethoxydiphenylborane term browser
Symbol Object Name Qualifiers Evidence Notes Source PubMed Reference(s) RGD Reference(s) Position
G Bax BCL2 associated X, apoptosis regulator multiple interactions EXP 2-aminoethoxydiphenylborane inhibits the reaction [cadmium acetate results in increased expression of BAX protein] CTD PMID:29883672 NCBI chr 1:101,451,801...101,457,207
Ensembl chr 1:101,451,802...101,457,207
JBrowse link
G Bcl2 BCL2, apoptosis regulator multiple interactions EXP 2-aminoethoxydiphenylborane inhibits the reaction [cadmium acetate results in decreased expression of BCL2 protein] CTD PMID:29883672 NCBI chr13:26,605,426...26,769,374
Ensembl chr13:26,605,426...26,769,374
JBrowse link
G Casp12 caspase 12 multiple interactions EXP 2-aminoethoxydiphenylborane inhibits the reaction [cadmium acetate results in increased cleavage of CASP12 protein] CTD PMID:29883672 NCBI chr 8:2,658,892...2,686,160
Ensembl chr 8:2,659,865...2,686,160
JBrowse link
G Casp3 caspase 3 multiple interactions EXP 2-aminoethoxydiphenylborane inhibits the reaction [cadmium acetate results in increased cleavage of CASP3 protein] CTD PMID:29883672 NCBI chr16:48,845,011...48,863,249
Ensembl chr16:48,845,012...48,863,204
JBrowse link
G Cd28 Cd28 molecule multiple interactions ISO 2-aminoethoxydiphenylborane inhibits the reaction [CD28 protein results in increased abundance of Calcium]; 2-aminoethoxydiphenylborane inhibits the reaction [CD28 protein results in increased abundance of Nitric Oxide]; 2-aminoethoxydiphenylborane inhibits the reaction [CD28 protein results in increased abundance of Reactive Oxygen Species] CTD PMID:14607919 NCBI chr 9:67,546,408...67,573,858
Ensembl chr 9:67,546,408...67,571,871
JBrowse link
G Grm1 glutamate metabotropic receptor 1 multiple interactions EXP 2-aminoethoxydiphenylborane inhibits the reaction [3,5-dihydroxyphenylglycine results in increased activity of GRM1 protein] CTD PMID:14622174 NCBI chr 1:4,753,141...5,165,859
Ensembl chr 1:4,753,144...5,165,859
JBrowse link
4,4-difluoro-4-bora-3a,4a-diaza-s-indacene term browser
Symbol Object Name Qualifiers Evidence Notes Source PubMed Reference(s) RGD Reference(s) Position
G Abcb11 ATP binding cassette subfamily B member 11 affects transport ISO ABCB11 protein affects the transport of 4,4-difluoro-4-bora-3a,4a-diaza-s-indacene CTD PMID:12739759 NCBI chr 3:55,480,024...55,587,946
Ensembl chr 3:55,480,024...55,587,946
JBrowse link
aluminium atom term browser
Symbol Object Name Qualifiers Evidence Notes Source PubMed Reference(s) RGD Reference(s) Position
G Ace angiotensin I converting enzyme decreases activity ISO Aluminum results in decreased activity of ACE protein CTD PMID:12008977 NCBI chr10:94,170,766...94,213,831
Ensembl chr10:94,170,766...94,187,822
JBrowse link
G Ache acetylcholinesterase multiple interactions
decreases activity
EXP [Cadmium co-treated with Aluminum co-treated with Fluorides] results in increased activity of ACHE protein; [Cadmium co-treated with Aluminum co-treated with Fluorides] results in increased expression of ACHE mRNA; Aluminum promotes the reaction [Lead results in decreased activity of ACHE protein]; Berberine inhibits the reaction [[Cadmium co-treated with Aluminum co-treated with Fluorides] results in increased activity of ACHE protein]; Berberine inhibits the reaction [[Cadmium co-treated with Aluminum co-treated with Fluorides] results in increased expression of ACHE mRNA]; Copper inhibits the reaction [Aluminum results in decreased activity of ACHE protein]; Plant Extracts inhibits the reaction [Aluminum results in decreased activity of ACHE protein] CTD PMID:15266904, PMID:23354609, PMID:24486960, PMID:29170048 NCBI chr12:22,472,358...22,477,052
Ensembl chr12:22,472,358...22,478,753
JBrowse link
G Acly ATP citrate lyase multiple interactions ISO Aluminum results in increased expression of and results in increased activity of ACLY protein CTD PMID:17762189 NCBI chr10:88,392,248...88,442,845
Ensembl chr10:88,392,248...88,442,845
JBrowse link
G Aco1 aconitase 1 decreases activity EXP Aluminum results in decreased activity of ACO1 protein CTD PMID:10806405 NCBI chr 5:56,425,076...56,481,218
Ensembl chr 5:56,425,024...56,481,218
JBrowse link
G Aco2 aconitase 2 decreases activity
multiple interactions
ISO
EXP
Aluminum results in decreased activity of ACO2 protein
Aluminum promotes the reaction [Nitroprusside results in decreased activity of ACO2 protein]
Aluminum results in decreased expression of and results in decreased activity of ACO2 protein
CTD PMID:12470706, PMID:16906525, PMID:19010380 NCBI chr 7:123,102,493...123,145,608
Ensembl chr 7:123,102,468...123,145,635
JBrowse link
G Alb albumin affects binding ISO ALB protein binds to Aluminum CTD PMID:14507469 NCBI chr14:19,176,275...19,191,793
Ensembl chr14:19,176,277...19,191,863
JBrowse link
G Alox5 arachidonate 5-lipoxygenase multiple interactions
increases expression
EXP caffeic acid inhibits the reaction [Aluminum results in increased expression of ALOX5 mRNA]; caffeic acid inhibits the reaction [Aluminum results in increased expression of ALOX5 protein]
Aluminum results in increased expression of ALOX5 mRNA; Aluminum results in increased expression of ALOX5 protein
CTD PMID:27368151 NCBI chr 4:148,398,004...148,446,308
Ensembl chr 4:148,398,892...148,446,303
JBrowse link
G Apob apolipoprotein B increases expression ISO Aluminum results in increased expression of APOB protein CTD PMID:17762189 NCBI chr 6:33,176,826...33,216,381
Ensembl chr 6:33,176,778...33,224,997
JBrowse link
G App amyloid beta precursor protein affects binding
multiple interactions
increases expression
increases cleavage
ISO
EXP
APP protein binds to Aluminum
[Cadmium co-treated with Aluminum co-treated with Fluorides] results in increased expression of APP mRNA; Berberine inhibits the reaction [[Cadmium co-treated with Aluminum co-treated with Fluorides] results in increased expression of APP mRNA]
[APP protein modified form binds to Aluminum] which results in increased expression of RCVRN mRNA
Aluminum results in increased expression of APP mRNA
APP protein promotes the reaction [Aluminum results in decreased activity of CHAT protein]; meloxicam inhibits the reaction [Aluminum results in increased expression of APP protein]; Vitamin E inhibits the reaction [Aluminum results in increased cleavage of APP protein]
CTD PMID:12039845, PMID:16308480, PMID:16724269, PMID:16928369, PMID:16942756, PMID:21298039, PMID:29170048 NCBI chr11:24,425,013...24,641,872
Ensembl chr11:24,425,005...24,641,858
JBrowse link
G Atxn3 ataxin 3 affects folding
multiple interactions
ISO Aluminum affects the folding of ATXN3 protein polymorphism
Aluminum promotes the reaction [ATXN3 protein polymorphism binds to ATXN3 protein polymorphism]
CTD PMID:17300980 NCBI chr 6:125,817,420...125,853,461
Ensembl chr 6:125,819,640...125,853,461
JBrowse link
G Bax BCL2 associated X, apoptosis regulator affects response to substance
multiple interactions
EXP
ISO
BAX protein affects the susceptibility to Aluminum
[aluminum chlorhydrate results in increased abundance of Aluminum] which affects the expression of BAX protein
CTD PMID:20385067, PMID:31945389 NCBI chr 1:101,451,801...101,457,207
Ensembl chr 1:101,451,802...101,457,207
JBrowse link
G Bbox1 gamma-butyrobetaine hydroxylase 1 multiple interactions
decreases expression
ISO Aluminum inhibits the reaction [BBOX1 protein results in increased chemical synthesis of Carnitine]; Ketoglutaric Acids inhibits the reaction [Aluminum inhibits the reaction [BBOX1 protein results in increased chemical synthesis of Carnitine]]
Aluminum results in decreased expression of BBOX1 protein
CTD PMID:21439360 NCBI chr 3:101,425,684...101,474,848
Ensembl chr 3:101,427,055...101,474,890
JBrowse link
G Bcl2 BCL2, apoptosis regulator multiple interactions ISO [aluminum chlorhydrate results in increased abundance of Aluminum] which results in decreased expression of BCL2 protein; Fulvestrant inhibits the reaction [[aluminum chlorhydrate results in increased abundance of Aluminum] which results in decreased expression of BCL2 protein] CTD PMID:31945389 NCBI chr13:26,605,426...26,769,374
Ensembl chr13:26,605,426...26,769,374
JBrowse link
G Bcl2l1 Bcl2-like 1 multiple interactions ISO [aluminum chlorhydrate results in increased abundance of Aluminum] which results in decreased expression of BCL2L1 protein CTD PMID:31945389 NCBI chr 3:148,259,594...148,314,191
Ensembl chr 3:148,259,596...148,313,810
JBrowse link
G Bglap bone gamma-carboxyglutamate protein multiple interactions
decreases secretion
EXP Aluminum inhibits the reaction [Calcitriol results in increased secretion of BGLAP protein]; Calcitriol inhibits the reaction [Aluminum results in decreased secretion of BGLAP protein] CTD PMID:9626627 NCBI chr 2:187,741,770...187,748,445
Ensembl chr 2:187,741,770...187,742,747
JBrowse link
G Casp12 caspase 12 multiple interactions ISO [aluminum chloride results in increased abundance of Aluminum] which results in increased expression of CASP12 mRNA CTD PMID:29635646 NCBI chr 8:2,658,892...2,686,160
Ensembl chr 8:2,659,865...2,686,160
JBrowse link
G Casp3 caspase 3 increases expression ISO Aluminum results in increased expression of CASP3 CTD PMID:21972528 NCBI chr16:48,845,011...48,863,249
Ensembl chr16:48,845,012...48,863,204
JBrowse link
G Casp9 caspase 9 multiple interactions ISO [aluminum chlorhydrate results in increased abundance of Aluminum] which results in decreased expression of CASP9 protein; Fulvestrant inhibits the reaction [[aluminum chlorhydrate results in increased abundance of Aluminum] which results in decreased expression of CASP9 protein] CTD PMID:31945389 NCBI chr 5:160,356,211...160,373,774
Ensembl chr 5:160,355,833...160,373,778
JBrowse link
G Casr calcium-sensing receptor multiple interactions EXP [Aluminum binds to and results in increased activity of CASR protein] which results in increased abundance of Calcium; [Aluminum binds to and results in increased activity of CASR protein] which results in increased abundance of Inositol Phosphates; Aluminum binds to and results in increased activity of CASR protein CTD PMID:10231437 NCBI chr11:67,188,204...67,262,261
Ensembl chr11:67,188,630...67,258,771
JBrowse link
G Cat catalase decreases activity
multiple interactions
ISO
EXP
Aluminum results in decreased activity of CAT protein
CAT protein results in decreased susceptibility to [Tyramine co-treated with Aluminum]; Plant Extracts inhibits the reaction [Aluminum results in decreased activity of CAT protein]
Vitamin E inhibits the reaction [Aluminum results in decreased activity of CAT protein]
CTD PMID:15526171, PMID:17709913, PMID:24486960 NCBI chr 3:93,379,872...93,412,058
Ensembl chr 3:93,379,874...93,412,058
JBrowse link
G Cdh1 cadherin 1 multiple interactions ISO 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide inhibits the reaction [[Aluminum Chloride results in increased abundance of Aluminum] which results in decreased expression of CDH1 protein]; [Aluminum Chloride results in increased abundance of Aluminum] which results in decreased expression of CDH1 mRNA; [Aluminum Chloride results in increased abundance of Aluminum] which results in decreased expression of CDH1 protein CTD PMID:32437896 NCBI chr19:38,768,467...38,838,395
Ensembl chr19:38,768,467...38,838,395
JBrowse link
G Chat choline O-acetyltransferase decreases expression
decreases activity
multiple interactions
ISO Aluminum results in decreased expression of CHAT protein
Aluminum results in decreased activity of CHAT protein
APP protein promotes the reaction [Aluminum results in decreased activity of CHAT protein]; meloxicam inhibits the reaction [Aluminum results in decreased expression of CHAT protein]
CTD PMID:16724269, PMID:16928369 NCBI chr16:8,576,858...8,686,131
Ensembl chr16:8,577,840...8,686,131
JBrowse link
G Crp C-reactive protein multiple interactions ISO [Zinc co-treated with Aluminum] results in increased expression of CRP protein; [Zinc co-treated with Copper co-treated with Aluminum] results in increased expression of CRP protein CTD PMID:27816692 NCBI chr13:91,080,448...91,081,358
Ensembl chr13:91,054,974...91,093,713
JBrowse link
G Daxx death-domain associated protein increases expression ISO Aluminum results in increased expression of DAXX mRNA CTD PMID:16308480 NCBI chr20:5,480,103...5,485,962
Ensembl chr20:5,480,103...5,485,926
JBrowse link
G Drd1 dopamine receptor D1 multiple interactions EXP Aluminum inhibits the reaction [SCH 23390 binds to DRD1 protein] CTD PMID:9109525 NCBI chr17:11,099,736...11,104,352
Ensembl chr17:11,101,306...11,103,541
JBrowse link
G Drd2 dopamine receptor D2 multiple interactions EXP Aluminum inhibits the reaction [3-N-methylspiperone binds to DRD2 protein] CTD PMID:9109525 NCBI chr 8:53,678,777...53,743,643
Ensembl chr 8:53,678,777...53,743,642
JBrowse link
G Eno2 enolase 2 decreases activity ISO Aluminum results in decreased activity of ENO2 protein CTD PMID:11860913 NCBI chr 4:157,285,192...157,294,090
Ensembl chr 4:157,285,179...157,294,047
JBrowse link
G Epor erythropoietin receptor affects expression ISO Aluminum affects the expression of EPOR protein CTD PMID:15777837 NCBI chr 8:22,969,737...22,974,468
Ensembl chr 8:22,969,745...22,974,321
JBrowse link
G Esr1 estrogen receptor 1 multiple interactions ISO [aluminum chlorhydrate results in increased abundance of Aluminum] inhibits the reaction [Estradiol results in increased phosphorylation of ESR1 protein]; [aluminum chlorhydrate results in increased abundance of Aluminum] inhibits the reaction [NRG1 protein results in increased phosphorylation of ESR1 protein]; [aluminum chlorhydrate results in increased abundance of Aluminum] which results in increased expression of ESR1 protein; [Estradiol co-treated with [aluminum chlorhydrate results in increased abundance of Aluminum]] results in increased expression of ESR1 protein CTD PMID:31945389 NCBI chr 1:41,192,029...41,594,799
Ensembl chr 1:41,192,824...41,594,796
JBrowse link
G Esr2 estrogen receptor 2 multiple interactions ISO [[aluminum chlorhydrate results in increased abundance of Aluminum] co-treated with [Tretinoin co-treated with Estradiol]] affects the localization of ESR2 protein; [[aluminum chlorhydrate results in increased abundance of Aluminum] which co-treated with Tretinoin] results in decreased expression of and affects the localization of ESR2 protein; [aluminum chlorhydrate results in increased abundance of Aluminum] which results in decreased expression of and affects the localization of ESR2 protein; [Estradiol co-treated with [aluminum chlorhydrate results in increased abundance of Aluminum]] results in decreased expression of ESR2 protein CTD PMID:31945389 NCBI chr 6:99,163,953...99,214,711
Ensembl chr 6:99,164,357...99,214,251
JBrowse link
G F8 coagulation factor VIII affects folding
multiple interactions
ISO Aluminum affects the folding of F8 protein
[Aluminum promotes the reaction [F8 protein binds to F8 protein]] which results in decreased activity of F8 protein
CTD PMID:15349964 NCBI chr18:367,862...399,242
Ensembl chr18:367,862...399,242
JBrowse link
G Fh fumarate hydratase multiple interactions ISO Aluminum results in decreased expression of and results in decreased activity of FH protein CTD PMID:16906525 NCBI chr13:93,651,486...93,677,371
Ensembl chr13:93,651,484...93,677,377
JBrowse link
G Fos Fos proto-oncogene, AP-1 transcription factor subunit multiple interactions ISO [Aluminum co-treated with Copper] inhibits the reaction [lipopolysaccharide, Escherichia coli O111 B4 affects the localization of FOS protein] CTD PMID:23690655 NCBI chr 6:109,300,433...109,303,299
Ensembl chr 6:109,300,433...109,303,299
JBrowse link
G G6pd glucose-6-phosphate dehydrogenase increases activity ISO
EXP
Aluminum results in increased activity of G6PD protein CTD PMID:16572710, PMID:16979867 NCBI chr  X:156,274,800...156,293,935
Ensembl chr  X:156,274,800...156,293,926
JBrowse link
G Gfap glial fibrillary acidic protein increases expression
multiple interactions
EXP
ISO
Aluminum results in increased expression of GFAP protein
[Aluminum Chloride results in increased abundance of Aluminum] which results in increased expression of GFAP protein
Vitamin E inhibits the reaction [Aluminum results in increased expression of GFAP protein]
CTD PMID:16545059, PMID:31363819 NCBI chr10:90,990,762...90,999,435
Ensembl chr10:90,990,762...90,999,506
JBrowse link
G Gnai1 G protein subunit alpha i1 decreases expression EXP Aluminum results in decreased expression of GNAI1 protein CTD PMID:9626627 NCBI chr 4:13,405,136...13,486,866
Ensembl chr 4:13,405,136...13,485,883
JBrowse link
G Gnai2 G protein subunit alpha i2 decreases expression EXP Aluminum results in decreased expression of GNAI2 protein CTD PMID:9626627 NCBI chr 8:116,370,730...116,391,337
Ensembl chr 8:116,370,744...116,391,307
JBrowse link
G Gnaq G protein subunit alpha q increases response to substance ISO GNAQ protein results in increased susceptibility to Aluminum CTD PMID:15068510 NCBI chr 1:233,382,778...233,622,584
Ensembl chr 1:233,382,708...233,622,786
JBrowse link
G Gpd1 glycerol-3-phosphate dehydrogenase 1 multiple interactions ISO Aluminum results in increased expression of and results in increased activity of GPD1 protein CTD PMID:17762189 NCBI chr 7:141,368,928...141,377,931
Ensembl chr 7:141,370,491...141,377,928
JBrowse link
G Gpx1 glutathione peroxidase 1 decreases activity
multiple interactions
ISO Aluminum results in decreased activity of GPX1 protein
Vitamin E inhibits the reaction [Aluminum results in decreased activity of GPX1 protein]
CTD PMID:17709913 NCBI chr 8:117,117,430...117,118,528
Ensembl chr 8:117,117,430...117,118,522
JBrowse link
G Gsr glutathione-disulfide reductase decreases expression
multiple interactions
EXP Aluminum results in decreased expression of GSR protein
Plant Extracts inhibits the reaction [Aluminum results in decreased expression of GSR protein]
CTD PMID:24486960 NCBI chr16:62,197,617...62,239,987
Ensembl chr16:62,197,617...62,241,361
JBrowse link
G Hif1a hypoxia inducible factor 1 subunit alpha increases localization ISO Aluminum results in increased localization of HIF1A protein CTD PMID:16979867 NCBI chr 6:96,810,868...96,856,303
Ensembl chr 6:96,810,907...96,856,052
JBrowse link
G Hk1 hexokinase 1 multiple interactions
decreases activity
EXP Meclofenoxate inhibits the reaction [Aluminum results in decreased activity of HK1 protein] CTD PMID:16969689 NCBI chr20:31,911,460...31,979,780
Ensembl chr20:31,912,262...31,956,649
JBrowse link
G Idh1 isocitrate dehydrogenase (NADP(+)) 1 decreases activity EXP Aluminum results in decreased activity of IDH1 protein CTD PMID:15486972 NCBI chr 9:71,882,108...71,911,645
Ensembl chr 9:71,882,105...71,900,044
JBrowse link
G Idh2 isocitrate dehydrogenase (NADP(+)) 2 decreases activity EXP Aluminum results in decreased activity of IDH2 protein CTD PMID:15486972 NCBI chr 1:141,874,354...141,893,674
Ensembl chr 1:141,866,283...141,893,705
JBrowse link
G Ifnb1 interferon beta 1 multiple interactions ISO [Aluminum co-treated with Copper] inhibits the reaction [lipopolysaccharide, Escherichia coli O111 B4 results in increased expression of IFNB1 mRNA] CTD PMID:23690655 NCBI chr 5:106,865,192...106,865,746
Ensembl chr 5:106,865,192...106,865,746
JBrowse link
G Igf1 insulin-like growth factor 1 multiple interactions ISO Aluminum inhibits the reaction [IGF1 protein results in increased activity of MTR protein] CTD PMID:14745455 NCBI chr 7:28,412,123...28,491,815
Ensembl chr 7:28,412,198...28,486,609
JBrowse link
G Il12b interleukin 12B multiple interactions ISO [Aluminum co-treated with Copper] inhibits the reaction [lipopolysaccharide, Escherichia coli O111 B4 results in increased expression of IL12B mRNA] CTD PMID:23690655 NCBI chr10:30,034,447...30,048,774
Ensembl chr10:30,038,709...30,048,085
JBrowse link
G Il1b interleukin 1 beta multiple interactions
increases expression
EXP [Cadmium co-treated with Aluminum co-treated with Fluorides] results in increased expression of IL1B protein; Berberine inhibits the reaction [[Cadmium co-treated with Aluminum co-treated with Fluorides] results in increased expression of IL1B protein]; caffeic acid inhibits the reaction [Aluminum results in increased expression of IL1B protein]; Vitamin E inhibits the reaction [Aluminum results in increased expression of IL1B protein] CTD PMID:16545059, PMID:27368151, PMID:29170048 NCBI chr 3:121,876,256...121,882,637
Ensembl chr 3:121,876,263...121,882,726
JBrowse link
G Il4 interleukin 4 increases expression ISO Aluminum results in increased expression of IL4 mRNA CTD PMID:16630673 NCBI chr10:38,963,979...38,969,531
Ensembl chr10:38,963,979...38,969,531
JBrowse link
G Il6 interleukin 6 increases expression
multiple interactions
EXP
ISO
Aluminum results in increased expression of IL6 protein
[Cadmium co-treated with Aluminum co-treated with Fluorides] results in increased expression of IL6 protein; Berberine inhibits the reaction [[Cadmium co-treated with Aluminum co-treated with Fluorides] results in increased expression of IL6 protein]; caffeic acid inhibits the reaction [Aluminum results in increased expression of IL6 protein]
[Zinc co-treated with Aluminum] results in increased expression of IL6 protein; [Zinc co-treated with Copper co-treated with Aluminum] results in increased expression of IL6 protein
CTD PMID:27368151, PMID:27816692, PMID:29170048 NCBI chr 4:3,043,231...3,047,807
Ensembl chr 4:3,043,231...3,047,807
JBrowse link
G Jun Jun proto-oncogene, AP-1 transcription factor subunit multiple interactions ISO [Aluminum co-treated with Copper] inhibits the reaction [lipopolysaccharide, Escherichia coli O111 B4 affects the localization of JUN protein] CTD PMID:23690655 NCBI chr 5:114,011,184...114,014,277
Ensembl chr 5:114,011,189...114,014,277
JBrowse link
G Klk1 kallikrein 1 multiple interactions ISO Aluminum binds to and results in decreased activity of KLK1 protein CTD PMID:15558947 NCBI chr 1:100,131,562...100,135,556
Ensembl chr 1:100,059,967...100,203,329
Ensembl chr 1:100,059,967...100,203,329
Ensembl chr 1:100,059,967...100,203,329
JBrowse link
G Litaf lipopolysaccharide-induced TNF factor multiple interactions ISO [Titanium co-treated with Vanadium co-treated with Aluminum] results in increased expression of LITAF mRNA CTD PMID:17408380 NCBI chr10:4,753,546...4,763,272
Ensembl chr10:4,719,713...4,763,510
JBrowse link
G LOC100360841 ribosomal protein L37-like decreases expression ISO Aluminum results in decreased expression of RPL37 mRNA; Aluminum results in decreased expression of RPL37 protein CTD PMID:27329587 NCBI chr 9:69,790,829...69,791,199
Ensembl chr 9:69,790,831...69,791,196
JBrowse link
G Lonrf2 LON peptidase N-terminal domain and ring finger 2 decreases expression EXP Aluminum results in decreased expression of LONRF2 mRNA CTD PMID:19010380 NCBI chr 9:45,468,001...45,506,448
Ensembl chr 9:45,466,688...45,505,767
JBrowse link
G Mapk3 mitogen activated protein kinase 3 multiple interactions EXP [Aluminum co-treated with Iron] results in increased phosphorylation of MAPK3 protein CTD PMID:16728372 NCBI chr 1:198,192,773...198,198,975
Ensembl chr 1:198,192,773...198,198,975
JBrowse link
G Mapt microtubule-associated protein tau increases phosphorylation
multiple interactions
EXP Aluminum results in increased phosphorylation of MAPT protein
[Cadmium co-treated with Aluminum co-treated with Fluorides] results in increased expression of MAPT mRNA; Berberine inhibits the reaction [[Cadmium co-treated with Aluminum co-treated with Fluorides] results in increased expression of MAPT mRNA]
CTD PMID:17662457, PMID:29170048 NCBI chr10:92,289,002...92,386,517
Ensembl chr10:92,288,910...92,386,517
JBrowse link
G Mir21 microRNA 21 multiple interactions ISO [Air Pollutants, Occupational results in increased abundance of Aluminum] which results in increased expression of MIR21 mRNA CTD PMID:27506416 NCBI chr10:73,902,210...73,902,301
Ensembl chr10:73,902,210...73,902,301
JBrowse link
G Mir30d microRNA 30d multiple interactions ISO [Air Pollutants, Occupational results in increased abundance of Aluminum] which results in increased expression of MIR30D mRNA CTD PMID:27506416 NCBI chr 7:109,286,463...109,286,544
Ensembl chr 7:109,286,463...109,286,544
JBrowse link
G Mir322 microRNA 322 multiple interactions ISO [Air Pollutants, Occupational results in increased abundance of Aluminum] which results in increased expression of MIR424 mRNA CTD PMID:27506416 NCBI chr  X:158,148,161...158,148,255
Ensembl chr  X:158,148,161...158,148,255
JBrowse link
G Mmp2 matrix metallopeptidase 2 increases expression EXP Aluminum results in increased expression of MMP2 protein CTD PMID:16052892 NCBI chr19:15,542,771...15,570,589
Ensembl chr19:15,542,765...15,570,611
JBrowse link
G Mmp7 matrix metallopeptidase 7 multiple interactions ISO [Aluminum Chloride results in increased abundance of Aluminum] which results in increased expression of MMP7 mRNA CTD PMID:32437896 NCBI chr 8:5,893,253...5,900,965
Ensembl chr 8:5,893,249...5,901,049
JBrowse link
G Mmp9 matrix metallopeptidase 9 increases expression
multiple interactions
EXP
ISO
Aluminum results in increased expression of MMP9 protein
[Aluminum Chloride results in increased abundance of Aluminum] which results in increased expression of MMP9 mRNA
CTD PMID:16052892, PMID:32437896 NCBI chr 3:161,413,410...161,421,473
Ensembl chr 3:161,413,298...161,421,520
JBrowse link
G Mpo myeloperoxidase increases expression ISO Aluminum results in increased expression of MPO protein CTD PMID:17402216 NCBI chr10:75,087,892...75,098,260
Ensembl chr10:75,087,892...75,098,260
JBrowse link
G Mtr 5-methyltetrahydrofolate-homocysteine methyltransferase multiple interactions ISO Aluminum inhibits the reaction [[Hydroxocobalamin co-treated with S-Adenosylmethionine] results in increased activity of MTR protein alternative form]; Aluminum inhibits the reaction [IGF1 protein results in increased activity of MTR protein]; Aluminum inhibits the reaction [mecobalamin results in increased activity of MTR protein alternative form] CTD PMID:14745455, PMID:26989453 NCBI chr17:66,210,444...66,295,014
Ensembl chr17:66,210,461...66,295,014
JBrowse link
G Nos2 nitric oxide synthase 2 multiple interactions EXP
ISO
[Aluminum co-treated with Iron] results in increased expression of NOS2 protein
[Aluminum co-treated with Copper] inhibits the reaction [lipopolysaccharide, Escherichia coli O111 B4 results in increased expression of NOS2 mRNA]
CTD PMID:16728372, PMID:23690655 NCBI chr10:66,188,290...66,221,621
Ensembl chr10:66,189,786...66,313,190
JBrowse link
G Nrg1 neuregulin 1 multiple interactions ISO [aluminum chlorhydrate results in increased abundance of Aluminum] inhibits the reaction [NRG1 protein results in increased phosphorylation of ESR1 protein] CTD PMID:31945389 NCBI chr16:62,969,573...64,065,063
Ensembl chr16:63,837,216...64,057,434
JBrowse link
G Ogdh oxoglutarate dehydrogenase multiple interactions
increases activity
ISO
EXP
Aluminum results in decreased expression of and results in decreased activity of OGDH protein
Aluminum results in increased activity of OGDH protein
CTD PMID:10806405, PMID:16906525 NCBI chr14:86,414,924...86,481,903
Ensembl chr14:86,414,949...86,613,327
JBrowse link
G Oprd1 opioid receptor, delta 1 multiple interactions EXP [Enkephalin, D-Penicillamine (2,5)- binds to and results in increased activity of OPRD1 protein] which results in decreased abundance of Aluminum CTD PMID:7477890 NCBI chr 5:150,288,126...150,323,063
Ensembl chr 5:150,288,126...150,323,063
JBrowse link
G Pck1 phosphoenolpyruvate carboxykinase 1 multiple interactions ISO [aluminum chlorhydrate results in increased abundance of Aluminum] which results in decreased expression of PCK1 protein CTD PMID:31945389 NCBI chr 3:171,213,936...171,219,885
Ensembl chr 3:171,213,936...171,219,871
JBrowse link
G Pcna proliferating cell nuclear antigen multiple interactions ISO [aluminum chloride results in increased abundance of Aluminum] which results in decreased expression of PCNA mRNA CTD PMID:29635646 NCBI chr 3:124,880,698...124,884,570
Ensembl chr 3:124,880,698...124,884,570
JBrowse link
G Pklr pyruvate kinase L/R increases activity ISO Aluminum results in increased activity of PKLR protein CTD PMID:16979867 NCBI chr 2:188,449,158...188,458,034
Ensembl chr 2:188,449,210...188,459,592
JBrowse link
G Plcd1 phospholipase C, delta 1 increases expression EXP Aluminum results in increased expression of PLCD1 protein CTD PMID:10814511 NCBI chr 8:127,753,514...127,782,070
Ensembl chr 8:127,753,539...127,782,070
JBrowse link
G Ptgs2 prostaglandin-endoperoxide synthase 2 increases expression
multiple interactions
ISO Aluminum results in increased expression of PTGS2 mRNA; Aluminum results in increased expression of PTGS2 protein
[Aluminum co-treated with Copper] inhibits the reaction [lipopolysaccharide, Escherichia coli O111 B4 results in increased expression of PTGS2 mRNA]; Meloxicam inhibits the reaction [Aluminum results in increased expression of PTGS2 mRNA]; Meloxicam inhibits the reaction [Aluminum results in increased expression of PTGS2 protein]
CTD PMID:16928369, PMID:23690655 NCBI chr13:67,351,230...67,356,920
Ensembl chr13:67,351,087...67,359,335
JBrowse link
G Pth parathyroid hormone multiple interactions ISO [TF protein binds to and results in increased uptake of Aluminum] which results in decreased secretion of PTH protein CTD PMID:10978387 NCBI chr 1:178,215,829...178,218,761
Ensembl chr 1:178,215,829...178,218,761
JBrowse link
G Rcvrn recoverin multiple interactions ISO [APP protein modified form binds to Aluminum] which results in increased expression of RCVRN mRNA CTD PMID:21298039 NCBI chr10:54,246,250...54,253,996
Ensembl chr10:54,246,250...54,253,996
JBrowse link
G Rela RELA proto-oncogene, NF-kB subunit multiple interactions ISO [Aluminum co-treated with Copper] inhibits the reaction [lipopolysaccharide, Escherichia coli O111 B4 affects the localization of RELA protein] CTD PMID:23690655 NCBI chr 1:220,992,770...221,003,249
Ensembl chr 1:220,992,770...221,003,249
JBrowse link
G S100b S100 calcium binding protein B increases expression
multiple interactions
EXP Aluminum results in increased expression of S100B protein
Vitamin E inhibits the reaction [Aluminum results in increased expression of S100B protein]
CTD PMID:16545059 NCBI chr20:13,130,633...13,142,856
Ensembl chr20:13,130,636...13,142,856
JBrowse link
G Scgb1a1 secretoglobin family 1A member 1 decreases expression EXP
ISO
Aluminum results in decreased expression of SCGB1A1 protein CTD PMID:16052892, PMID:16099050 NCBI chr 1:225,279,698...225,283,246
Ensembl chr 1:225,279,676...225,283,326
JBrowse link
G Slc2a1 solute carrier family 2 member 1 increases expression ISO Aluminum results in increased expression of SLC2A1 protein CTD PMID:16979867 NCBI chr 5:138,154,677...138,182,897
Ensembl chr 5:138,154,673...138,182,897
JBrowse link
G Snai1 snail family transcriptional repressor 1 multiple interactions ISO 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide inhibits the reaction [[Aluminum Chloride results in increased abundance of Aluminum] which results in increased expression of SNAI1 protein]; [Aluminum Chloride results in increased abundance of Aluminum] which results in increased expression of SNAI1 mRNA; [Aluminum Chloride results in increased abundance of Aluminum] which results in increased expression of SNAI1 protein CTD PMID:32437896 NCBI chr 3:164,274,710...164,279,199
Ensembl chr 3:164,274,710...164,279,378
JBrowse link
G Snca synuclein alpha affects response to substance ISO SNCA protein affects the susceptibility to Aluminum CTD PMID:23106139 NCBI chr 4:90,782,412...90,883,236
Ensembl chr 4:90,782,374...90,882,285
JBrowse link
G Sod2 superoxide dismutase 2 decreases activity EXP Aluminum results in decreased activity of SOD2 protein CTD PMID:19010380 NCBI chr 1:47,914,757...47,921,587
Ensembl chr 1:47,914,759...47,921,587
JBrowse link
G Tf transferrin multiple interactions
increases uptake
affects binding
ISO [Aluminum binds to TF protein] which results in decreased uptake of Iron; [Aluminum binds to TF protein] which results in decreased uptake of Manganese; [Aluminum binds to TF protein] which results in increased uptake of Aluminum; [TF protein binds to Aluminum] affects the activity of [TF protein binds to Iron]; [TF protein binds to Aluminum] which results in increased uptake of Aluminum; [TF protein binds to Aluminum] which results in increased uptake of Iron; [TF protein binds to and results in increased uptake of Aluminum] which results in decreased secretion of PTH protein; TF protein binds to [Aluminum co-treated with Iron]; TF protein binds to and results in increased uptake of Aluminum
TF protein results in increased uptake of Aluminum
Aluminum binds to TF protein; TF protein binds to Aluminum
TRF protein binds to Aluminum
CTD PMID:1375080, PMID:2039817, PMID:2308257, PMID:8782865, PMID:10978387, PMID:11193083, PMID:12627980, PMID:15149824, PMID:19859668, PMID:22873711 NCBI chr 8:111,694,570...111,721,275
Ensembl chr 8:111,673,547...111,721,333
JBrowse link
G Tfrc transferrin receptor decreases expression
affects uptake
EXP Aluminum results in decreased expression of TFRC mRNA
TFRC protein affects the uptake of Aluminum
CTD PMID:9630424, PMID:11068183 NCBI chr11:71,397,423...71,419,263
Ensembl chr11:71,397,383...71,419,223
JBrowse link
G Tgfb1 transforming growth factor, beta 1 multiple interactions ISO [Aluminum Chloride results in increased abundance of Aluminum] which results in increased expression of TGFB1 mRNA CTD PMID:32437896 NCBI chr 1:82,480,875...82,497,196
Ensembl chr 1:82,480,195...82,497,199
JBrowse link
G Tnf tumor necrosis factor increases expression
multiple interactions
EXP
ISO
Aluminum results in increased expression of TNF protein
[Aluminum co-treated with Copper] inhibits the reaction [lipopolysaccharide, Escherichia coli O111 B4 results in increased expression of TNF mRNA]
[Cadmium co-treated with Aluminum co-treated with Fluorides] results in increased expression of TNF mRNA; [Cadmium co-treated with Aluminum co-treated with Fluorides] results in increased expression of TNF protein; Berberine inhibits the reaction [[Cadmium co-treated with Aluminum co-treated with Fluorides] results in increased expression of TNF mRNA]; Berberine inhibits the reaction [[Cadmium co-treated with Aluminum co-treated with Fluorides] results in increased expression of TNF protein]; caffeic acid inhibits the reaction [Aluminum results in increased expression of TNF protein]; Vitamin E inhibits the reaction [Aluminum results in increased expression of TNF protein]
[Titanium co-treated with Vanadium co-treated with Aluminum] results in increased expression of TNF mRNA
CTD PMID:16545059, PMID:17408380, PMID:23690655, PMID:27368151, PMID:29170048 NCBI chr20:5,189,382...5,192,000
Ensembl chr20:5,189,390...5,192,000
JBrowse link
G Tubb3 tubulin, beta 3 class III multiple interactions ISO [Aluminum Chloride results in increased abundance of Aluminum] which results in decreased expression of TUBB3 protein CTD PMID:31363819 NCBI chr19:56,220,759...56,229,813
Ensembl chr19:56,220,755...56,229,813
JBrowse link
G Txn2 thioredoxin 2 multiple interactions ISO [aluminum chlorhydrate results in increased abundance of Aluminum] which results in decreased expression of TXN2 protein CTD PMID:31945389 NCBI chr 7:119,144,350...119,158,173
Ensembl chr 7:119,144,351...119,158,201
JBrowse link
G Uba52 ubiquitin A-52 residue ribosomal protein fusion product 1 decreases expression ISO Aluminum results in decreased expression of UBA52 mRNA; Aluminum results in decreased expression of UBA52 protein CTD PMID:27329587 NCBI chr16:20,668,925...20,671,127
Ensembl chr16:20,668,971...20,671,127
JBrowse link
G Vegfa vascular endothelial growth factor A multiple interactions ISO 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide inhibits the reaction [[Aluminum Chloride results in increased abundance of Aluminum] which results in increased expression of VEGFA protein]; [Aluminum Chloride results in increased abundance of Aluminum] which results in increased expression of and results in increased secretion of VEGFA protein; [Aluminum Chloride results in increased abundance of Aluminum] which results in increased secretion of VEGFA protein CTD PMID:32437896 NCBI chr 9:17,340,341...17,355,681
Ensembl chr 9:17,340,341...17,355,681
JBrowse link
G Vim vimentin multiple interactions ISO 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide inhibits the reaction [[Aluminum Chloride results in increased abundance of Aluminum] which results in increased expression of VIM protein]; [Aluminum Chloride results in increased abundance of Aluminum] which results in increased expression of VIM mRNA; [Aluminum Chloride results in increased abundance of Aluminum] which results in increased expression of VIM protein CTD PMID:32437896 NCBI chr17:80,882,715...80,891,200
Ensembl chr17:80,882,666...80,891,212
JBrowse link
G Xdh xanthine dehydrogenase increases activity EXP Aluminum results in increased activity of XDH protein CTD PMID:11787993 NCBI chr 6:25,149,570...25,211,273
Ensembl chr 6:25,149,235...25,211,494
JBrowse link
aluminium hydroxide term browser
Symbol Object Name Qualifiers Evidence Notes Source PubMed Reference(s) RGD Reference(s) Position
G Abcc2 ATP binding cassette subfamily C member 2 decreases expression EXP Aluminum Hydroxide results in decreased expression of ABCC2 protein CTD PMID:14976346 NCBI chr 1:263,554,426...263,612,556
Ensembl chr 1:263,554,453...263,613,252
JBrowse link
G Casp1 caspase 1 multiple interactions ISO [Aluminum Hydroxide co-treated with Magnesium Hydroxide] promotes the reaction [N-t-butyl-n'-tetradecyl-3-tetradecylaminopropionamidine results in increased activity of CASP1 protein]; [Aluminum Hydroxide co-treated with Magnesium Hydroxide] promotes the reaction [N-t-butyl-n'-tetradecyl-3-tetradecylaminopropionamidine results in increased expression of and results in increased secretion of CASP1 protein modified form]; CASP1 protein affects the reaction [[Lipopolysaccharides co-treated with [Aluminum Hydroxide co-treated with Magnesium Hydroxide]] results in increased cleavage of and results in increased secretion of IL1B protein] CTD PMID:18604214, PMID:22075093 NCBI chr 8:2,605,743...2,614,637
Ensembl chr 8:2,604,962...2,614,631
JBrowse link
G Cat catalase decreases activity EXP Aluminum Hydroxide results in decreased activity of CAT protein CTD PMID:14976346 NCBI chr 3:93,379,872...93,412,058
Ensembl chr 3:93,379,874...93,412,058
JBrowse link
G Ccl2 C-C motif chemokine ligand 2 increases secretion ISO Aluminum Hydroxide results in increased secretion of CCL2 protein CTD PMID:18390722 NCBI chr10:69,412,065...69,413,863
Ensembl chr10:69,412,017...69,413,870
JBrowse link
G Ccl3 C-C motif chemokine ligand 3 increases secretion ISO Aluminum Hydroxide results in increased secretion of CCL3 protein CTD PMID:18390722 NCBI chr10:70,869,516...70,871,066
Ensembl chr10:70,869,513...70,871,066
JBrowse link
G Ccl4 C-C motif chemokine ligand 4 increases secretion ISO Aluminum Hydroxide results in increased secretion of CCL4 protein CTD PMID:18390722 NCBI chr10:70,870,926...70,886,357
Ensembl chr10:70,884,531...70,886,355
JBrowse link
G Ccl5 C-C motif chemokine ligand 5 increases secretion ISO Aluminum Hydroxide results in increased secretion of CCL5 protein CTD PMID:18390722 NCBI chr10:70,739,764...70,744,303
Ensembl chr10:70,739,800...70,744,315
JBrowse link
G Ccr7 C-C motif chemokine receptor 7 multiple interactions ISO Aluminum Hydroxide promotes the reaction [[CSF2 protein co-treated with IL4 protein] results in increased expression of CCR7 protein] CTD PMID:18390722 NCBI chr10:87,057,335...87,067,444
Ensembl chr10:87,057,136...87,067,456
JBrowse link
G Cd14 CD14 molecule decreases expression ISO Aluminum Hydroxide results in decreased expression of CD14 protein CTD PMID:18390722 NCBI chr18:29,560,341...29,562,290
Ensembl chr18:29,560,365...29,562,153
JBrowse link
G Cd4 Cd4 molecule affects response to substance ISO CD4 protein affects the susceptibility to Aluminum Hydroxide CTD PMID:11160013 NCBI chr 4:157,381,862...157,408,357
Ensembl chr 4:157,383,052...157,408,176
JBrowse link
G Cd40 CD40 molecule increases expression ISO Aluminum Hydroxide results in increased expression of CD40 protein CTD PMID:11160013 NCBI chr 3:161,519,789...161,534,943
Ensembl chr 3:161,519,743...161,534,704
JBrowse link
G Cd80 Cd80 molecule multiple interactions ISO Aluminum Hydroxide inhibits the reaction [[CSF2 protein co-treated with IL4 protein] results in increased expression of CD80 protein] CTD PMID:18390722 NCBI chr11:64,815,201...64,855,293
Ensembl chr11:64,827,635...64,855,353
JBrowse link
G Cd83 CD83 molecule increases expression ISO Aluminum Hydroxide results in increased expression of CD83 protein CTD PMID:11160013 NCBI chr17:24,416,651...24,435,790
Ensembl chr17:24,416,651...24,435,790
JBrowse link
G Cd86 CD86 molecule increases expression
multiple interactions
ISO Aluminum Hydroxide results in increased expression of CD86 protein
Aluminum Hydroxide promotes the reaction [CSF2 protein results in increased expression of CD86 protein]
CTD PMID:11160013, PMID:18390722 NCBI chr11:67,060,305...67,117,990
Ensembl chr11:67,082,193...67,118,795
JBrowse link
G Chrna4 cholinergic receptor nicotinic alpha 4 subunit multiple interactions ISO Aluminum Hydroxide inhibits the reaction [Acetylcholine results in increased activity of [CHRNA4 protein co-treated with CHRNB2 protein]] CTD PMID:22750351 NCBI chr 3:176,533,182...176,547,965
Ensembl chr 3:176,527,516...176,548,208
JBrowse link
G Chrnb2 cholinergic receptor nicotinic beta 2 subunit multiple interactions ISO Aluminum Hydroxide inhibits the reaction [Acetylcholine results in increased activity of [CHRNA4 protein co-treated with CHRNB2 protein]] CTD PMID:22750351 NCBI chr 2:189,088,570...189,096,785
Ensembl chr 2:189,088,570...189,096,785
JBrowse link
G Csf2 colony stimulating factor 2 multiple interactions ISO Aluminum Hydroxide inhibits the reaction [[CSF2 protein co-treated with IL4 protein] results in increased expression of CD1A protein]; Aluminum Hydroxide inhibits the reaction [[CSF2 protein co-treated with IL4 protein] results in increased expression of CD80 protein]; Aluminum Hydroxide promotes the reaction [[CSF2 protein co-treated with IL4 protein] results in increased expression of CCR7 protein]; Aluminum Hydroxide promotes the reaction [[CSF2 protein co-treated with IL4 protein] results in increased expression of TFRC protein]; Aluminum Hydroxide promotes the reaction [CSF2 protein results in increased expression of CD86 protein] CTD PMID:18390722 NCBI chr10:39,602,089...39,604,070
Ensembl chr10:39,602,089...39,604,070
JBrowse link
G Cxcl10 C-X-C motif chemokine ligand 10 multiple interactions ISO [Aluminum Hydroxide co-treated with Magnesium Hydroxide] inhibits the reaction [K-12 lipopolysaccharide results in increased secretion of CXCL10 protein] CTD PMID:17404311 NCBI chr14:17,210,733...17,212,930
Ensembl chr14:17,210,733...17,212,930
JBrowse link
G Icam1 intercellular adhesion molecule 1 increases expression ISO Aluminum Hydroxide results in increased expression of ICAM1 protein CTD PMID:11160013 NCBI chr 8:22,035,287...22,047,049
Ensembl chr 8:22,035,256...22,047,059
JBrowse link
G Il13 interleukin 13 increases expression ISO Aluminum Hydroxide results in increased expression of IL13 mRNA CTD PMID:9328138 NCBI chr10:38,982,909...38,985,466
Ensembl chr10:38,982,909...38,985,466
JBrowse link
G Il1b interleukin 1 beta multiple interactions ISO [[Aluminum Hydroxide co-treated with Magnesium Hydroxide] co-treated with K-12 lipopolysaccharide] results in increased secretion of IL1B protein modified form; [Aluminum Hydroxide co-treated with Magnesium Hydroxide] results in increased secretion of IL1B protein; [Lipopolysaccharides co-treated with [Aluminum Hydroxide co-treated with Magnesium Hydroxide]] results in increased cleavage of and results in increased secretion of IL1B protein; CASP1 protein affects the reaction [[Lipopolysaccharides co-treated with [Aluminum Hydroxide co-treated with Magnesium Hydroxide]] results in increased cleavage of and results in increased secretion of IL1B protein]; N-t-butyl-n'-tetradecyl-3-tetradecylaminopropionamidine promotes the reaction [[Aluminum Hydroxide co-treated with Magnesium Hydroxide] results in increased secretion of IL1B protein]
[[Aluminum Hydroxide co-treated with Magnesium Hydroxide] co-treated with N-t-butyl-n'-tetradecyl-3-tetradecylaminopropionamidine] results in increased secretion of IL1B protein; [Lipopolysaccharides co-treated with [Aluminum Hydroxide co-treated with Magnesium Hydroxide]] results in increased cleavage of and results in increased secretion of IL1B protein; IL1R1 protein affects the reaction [[Lipopolysaccharides co-treated with [Aluminum Hydroxide co-treated with Magnesium Hydroxide]] results in increased cleavage of and results in increased secretion of IL1B protein]; NLRP3 protein affects the reaction [[Lipopolysaccharides co-treated with [Aluminum Hydroxide co-treated with Magnesium Hydroxide]] results in increased cleavage of and results in increased secretion of IL1B protein]; PYCARD protein affects the reaction [[Lipopolysaccharides co-treated with [Aluminum Hydroxide co-treated with Magnesium Hydroxide]] results in increased cleavage of and results in increased secretion of IL1B protein]
CTD PMID:17404311, PMID:18604214, PMID:22075093 NCBI chr 3:121,876,256...121,882,637
Ensembl chr 3:121,876,263...121,882,726
JBrowse link
G Il1r1 interleukin 1 receptor type 1 multiple interactions ISO IL1R1 protein affects the reaction [[Lipopolysaccharides co-treated with [Aluminum Hydroxide co-treated with Magnesium Hydroxide]] results in increased cleavage of and results in increased secretion of IL1B protein] CTD PMID:18604214 NCBI chr 9:46,962,291...47,038,139
Ensembl chr 9:46,962,288...47,036,670
JBrowse link
G Il1rn interleukin 1 receptor antagonist increases secretion ISO Aluminum Hydroxide results in increased secretion of IL1RN protein CTD PMID:18390722 NCBI chr 3:1,449,778...1,468,624
Ensembl chr 3:1,452,644...1,468,614
JBrowse link
G Il2 interleukin 2 increases expression
multiple interactions
ISO Aluminum Hydroxide results in increased expression of IL2 mRNA
[Aluminum Hydroxide co-treated with Magnesium Hydroxide] results in increased secretion of IL2 protein; N-t-butyl-n'-tetradecyl-3-tetradecylaminopropionamidine promotes the reaction [[Aluminum Hydroxide co-treated with Magnesium Hydroxide] results in increased secretion of IL2 protein]; TLR4 protein affects the reaction [N-t-butyl-n'-tetradecyl-3-tetradecylaminopropionamidine promotes the reaction [[Aluminum Hydroxide co-treated with Magnesium Hydroxide] results in increased secretion of IL2 protein]]
CTD PMID:9328138, PMID:22075093 NCBI chr 2:123,847,150...123,851,854
Ensembl chr 2:123,847,150...123,851,854
JBrowse link
G Il4 interleukin 4 increases expression
affects response to substance
multiple interactions
ISO Aluminum Hydroxide results in increased expression of IL4 mRNA
IL4 protein affects the susceptibility to Aluminum Hydroxide
Aluminum Hydroxide inhibits the reaction [[CSF2 protein co-treated with IL4 protein] results in increased expression of CD1A protein]; Aluminum Hydroxide inhibits the reaction [[CSF2 protein co-treated with IL4 protein] results in increased expression of CD80 protein]; Aluminum Hydroxide promotes the reaction [[CSF2 protein co-treated with IL4 protein] results in increased expression of CCR7 protein]; Aluminum Hydroxide promotes the reaction [[CSF2 protein co-treated with IL4 protein] results in increased expression of TFRC protein]
CTD PMID:9328138, PMID:11160013, PMID:18390722 NCBI chr10:38,963,979...38,969,531
Ensembl chr10:38,963,979...38,969,531
JBrowse link
G Il5 interleukin 5 increases expression ISO Aluminum Hydroxide results in increased expression of IL5 mRNA CTD PMID:9328138 NCBI chr10:39,066,716...39,069,587
Ensembl chr10:39,066,716...39,069,587
JBrowse link
G Il6 interleukin 6 increases expression ISO Aluminum Hydroxide results in increased expression of IL6 mRNA CTD PMID:9328138 NCBI chr 4:3,043,231...3,047,807
Ensembl chr 4:3,043,231...3,047,807
JBrowse link
G Mydgf myeloid-derived growth factor increases expression ISO Aluminium hydroxide co-treated with ovalbumin increases expression of Mydgf mRNAand protein in lung and epithelium RGD PMID:25273095 RGD:39128256 NCBI chr 9:10,885,521...10,892,744
Ensembl chr 9:10,885,560...10,892,405
JBrowse link
G Nlrp3 NLR family, pyrin domain containing 3 multiple interactions ISO NLRP3 protein affects the reaction [[Lipopolysaccharides co-treated with [Aluminum Hydroxide co-treated with Magnesium Hydroxide]] results in increased cleavage of and results in increased secretion of IL1B protein] CTD PMID:18604214 NCBI chr10:45,884,324...45,918,290
Ensembl chr10:45,893,018...45,918,254
JBrowse link
G Pycard PYD and CARD domain containing multiple interactions ISO PYCARD protein affects the reaction [[Lipopolysaccharides co-treated with [Aluminum Hydroxide co-treated with Magnesium Hydroxide]] results in increased cleavage of and results in increased secretion of IL1B protein] CTD PMID:18604214 NCBI chr 1:199,438,029...199,439,062
Ensembl chr 1:199,437,832...199,439,210
JBrowse link
G Tfrc transferrin receptor multiple interactions ISO Aluminum Hydroxide promotes the reaction [[CSF2 protein co-treated with IL4 protein] results in increased expression of TFRC protein] CTD PMID:18390722 NCBI chr11:71,397,423...71,419,263
Ensembl chr11:71,397,383...71,419,223
JBrowse link
G Tlr4 toll-like receptor 4 multiple interactions ISO TLR4 protein affects the reaction [N-t-butyl-n'-tetradecyl-3-tetradecylaminopropionamidine promotes the reaction [[Aluminum Hydroxide co-treated with Magnesium Hydroxide] results in increased secretion of IL2 protein]]; TLR4 protein affects the susceptibility to [[Aluminum Hydroxide co-treated with Magnesium Hydroxide] co-treated with N-t-butyl-n'-tetradecyl-3-tetradecylaminopropionamidine]; TLR4 protein affects the susceptibility to [Aluminum Hydroxide co-treated with Magnesium Hydroxide] CTD PMID:22075093 NCBI chr 5:82,587,424...82,601,056
Ensembl chr 5:82,587,420...82,601,052
JBrowse link
aluminium ion term browser
Symbol Object Name Qualifiers Evidence Notes Source PubMed Reference(s) RGD Reference(s) Position
G Hmbs hydroxymethylbilane synthase decreases activity EXP Aluminium ion decreases activity of purified Hmbs protein RGD PMID:6732900 RGD:25394584 NCBI chr 8:48,667,278...48,674,673
Ensembl chr 8:48,667,275...48,674,748
JBrowse link
aluminium oxide term browser
Symbol Object Name Qualifiers Evidence Notes Source PubMed Reference(s) RGD Reference(s) Position
G Acp5 acid phosphatase 5, tartrate resistant decreases expression ISO Aluminum Oxide results in decreased expression of ACP5 mRNA CTD PMID:15585240 NCBI chr 8:23,142,733...23,149,067
Ensembl chr 8:23,142,734...23,148,396
JBrowse link
G Actr2 actin related protein 2 multiple interactions ISO [Nanotubes, Carbon co-treated with Aluminum Oxide] results in increased secretion of ACTR2 protein CTD PMID:25598225 NCBI chr14:104,338,486...104,375,840
Ensembl chr14:104,340,434...104,375,649
JBrowse link
G Alpl alkaline phosphatase, biomineralization associated increases expression ISO Aluminum Oxide results in increased expression of ALPL mRNA CTD PMID:19464052 NCBI chr 5:156,086,496...156,141,513
Ensembl chr 5:156,086,497...156,141,537
JBrowse link
G Bcl2l1 Bcl2-like 1 increases expression ISO Aluminum Oxide analog results in increased expression of BCL2L1 mRNA CTD PMID:23132795 NCBI chr 3:148,259,594...148,314,191
Ensembl chr 3:148,259,596...148,313,810
JBrowse link
G Bglap bone gamma-carboxyglutamate protein increases expression ISO Aluminum Oxide results in increased expression of BGLAP mRNA CTD PMID:19464052 NCBI chr 2:187,741,770...187,748,445
Ensembl chr 2:187,741,770...187,742,747
JBrowse link
G Bgn biglycan increases expression ISO Aluminum Oxide results in increased expression of BGN mRNA CTD PMID:19464052 NCBI chr  X:157,319,042...157,331,204
Ensembl chr  X:157,319,046...157,331,204
JBrowse link
G Bmp1 bone morphogenetic protein 1 increases expression ISO Aluminum Oxide results in increased expression of BMP1 mRNA CTD PMID:19464052 NCBI chr15:52,166,401...52,210,786
Ensembl chr15:52,166,401...52,210,746
JBrowse link
G Bmp2 bone morphogenetic protein 2 increases expression ISO Aluminum Oxide results in increased expression of BMP2 mRNA CTD PMID:19464052 NCBI chr 3:126,335,963...126,346,771
Ensembl chr 3:126,335,863...126,346,318
JBrowse link
G Bmp4 bone morphogenetic protein 4 increases expression ISO Aluminum Oxide results in increased expression of BMP4 mRNA CTD PMID:19464052 NCBI chr15:20,776,060...20,791,013
Ensembl chr15:20,776,054...20,822,740
JBrowse link
G Bmp6 bone morphogenetic protein 6 decreases expression ISO Aluminum Oxide results in decreased expression of BMP6 mRNA CTD PMID:19464052 NCBI chr17:26,955,142...27,112,820
Ensembl chr17:26,955,142...27,112,820
JBrowse link
G C3 complement C3 multiple interactions ISO [Nanotubes, Carbon co-treated with Aluminum Oxide] results in increased secretion of C3 protein CTD PMID:25598225 NCBI chr 9:9,721,137...9,747,084
Ensembl chr 9:9,721,105...9,747,167
JBrowse link
G Camp cathelicidin antimicrobial peptide multiple interactions ISO [Nanotubes, Carbon co-treated with Aluminum Oxide] results in increased secretion of CAMP protein CTD PMID:25598225 NCBI chr 8:117,930,557...117,932,371
Ensembl chr 8:117,930,546...117,932,518
JBrowse link
G Casp3 caspase 3 increases expression ISO Aluminum Oxide results in increased expression of CASP3 CTD PMID:21329562 NCBI chr16:48,845,011...48,863,249
Ensembl chr16:48,845,012...48,863,204
JBrowse link
G Cat catalase increases activity EXP Aluminum Oxide results in increased activity of CAT protein CTD PMID:22161306 NCBI chr 3:93,379,872...93,412,058
Ensembl chr 3:93,379,874...93,412,058
JBrowse link
G Ccl2 C-C motif chemokine ligand 2 increases secretion ISO Aluminum Oxide results in increased secretion of CCL2 protein CTD PMID:17618502 NCBI chr10:69,412,065...69,413,863
Ensembl chr10:69,412,017...69,413,870
JBrowse link
G Cd14 CD14 molecule multiple interactions ISO [Nanotubes, Carbon co-treated with Aluminum Oxide] results in increased secretion of CD14 protein CTD PMID:25598225 NCBI chr18:29,560,341...29,562,290
Ensembl chr18:29,560,365...29,562,153
JBrowse link
G Cd36 CD36 molecule increases expression ISO Aluminum Oxide results in increased expression of CD36 mRNA CTD PMID:19464052 NCBI chr 4:14,150,309...14,191,498
Ensembl chr 4:14,001,761...14,249,749
JBrowse link
G Cdh11 cadherin 11 increases expression ISO Aluminum Oxide results in increased expression of CDH11 mRNA CTD PMID:19464052 NCBI chr19:2,391,181...2,551,245
Ensembl chr19:2,393,059...2,551,245
JBrowse link
G Cdkn1a cyclin-dependent kinase inhibitor 1A increases expression ISO Aluminum Oxide analog results in increased expression of CDKN1A mRNA CTD PMID:23132795 NCBI chr20:6,348,422...6,358,864
Ensembl chr20:6,351,458...6,358,864
JBrowse link
G Clu clusterin multiple interactions ISO [Nanotubes, Carbon co-treated with Aluminum Oxide] results in increased secretion of CLU protein CTD PMID:25598225 NCBI chr15:42,626,612...42,665,858
Ensembl chr15:42,640,146...42,665,857
JBrowse link
G Col10a1 collagen type X alpha 1 chain increases expression ISO Aluminum Oxide results in increased expression of COL10A1 mRNA CTD PMID:19464052 NCBI chr20:41,180,295...41,190,664
Ensembl chr20:41,184,287...41,189,633
JBrowse link
G Col11a1 collagen type XI alpha 1 chain increases expression ISO Aluminum Oxide results in increased expression of COL11A1 mRNA CTD PMID:19464052 NCBI chr 2:216,863,423...217,056,523
Ensembl chr 2:216,863,428...217,056,523
JBrowse link
G Col15a1 collagen type XV alpha 1 chain increases expression ISO Aluminum Oxide results in increased expression of COL15A1 mRNA CTD PMID:19464052 NCBI chr 5:62,840,360...62,950,240 JBrowse link
G Col1a1 collagen type I alpha 1 chain multiple interactions ISO [Aluminum Oxide co-treated with Magnesium] results in increased expression of COL1A1 protein CTD PMID:12209937 NCBI chr10:82,745,801...82,762,790
Ensembl chr10:82,745,801...82,762,789
JBrowse link
G Col1a2 collagen type I alpha 2 chain increases expression ISO Aluminum Oxide results in increased expression of COL1A2 mRNA CTD PMID:19464052 NCBI chr 4:31,534,225...31,569,152
Ensembl chr 4:31,534,225...31,569,151
JBrowse link
G Comp cartilage oligomeric matrix protein increases expression ISO Aluminum Oxide results in increased expression of COMP mRNA CTD PMID:19464052 NCBI chr16:20,798,437...20,807,070
Ensembl chr16:20,798,437...20,807,070
JBrowse link
G Csf2 colony stimulating factor 2 increases secretion ISO Aluminum Oxide results in increased secretion of CSF2 protein CTD PMID:15046894 NCBI chr10:39,602,089...39,604,070
Ensembl chr10:39,602,089...39,604,070
JBrowse link
G Ctsk cathepsin K increases expression ISO Aluminum Oxide results in increased expression of CTSK mRNA CTD PMID:19464052 NCBI chr 2:196,655,469...196,666,447
Ensembl chr 2:196,655,469...196,666,446
JBrowse link
G Egfr epidermal growth factor receptor increases expression ISO Aluminum Oxide results in increased expression of EGFR mRNA CTD PMID:19464052 NCBI chr14:99,919,485...100,104,136
Ensembl chr14:99,919,485...100,098,796
JBrowse link
G Fgb fibrinogen beta chain multiple interactions ISO [Nanotubes, Carbon co-treated with Aluminum Oxide] results in increased secretion of FGB protein CTD PMID:25598225 NCBI chr 2:182,028,044...182,035,026
Ensembl chr 2:182,027,115...182,038,178
JBrowse link
G Flt1 Fms related receptor tyrosine kinase 1 increases expression ISO Aluminum Oxide results in increased expression of FLT1 mRNA CTD PMID:19464052 NCBI chr12:9,033,993...9,205,886
Ensembl chr12:9,034,308...9,205,905
JBrowse link
G Fn1 fibronectin 1 increases expression ISO Aluminum Oxide results in increased expression of FN1 mRNA CTD PMID:19464052 NCBI chr 9:78,900,111...78,969,018
Ensembl chr 9:78,900,103...78,969,078
JBrowse link
G Fos Fos proto-oncogene, AP-1 transcription factor subunit decreases expression ISO Aluminum Oxide results in decreased expression of FOS mRNA CTD PMID:15585240 NCBI chr 6:109,300,433...109,303,299
Ensembl chr 6:109,300,433...109,303,299
JBrowse link
G Gsr glutathione-disulfide reductase decreases activity EXP Aluminum Oxide results in decreased activity of GSR protein CTD PMID:22161306 NCBI chr16:62,197,617...62,239,987
Ensembl chr16:62,197,617...62,241,361
JBrowse link
G Ibsp integrin-binding sialoprotein increases expression ISO Aluminum Oxide results in increased expression of IBSP mRNA CTD PMID:19464052 NCBI chr14:6,801,200...6,813,987
Ensembl chr14:6,801,204...6,813,945
JBrowse link
G Icam1 intercellular adhesion molecule 1 increases expression ISO Aluminum Oxide results in increased expression of ICAM1 protein CTD PMID:18456438 NCBI chr 8:22,035,287...22,047,049
Ensembl chr 8:22,035,256...22,047,059
JBrowse link
G Igf1 insulin-like growth factor 1 affects expression ISO Aluminum Oxide affects the expression of IGF1 mRNA CTD PMID:19464052 NCBI chr 7:28,412,123...28,491,815
Ensembl chr 7:28,412,198...28,486,609
JBrowse link
G Il10 interleukin 10 increases expression ISO Aluminum Oxide results in increased expression of IL10 mRNA CTD PMID:15183442 NCBI chr13:47,738,933...47,743,392
Ensembl chr13:47,739,526...47,743,392
JBrowse link
G Il1a interleukin 1 alpha increases expression ISO Aluminum Oxide results in increased expression of IL1A mRNA CTD PMID:15183442 NCBI chr 3:121,824,712...121,836,122
Ensembl chr 3:121,825,412...121,836,086
JBrowse link
G Il1b interleukin 1 beta increases expression
increases secretion
multiple interactions
ISO Aluminum Oxide results in increased expression of IL1B mRNA
Aluminum Oxide results in increased secretion of IL1B protein
[Aluminum Oxide co-treated with Nanotubes, Carbon] results in decreased secretion of IL1B protein; Aluminum Oxide inhibits the reaction [Nanotubes, Carbon results in increased secretion of IL1B protein]
[Aluminum Oxide co-treated with Lipopolysaccharides] results in increased secretion of IL1B protein; [Aluminum Oxide co-treated with Nanotubes, Carbon co-treated with Lipopolysaccharides] results in increased secretion of IL1B protein; [Aluminum Oxide co-treated with Nanotubes, Carbon] promotes the reaction [Lipopolysaccharides results in increased secretion of IL1B protein]; Aluminum Oxide promotes the reaction [Lipopolysaccharides results in increased secretion of IL1B protein]; Aluminum Oxide promotes the reaction [Nanotubes, Carbon results in increased secretion of IL1B protein]
CTD PMID:15183442, PMID:16488289, PMID:17618502, PMID:25216247 NCBI chr 3:121,876,256...121,882,637
Ensembl chr 3:121,876,263...121,882,726
JBrowse link
G Il6 interleukin 6 increases expression
multiple interactions
decreases secretion
ISO Aluminum Oxide results in increased expression of IL6 mRNA; Aluminum Oxide results in increased expression of IL6 protein
[Aluminum Oxide co-treated with Nanotubes, Carbon] results in increased secretion of IL6 protein
Aluminum Oxide results in decreased secretion of IL6 protein
Aluminum Oxide inhibits the reaction [Nanotubes, Carbon results in increased secretion of IL6 protein]
CTD PMID:11771709, PMID:25216247 NCBI chr 4:3,043,231...3,047,807
Ensembl chr 4:3,043,231...3,047,807
JBrowse link
G Itga1 integrin subunit alpha 1 increases expression ISO Aluminum Oxide results in increased expression of ITGA1 mRNA CTD PMID:19464052 NCBI chr 2:47,127,403...47,281,387
Ensembl chr 2:47,127,219...47,281,421
JBrowse link
G Itga3 integrin subunit alpha 3 increases expression ISO Aluminum Oxide results in increased expression of ITGA3 mRNA CTD PMID:19464052 NCBI chr10:82,855,841...82,887,755
Ensembl chr10:82,855,613...82,887,497
JBrowse link
G Itga5 integrin subunit alpha 5 multiple interactions ISO [Aluminum Oxide co-treated with Magnesium] results in increased expression of ITGA5 protein CTD PMID:12209937 NCBI chr 7:144,970,444...144,993,652
Ensembl chr 7:144,970,444...144,993,652
JBrowse link
G Itgb1 integrin subunit beta 1 multiple interactions ISO [Aluminum Oxide co-treated with Magnesium] results in increased expression of ITGB1 protein CTD PMID:12209937 NCBI chr19:61,677,512...61,725,537
Ensembl chr19:61,677,542...61,725,535
JBrowse link
G Itih4 inter-alpha-trypsin inhibitor heavy chain 4 multiple interactions ISO [Nanotubes, Carbon co-treated with Aluminum Oxide] results in increased secretion of ITIH4 protein CTD PMID:25598225 NCBI chr16:6,970,367...6,985,538
Ensembl chr16:6,970,342...6,985,579
JBrowse link
G Jun Jun proto-oncogene, AP-1 transcription factor subunit increases expression ISO Aluminum Oxide results in increased expression of JUN mRNA CTD PMID:16488289 NCBI chr 5:114,011,184...114,014,277
Ensembl chr 5:114,011,189...114,014,277
JBrowse link
G Lcn2 lipocalin 2 multiple interactions ISO [Nanotubes, Carbon co-treated with Aluminum Oxide] results in increased secretion of LCN2 protein CTD PMID:25598225 NCBI chr 3:11,414,189...11,417,534
Ensembl chr 3:11,414,186...11,417,546
JBrowse link
G Ltf lactotransferrin multiple interactions ISO [Nanotubes, Carbon co-treated with Aluminum Oxide] results in increased secretion of LTF protein CTD PMID:25598225 NCBI chr 8:119,290,416...119,313,261
Ensembl chr 8:119,290,416...119,313,261
JBrowse link
G Mmp1 matrix metallopeptidase 1 increases expression ISO Aluminum Oxide results in increased expression of MMP1 mRNA CTD PMID:16488289 NCBI chr 8:5,703,206...5,723,593
Ensembl chr 8:5,703,206...5,723,591
JBrowse link
G Mmp2 matrix metallopeptidase 2 increases expression ISO Aluminum Oxide results in increased expression of MMP2 mRNA CTD PMID:14661256 NCBI chr19:15,542,771...15,570,589
Ensembl chr19:15,542,765...15,570,611
JBrowse link
G Mmp3 matrix metallopeptidase 3 increases expression ISO Aluminum Oxide results in increased expression of MMP3 mRNA CTD PMID:16488289 NCBI chr 8:5,676,608...5,698,579
Ensembl chr 8:5,676,665...5,698,579
JBrowse link
G Mmp8 matrix metallopeptidase 8 decreases expression ISO Aluminum Oxide results in decreased expression of MMP8 mRNA CTD PMID:19464052 NCBI chr 8:5,768,808...5,777,741
Ensembl chr 8:5,768,811...5,778,702
JBrowse link
G Mmp9 matrix metallopeptidase 9 increases expression ISO Aluminum Oxide results in increased expression of MMP9 mRNA CTD PMID:16488289 NCBI chr 3:161,413,410...161,421,473
Ensembl chr 3:161,413,298...161,421,520
JBrowse link
G Mpo myeloperoxidase multiple interactions ISO [Nanotubes, Carbon co-treated with Aluminum Oxide] results in increased secretion of MPO protein CTD PMID:25598225 NCBI chr10:75,087,892...75,098,260
Ensembl chr10:75,087,892...75,098,260
JBrowse link
G Pdgfa platelet derived growth factor subunit A increases expression ISO Aluminum Oxide results in increased expression of PDGFA mRNA CTD PMID:19464052 NCBI chr12:17,734,141...17,756,186
Ensembl chr12:17,734,133...17,755,285
JBrowse link
G Phex phosphate regulating endopeptidase homolog, X-linked increases expression ISO Aluminum Oxide results in increased expression of PHEX mRNA CTD PMID:19464052 NCBI chr  X:40,460,047...40,717,982
Ensembl chr  X:40,460,047...40,717,982
JBrowse link
G Ptk2 protein tyrosine kinase 2 multiple interactions ISO [Aluminum Oxide co-treated with Magnesium] results in increased expression of PTK2 protein CTD PMID:12209937 NCBI chr 7:114,436,419...114,611,317
Ensembl chr 7:114,437,361...114,590,119
JBrowse link
G S100a8 S100 calcium binding protein A8 multiple interactions ISO [Nanotubes, Carbon co-treated with Aluminum Oxide] results in increased secretion of S100A8 protein CTD PMID:25598225 NCBI chr 2:190,073,239...190,074,333
Ensembl chr 2:190,073,815...190,074,354
JBrowse link
G S100a9 S100 calcium binding protein A9 multiple interactions ISO [Nanotubes, Carbon co-treated with Aluminum Oxide] results in increased secretion of S100A9 protein CTD PMID:25598225 NCBI chr 2:190,097,436...190,100,209
Ensembl chr 2:190,097,554...190,100,276
JBrowse link
G Scarb1 scavenger receptor class B, member 1 decreases expression ISO Aluminum Oxide results in decreased expression of SCARB1 mRNA CTD PMID:19464052 NCBI chr12:36,694,952...36,761,445
Ensembl chr12:36,694,960...36,761,455
JBrowse link
G Sele selectin E increases expression ISO Aluminum Oxide results in increased expression of SELE protein CTD PMID:18456438 NCBI chr13:82,355,234...82,365,323
Ensembl chr13:82,355,471...82,365,341
JBrowse link
G Serpinh1 serpin family H member 1 increases expression ISO Aluminum Oxide results in increased expression of SERPINH1 mRNA CTD PMID:19464052 NCBI chr 1:164,301,010...164,308,306
Ensembl chr 1:164,301,010...164,308,317
JBrowse link
G Shc1 SHC adaptor protein 1 multiple interactions ISO [Aluminum Oxide co-treated with Magnesium] results in increased expression of SHC1 protein; [Aluminum Oxide co-treated with Magnesium] results in increased expression of SHC1 protein alternative form CTD PMID:12209937 NCBI chr 2:188,745,503...188,757,066
Ensembl chr 2:188,745,503...188,757,066
JBrowse link
G Sp7 Sp7 transcription factor increases expression ISO Aluminum Oxide results in increased expression of SP7 mRNA CTD PMID:19464052 NCBI chr 7:143,957,316...143,967,488
Ensembl chr 7:143,958,858...143,967,484
JBrowse link
G Spp1 secreted phosphoprotein 1 increases expression
multiple interactions
decreases secretion
ISO Aluminum Oxide results in increased expression of SPP1 mRNA
[Aluminum Oxide co-treated with Nanotubes, Carbon] results in increased secretion of SPP1 protein; Aluminum Oxide inhibits the reaction [Nanotubes, Carbon results in increased expression of SPP1 mRNA]; Aluminum Oxide inhibits the reaction [Nanotubes, Carbon results in increased secretion of SPP1 protein]
Aluminum Oxide results in decreased secretion of SPP1 protein
[Aluminum Oxide co-treated with Nanotubes, Carbon] inhibits the reaction [Lipopolysaccharides results in increased secretion of SPP1 protein]; Aluminum Oxide inhibits the reaction [Lipopolysaccharides results in increased secretion of SPP1 protein]; Aluminum Oxide inhibits the reaction [Nanotubes, Carbon results in increased secretion of SPP1 protein]
CTD PMID:19464052, PMID:25216247 NCBI chr14:6,673,686...6,679,965
Ensembl chr14:6,673,686...6,679,901
JBrowse link
G Stath statherin increases expression ISO Aluminum Oxide results in increased expression of STATH mRNA CTD PMID:19464052 NCBI chr14:21,957,013...21,960,871
Ensembl chr14:21,957,013...21,960,871
JBrowse link
G Tgfb1 transforming growth factor, beta 1 increases expression ISO Aluminum Oxide results in increased expression of TGFB1 mRNA CTD PMID:19464052 NCBI chr 1:82,480,875...82,497,196
Ensembl chr 1:82,480,195...82,497,199
JBrowse link
G Tgfbr2 transforming growth factor, beta receptor 2 increases expression ISO Aluminum Oxide results in increased expression of TGFBR2 mRNA CTD PMID:19464052 NCBI chr 8:124,310,288...124,399,345
Ensembl chr 8:124,312,754...124,399,494
JBrowse link
G Tnf tumor necrosis factor increases activity
multiple interactions
affects secretion
increases expression
EXP
ISO
Aluminum Oxide results in increased activity of TNF protein
[Aluminum Oxide co-treated with Nanotubes, Carbon] results in increased expression of TNF mRNA
Aluminum Oxide inhibits the reaction [Nanotubes, Carbon results in increased secretion of TNF protein]
Aluminum Oxide affects the secretion of TNF protein
Aluminum Oxide results in increased expression of TNF mRNA
CTD PMID:10413987, PMID:11306444, PMID:15183442, PMID:16488289, PMID:25216247 NCBI chr20:5,189,382...5,192,000
Ensembl chr20:5,189,390...5,192,000
JBrowse link
G Tnfsf10 TNF superfamily member 10 increases expression ISO Aluminum Oxide analog results in increased expression of TNFSF10 mRNA CTD PMID:23132795 NCBI chr 2:113,008,008...113,026,899
Ensembl chr 2:113,007,549...113,026,899
JBrowse link
G Tp53 tumor protein p53 increases expression ISO Aluminum Oxide analog results in increased expression of TP53 mRNA CTD PMID:23132795 NCBI chr10:56,186,299...56,198,449
Ensembl chr10:56,187,020...56,198,449
JBrowse link
G Vcam1 vascular cell adhesion molecule 1 increases expression ISO Aluminum Oxide results in increased expression of VCAM1 mRNA; Aluminum Oxide results in increased expression of VCAM1 protein CTD PMID:18456438, PMID:19464052 NCBI chr 2:219,071,193...219,090,931
Ensembl chr 2:219,071,193...219,097,619
JBrowse link
G Vegfa vascular endothelial growth factor A increases expression ISO Aluminum Oxide results in increased expression of VEGFA mRNA CTD PMID:19464052 NCBI chr 9:17,340,341...17,355,681
Ensembl chr 9:17,340,341...17,355,681
JBrowse link
G Vegfb vascular endothelial growth factor B increases expression ISO Aluminum Oxide results in increased expression of VEGFB mRNA CTD PMID:19464052 NCBI chr 1:222,237,000...222,242,786
Ensembl chr 1:222,239,022...222,242,644
JBrowse link
aluminium phosphide term browser
Symbol Object Name Qualifiers Evidence Notes Source PubMed Reference(s) RGD Reference(s) Position
G Cat catalase decreases expression
decreases activity
EXP aluminum phosphide results in decreased expression of CAT protein
aluminum phosphide results in decreased activity of CAT protein
CTD PMID:11742581, PMID:23041170 NCBI chr 3:93,379,872...93,412,058
Ensembl chr 3:93,379,874...93,412,058
JBrowse link
G G6pc1 glucose-6-phosphatase catalytic subunit 1 increases activity EXP aluminum phosphide results in increased activity of G6PC protein CTD PMID:20929055 NCBI chr10:89,286,009...89,296,213
Ensembl chr10:89,285,855...89,296,213
JBrowse link
G G6pd glucose-6-phosphate dehydrogenase decreases activity EXP aluminum phosphide results in decreased activity of G6PD protein CTD PMID:20929055 NCBI chr  X:156,274,800...156,293,935
Ensembl chr  X:156,274,800...156,293,926
JBrowse link
G Pfkl phosphofructokinase, liver type decreases activity EXP aluminum phosphide results in decreased activity of PFKL protein CTD PMID:20929055 NCBI chr20:11,393,860...11,415,889
Ensembl chr20:11,393,877...11,415,882
JBrowse link
G Pygl glycogen phosphorylase L increases activity EXP aluminum phosphide results in increased activity of PYGL protein CTD PMID:20929055 NCBI chr 6:92,597,759...92,643,734
Ensembl chr 6:92,597,706...92,643,847
JBrowse link
G Ren renin increases activity ISO aluminum phosphide results in increased activity of REN protein CTD PMID:2200784 NCBI chr13:50,502,724...50,513,953
Ensembl chr13:50,502,724...50,514,151
JBrowse link
aluminium sulfate (anhydrous) term browser
Symbol Object Name Qualifiers Evidence Notes Source PubMed Reference(s) RGD Reference(s) Position
G Adam9 ADAM metallopeptidase domain 9 decreases expression ISO aluminum sulfate results in decreased expression of ADAM9 mRNA CTD PMID:15961160 NCBI chr16:71,810,377...71,887,926
Ensembl chr16:71,810,377...71,887,926
JBrowse link
G App amyloid beta precursor protein affects expression
increases expression
ISO aluminum sulfate affects the expression of APP protein
aluminum sulfate results in increased expression of APP mRNA
CTD PMID:10721010, PMID:15961160 NCBI chr11:24,425,013...24,641,872
Ensembl chr11:24,425,005...24,641,858
JBrowse link
G Casp1 caspase 1 multiple interactions ISO [Lipopolysaccharides co-treated with aluminum sulfate] results in increased activity of CASP1 protein; CASP1 protein promotes the reaction [[Lipopolysaccharides co-treated with aluminum sulfate] results in increased secretion of IL1B protein]; leptomycin B inhibits the reaction [[Lipopolysaccharides co-treated with aluminum sulfate] results in increased activity of CASP1 protein] CTD PMID:23430110, PMID:24158569 NCBI chr 8:2,605,743...2,614,637
Ensembl chr 8:2,604,962...2,614,631
JBrowse link
G Ctsb cathepsin B increases expression ISO aluminum sulfate results in increased expression of CTSB protein CTD PMID:24158569 NCBI chr15:46,316,741...46,337,613
Ensembl chr15:46,316,741...46,337,612
JBrowse link
G Daxx death-domain associated protein increases expression ISO aluminum sulfate results in increased expression of DAXX mRNA CTD PMID:15961160 NCBI chr20:5,480,103...5,485,962
Ensembl chr20:5,480,103...5,485,926
JBrowse link
G Gata2 GATA binding protein 2 decreases expression ISO aluminum sulfate results in decreased expression of GATA2 mRNA CTD PMID:15961160 NCBI chr 4:120,129,028...120,142,490
Ensembl chr 4:120,133,713...120,142,488
JBrowse link
G Gtf2h1 general transcription factor IIH subunit 1 decreases expression ISO aluminum sulfate results in decreased expression of GTF2H1 mRNA CTD PMID:15961160 NCBI chr 1:102,849,618...102,877,939
Ensembl chr 1:102,849,889...102,877,944
JBrowse link
G Igf1 insulin-like growth factor 1 increases secretion ISO aluminum sulfate results in increased secretion of IGF1 protein CTD PMID:7685579 NCBI chr 7:28,412,123...28,491,815
Ensembl chr 7:28,412,198...28,486,609
JBrowse link
G Igf2 insulin-like growth factor 2 increases secretion ISO aluminum sulfate results in increased secretion of IGF2 mRNA; aluminum sulfate results in increased secretion of IGF2 protein CTD PMID:7685579 NCBI chr 1:215,828,102...215,839,081
Ensembl chr 1:215,828,102...215,846,911
JBrowse link
G Igfbp3 insulin-like growth factor binding protein 3 decreases secretion ISO aluminum sulfate results in decreased secretion of IGFBP3 protein CTD PMID:7685579 NCBI chr14:87,457,647...87,465,374
Ensembl chr14:87,457,647...87,465,374
JBrowse link
G Igfbp4 insulin-like growth factor binding protein 4 decreases secretion ISO aluminum sulfate results in decreased secretion of IGFBP4 protein CTD PMID:7685579 NCBI chr10:86,950,555...86,962,563
Ensembl chr10:86,950,557...86,962,578
JBrowse link
G Il18 interleukin 18 increases expression ISO aluminum sulfate results in increased expression of IL18 protein CTD PMID:16100009 NCBI chr 8:55,009,666...55,016,286
Ensembl chr 8:54,993,859...55,016,299
JBrowse link
G Il1b interleukin 1 beta increases expression
multiple interactions
ISO aluminum sulfate results in increased expression of IL1B mRNA
[Tetradecanoylphorbol Acetate co-treated with aluminum sulfate] results in increased secretion of IL1B protein; bafilomycin A1 inhibits the reaction [[Tetradecanoylphorbol Acetate co-treated with aluminum sulfate] results in increased secretion of IL1B protein]; Cytochalasin D inhibits the reaction [[Tetradecanoylphorbol Acetate co-treated with aluminum sulfate] results in increased secretion of IL1B protein]; Sodium inhibits the reaction [[Tetradecanoylphorbol Acetate co-treated with aluminum sulfate] results in increased secretion of IL1B protein]
1,2-bis(2-aminophenoxy)ethane N,N,N',N'-tetraacetic acid acetoxymethyl ester inhibits the reaction [[Lipopolysaccharides co-treated with aluminum sulfate] results in increased secretion of IL1B protein]; [Lipopolysaccharides co-treated with aluminum sulfate] results in increased expression of and results in increased activity of and results in increased secretion of IL1B protein; [Lipopolysaccharides co-treated with aluminum sulfate] results in increased secretion of IL1B protein; CASP1 protein promotes the reaction [[Lipopolysaccharides co-treated with aluminum sulfate] results in increased secretion of IL1B protein]; leptomycin B inhibits the reaction [[Lipopolysaccharides co-treated with aluminum sulfate] results in increased expression of IL1B protein]; NLRP3 protein promotes the reaction [[Lipopolysaccharides co-treated with aluminum sulfate] results in increased secretion of IL1B protein]; PYCARD protein promotes the reaction [[Lipopolysaccharides co-treated with aluminum sulfate] results in increased secretion of IL1B protein]
CTD PMID:15961160, PMID:23430110, PMID:24158569 NCBI chr 3:121,876,256...121,882,637
Ensembl chr 3:121,876,263...121,882,726
JBrowse link
G Map2 microtubule-associated protein 2 multiple interactions EXP aluminum sulfate inhibits the reaction [Excitatory Amino Acid Agents results in increased metabolism of MAP2 protein] CTD PMID:10428068 NCBI chr 9:73,204,753...73,462,965
Ensembl chr 9:73,319,710...73,462,972
JBrowse link
G Mapt microtubule-associated protein tau increases phosphorylation EXP aluminum sulfate results in increased phosphorylation of MAPT protein CTD PMID:11388372 NCBI chr10:92,289,002...92,386,517
Ensembl chr10:92,288,910...92,386,517
JBrowse link
G Mir146a microRNA 146a multiple interactions ISO [ferrous sulfate co-treated with aluminum sulfate] results in increased expression of MIR146A mRNA; Curcumin inhibits the reaction [[ferrous sulfate co-treated with aluminum sulfate] results in increased expression of MIR146A mRNA]; pyrrolidine dithiocarbamic acid inhibits the reaction [[ferrous sulfate co-treated with aluminum sulfate] results in increased expression of MIR146A mRNA]; resveratrol analog inhibits the reaction [[ferrous sulfate co-treated with aluminum sulfate] results in increased expression of MIR146A mRNA] CTD PMID:22099153 NCBI chr10:28,962,476...28,962,570
Ensembl chr10:28,962,476...28,962,570
JBrowse link
G Mtf1 metal-regulatory transcription factor 1 decreases expression ISO aluminum sulfate results in decreased expression of MTF1 mRNA CTD PMID:15961160 NCBI chr 5:142,797,340...142,843,896
Ensembl chr 5:142,797,366...142,842,122
JBrowse link
G Nefl neurofilament light decreases expression ISO aluminum sulfate results in decreased expression of NEFL mRNA CTD PMID:15961160 NCBI chr15:44,799,378...44,803,251
Ensembl chr15:44,799,334...44,804,574
JBrowse link
G Nfkb1 nuclear factor kappa B subunit 1 increases expression
multiple interactions
ISO aluminum sulfate results in increased expression of NFKB1 mRNA
[ferrous sulfate co-treated with aluminum sulfate] results in increased expression of and results in increased activity of [RELA protein binds to NFKB1 protein]
CTD PMID:15961160, PMID:22099153 NCBI chr 2:240,773,520...240,890,053
Ensembl chr 2:240,773,456...240,866,689
JBrowse link
G Nlrp3 NLR family, pyrin domain containing 3 multiple interactions ISO NLRP3 protein promotes the reaction [[Lipopolysaccharides co-treated with aluminum sulfate] results in increased secretion of IL1B protein] CTD PMID:24158569 NCBI chr10:45,884,324...45,918,290
Ensembl chr10:45,893,018...45,918,254
JBrowse link
G Nos1 nitric oxide synthase 1 decreases expression EXP aluminum sulfate results in decreased expression of NOS1 protein CTD PMID:10428068 NCBI chr12:44,214,949...44,405,530
Ensembl chr12:44,213,943...44,520,341
JBrowse link
G P2rx1 purinergic receptor P2X 1 decreases expression ISO aluminum sulfate results in decreased expression of P2RX1 mRNA CTD PMID:15961160 NCBI chr10:59,566,268...59,581,328
Ensembl chr10:59,566,223...59,581,325
JBrowse link
G Pla2g4a phospholipase A2 group IVA increases expression ISO aluminum sulfate results in increased expression of PLA2G4A mRNA CTD PMID:15961160 NCBI chr13:67,062,252...67,206,688
Ensembl chr13:66,988,937...67,206,693
JBrowse link
G Pml PML nuclear body scaffold multiple interactions ISO [Lipopolysaccharides co-treated with aluminum sulfate] results in increased expression of PML protein CTD PMID:23430110 NCBI chr 8:63,002,515...63,034,310
Ensembl chr 8:63,004,870...63,034,226
JBrowse link
G Ptgs2 prostaglandin-endoperoxide synthase 2 increases expression ISO aluminum sulfate results in increased expression of PTGS2 mRNA CTD PMID:15961160 NCBI chr13:67,351,230...67,356,920
Ensembl chr13:67,351,087...67,359,335
JBrowse link
G Pycard PYD and CARD domain containing multiple interactions ISO PYCARD protein promotes the reaction [[Lipopolysaccharides co-treated with aluminum sulfate] results in increased secretion of IL1B protein] CTD PMID:24158569 NCBI chr 1:199,438,029...199,439,062
Ensembl chr 1:199,437,832...199,439,210
JBrowse link
G Rela RELA proto-oncogene, NF-kB subunit multiple interactions ISO [ferrous sulfate co-treated with aluminum sulfate] results in increased expression of and results in increased activity of [RELA protein binds to NFKB1 protein] CTD PMID:22099153 NCBI chr 1:220,992,770...221,003,249
Ensembl chr 1:220,992,770...221,003,249
JBrowse link
G Robo2 roundabout guidance receptor 2 decreases expression ISO aluminum sulfate results in decreased expression of ROBO2 mRNA CTD PMID:15961160 NCBI chr11:11,062,866...12,618,793
Ensembl chr11:11,062,790...11,585,765
JBrowse link
G Syn1 synapsin I decreases expression ISO aluminum sulfate results in decreased expression of SYN1 mRNA CTD PMID:15961160 NCBI chr  X:1,321,315...1,379,202
Ensembl chr  X:1,321,315...1,379,198
JBrowse link
G Syp synaptophysin decreases expression ISO aluminum sulfate results in decreased expression of SYP mRNA CTD PMID:15961160 NCBI chr  X:15,694,699...15,709,244
Ensembl chr  X:15,695,566...15,707,436
JBrowse link
aluminium trifluoride term browser
Symbol Object Name Qualifiers Evidence Notes Source PubMed Reference(s) RGD Reference(s) Position
G Arf6 ADP-ribosylation factor 6 increases activity ISO aluminum fluoride results in increased activity of ARF6 protein CTD PMID:16280360 NCBI chr 6:91,697,109...91,698,257
Ensembl chr 6:91,697,109...91,698,255
JBrowse link
G Cd3e CD3e molecule increases phosphorylation
multiple interactions
ISO aluminum fluoride results in increased phosphorylation of CD3E protein
Tetradecanoylphorbol Acetate inhibits the reaction [aluminum fluoride results in increased phosphorylation of CD3E protein]
CTD PMID:2824607 NCBI chr 8:49,297,604...49,309,370
Ensembl chr 8:49,297,608...49,308,806
JBrowse link
G Cd3g CD3g molecule multiple interactions
increases phosphorylation
ISO Tetradecanoylphorbol Acetate inhibits the reaction [aluminum fluoride results in increased phosphorylation of CD3G protein] CTD PMID:2824607 NCBI chr 8:49,274,553...49,280,943
Ensembl chr 8:49,274,960...49,280,901
JBrowse link
G Cd79a CD79a molecule increases phosphorylation ISO aluminum fluoride results in increased phosphorylation of CD79A protein CTD PMID:8559152 NCBI chr 1:81,763,609...81,768,039
Ensembl chr 1:81,763,614...81,767,980
JBrowse link
G Cd79b CD79b molecule increases phosphorylation ISO aluminum fluoride results in increased phosphorylation of CD79B protein CTD PMID:8559152 NCBI chr10:94,497,445...94,500,591
Ensembl chr10:94,497,448...94,500,591
JBrowse link
G Herc1 HECT and RLD domain containing E3 ubiquitin protein ligase family member 1 affects localization ISO aluminum fluoride affects the localization of HERC1 protein CTD PMID:14960311 NCBI chr 8:72,029,550...72,198,363
Ensembl chr 8:72,029,489...72,198,358
JBrowse link
G Igf2 insulin-like growth factor 2 increases expression ISO aluminum fluoride results in increased expression of IGF2 mRNA; aluminum fluoride results in increased expression of IGF2 protein CTD PMID:11996908 NCBI chr 1:215,828,102...215,839,081
Ensembl chr 1:215,828,102...215,846,911
JBrowse link
G Igfbp4 insulin-like growth factor binding protein 4 decreases expression ISO aluminum fluoride results in decreased expression of IGFBP4 mRNA; aluminum fluoride results in decreased expression of IGFBP4 protein CTD PMID:11996908 NCBI chr10:86,950,555...86,962,563
Ensembl chr10:86,950,557...86,962,578
JBrowse link
G Igfbp5 insulin-like growth factor binding protein 5 increases expression ISO aluminum fluoride results in increased expression of IGFBP5 mRNA; aluminum fluoride results in increased expression of IGFBP5 protein CTD PMID:11996908 NCBI chr 9:80,154,230...80,166,813
Ensembl chr 9:80,150,211...80,167,033
JBrowse link
G Lyn LYN proto-oncogene, Src family tyrosine kinase increases phosphorylation ISO aluminum fluoride results in increased phosphorylation of LYN protein CTD PMID:8559152 NCBI chr 5:16,526,058...16,642,648
Ensembl chr 5:16,526,058...16,642,648
JBrowse link
G Plcb1 phospholipase C beta 1 multiple interactions EXP PLCB1 protein promotes the reaction [aluminum fluoride results in increased abundance of Inositol Phosphates] CTD PMID:11377826 NCBI chr 3:127,721,244...128,419,565
Ensembl chr 3:128,155,069...128,419,545
JBrowse link
aluminium(0) term browser
Symbol Object Name Qualifiers Evidence Notes Source PubMed Reference(s) RGD Reference(s) Position
G Ace angiotensin I converting enzyme decreases activity ISO Aluminum results in decreased activity of ACE protein CTD PMID:12008977 NCBI chr10:94,170,766...94,213,831
Ensembl chr10:94,170,766...94,187,822
JBrowse link
G Ache acetylcholinesterase multiple interactions
decreases activity
EXP [Cadmium co-treated with Aluminum co-treated with Fluorides] results in increased activity of ACHE protein; [Cadmium co-treated with Aluminum co-treated with Fluorides] results in increased expression of ACHE mRNA; Aluminum promotes the reaction [Lead results in decreased activity of ACHE protein]; Berberine inhibits the reaction [[Cadmium co-treated with Aluminum co-treated with Fluorides] results in increased activity of ACHE protein]; Berberine inhibits the reaction [[Cadmium co-treated with Aluminum co-treated with Fluorides] results in increased expression of ACHE mRNA]; Copper inhibits the reaction [Aluminum results in decreased activity of ACHE protein]; Plant Extracts inhibits the reaction [Aluminum results in decreased activity of ACHE protein] CTD PMID:15266904, PMID:23354609, PMID:24486960, PMID:29170048 NCBI chr12:22,472,358...22,477,052
Ensembl chr12:22,472,358...22,478,753
JBrowse link
G Acly ATP citrate lyase multiple interactions ISO Aluminum results in increased expression of and results in increased activity of ACLY protein CTD PMID:17762189 NCBI chr10:88,392,248...88,442,845
Ensembl chr10:88,392,248...88,442,845
JBrowse link
G Aco1 aconitase 1 decreases activity EXP Aluminum results in decreased activity of ACO1 protein CTD PMID:10806405 NCBI chr 5:56,425,076...56,481,218
Ensembl chr 5:56,425,024...56,481,218
JBrowse link
G Aco2 aconitase 2 decreases activity
multiple interactions
ISO
EXP
Aluminum results in decreased activity of ACO2 protein
Aluminum results in decreased expression of and results in decreased activity of ACO2 protein
Aluminum promotes the reaction [Nitroprusside results in decreased activity of ACO2 protein]
CTD PMID:12470706, PMID:16906525, PMID:19010380 NCBI chr 7:123,102,493...123,145,608
Ensembl chr 7:123,102,468...123,145,635
JBrowse link
G Alb albumin affects binding ISO ALB protein binds to Aluminum CTD PMID:14507469 NCBI chr14:19,176,275...19,191,793
Ensembl chr14:19,176,277...19,191,863
JBrowse link
G Alox5 arachidonate 5-lipoxygenase multiple interactions
increases expression
EXP caffeic acid inhibits the reaction [Aluminum results in increased expression of ALOX5 mRNA]; caffeic acid inhibits the reaction [Aluminum results in increased expression of ALOX5 protein]
Aluminum results in increased expression of ALOX5 mRNA; Aluminum results in increased expression of ALOX5 protein
CTD PMID:27368151 NCBI chr 4:148,398,004...148,446,308
Ensembl chr 4:148,398,892...148,446,303
JBrowse link
G Apob apolipoprotein B increases expression ISO Aluminum results in increased expression of APOB protein CTD PMID:17762189 NCBI chr 6:33,176,826...33,216,381
Ensembl chr 6:33,176,778...33,224,997
JBrowse link
G App amyloid beta precursor protein affects binding
multiple interactions
increases expression
increases cleavage
ISO
EXP
APP protein binds to Aluminum
[Cadmium co-treated with Aluminum co-treated with Fluorides] results in increased expression of APP mRNA; Berberine inhibits the reaction [[Cadmium co-treated with Aluminum co-treated with Fluorides] results in increased expression of APP mRNA]
[APP protein modified form binds to Aluminum] which results in increased expression of RCVRN mRNA
Aluminum results in increased expression of APP mRNA
APP protein promotes the reaction [Aluminum results in decreased activity of CHAT protein]; meloxicam inhibits the reaction [Aluminum results in increased expression of APP protein]; Vitamin E inhibits the reaction [Aluminum results in increased cleavage of APP protein]
CTD PMID:12039845, PMID:16308480, PMID:16724269, PMID:16928369, PMID:16942756, PMID:21298039, PMID:29170048 NCBI chr11:24,425,013...24,641,872
Ensembl chr11:24,425,005...24,641,858
JBrowse link
G Atxn3 ataxin 3 affects folding
multiple interactions
ISO Aluminum affects the folding of ATXN3 protein polymorphism
Aluminum promotes the reaction [ATXN3 protein polymorphism binds to ATXN3 protein polymorphism]
CTD PMID:17300980 NCBI chr 6:125,817,420...125,853,461
Ensembl chr 6:125,819,640...125,853,461
JBrowse link
G Bax BCL2 associated X, apoptosis regulator affects response to substance
multiple interactions
EXP
ISO
BAX protein affects the susceptibility to Aluminum
[aluminum chlorhydrate results in increased abundance of Aluminum] which affects the expression of BAX protein
CTD PMID:20385067, PMID:31945389 NCBI chr 1:101,451,801...101,457,207
Ensembl chr 1:101,451,802...101,457,207
JBrowse link
G Bbox1 gamma-butyrobetaine hydroxylase 1 multiple interactions
decreases expression
ISO Aluminum inhibits the reaction [BBOX1 protein results in increased chemical synthesis of Carnitine]; Ketoglutaric Acids inhibits the reaction [Aluminum inhibits the reaction [BBOX1 protein results in increased chemical synthesis of Carnitine]]
Aluminum results in decreased expression of BBOX1 protein
CTD PMID:21439360 NCBI chr 3:101,425,684...101,474,848
Ensembl chr 3:101,427,055...101,474,890
JBrowse link
G Bcl2 BCL2, apoptosis regulator multiple interactions ISO [aluminum chlorhydrate results in increased abundance of Aluminum] which results in decreased expression of BCL2 protein; Fulvestrant inhibits the reaction [[aluminum chlorhydrate results in increased abundance of Aluminum] which results in decreased expression of BCL2 protein] CTD PMID:31945389 NCBI chr13:26,605,426...26,769,374
Ensembl chr13:26,605,426...26,769,374
JBrowse link
G Bcl2l1 Bcl2-like 1 multiple interactions ISO [aluminum chlorhydrate results in increased abundance of Aluminum] which results in decreased expression of BCL2L1 protein CTD PMID:31945389 NCBI chr 3:148,259,594...148,314,191
Ensembl chr 3:148,259,596...148,313,810
JBrowse link
G Bglap bone gamma-carboxyglutamate protein multiple interactions
decreases secretion
EXP Aluminum inhibits the reaction [Calcitriol results in increased secretion of BGLAP protein]; Calcitriol inhibits the reaction [Aluminum results in decreased secretion of BGLAP protein] CTD PMID:9626627 NCBI chr 2:187,741,770...187,748,445
Ensembl chr 2:187,741,770...187,742,747
JBrowse link
G Casp12 caspase 12 multiple interactions ISO [aluminum chloride results in increased abundance of Aluminum] which results in increased expression of CASP12 mRNA CTD PMID:29635646 NCBI chr 8:2,658,892...2,686,160
Ensembl chr 8:2,659,865...2,686,160
JBrowse link
G Casp3 caspase 3 increases expression ISO Aluminum results in increased expression of CASP3 CTD PMID:21972528 NCBI chr16:48,845,011...48,863,249
Ensembl chr16:48,845,012...48,863,204
JBrowse link
G Casp9 caspase 9 multiple interactions ISO [aluminum chlorhydrate results in increased abundance of Aluminum] which results in decreased expression of CASP9 protein; Fulvestrant inhibits the reaction [[aluminum chlorhydrate results in increased abundance of Aluminum] which results in decreased expression of CASP9 protein] CTD PMID:31945389 NCBI chr 5:160,356,211...160,373,774
Ensembl chr 5:160,355,833...160,373,778
JBrowse link
G Casr calcium-sensing receptor multiple interactions EXP [Aluminum binds to and results in increased activity of CASR protein] which results in increased abundance of Calcium; [Aluminum binds to and results in increased activity of CASR protein] which results in increased abundance of Inositol Phosphates; Aluminum binds to and results in increased activity of CASR protein CTD PMID:10231437 NCBI chr11:67,188,204...67,262,261
Ensembl chr11:67,188,630...67,258,771
JBrowse link
G Cat catalase decreases activity
multiple interactions
ISO
EXP
Aluminum results in decreased activity of CAT protein
CAT protein results in decreased susceptibility to [Tyramine co-treated with Aluminum]; Plant Extracts inhibits the reaction [Aluminum results in decreased activity of CAT protein]
Vitamin E inhibits the reaction [Aluminum results in decreased activity of CAT protein]
CTD PMID:15526171, PMID:17709913, PMID:24486960 NCBI chr 3:93,379,872...93,412,058
Ensembl chr 3:93,379,874...93,412,058
JBrowse link
G Cdh1 cadherin 1 multiple interactions ISO 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide inhibits the reaction [[Aluminum Chloride results in increased abundance of Aluminum] which results in decreased expression of CDH1 protein]; [Aluminum Chloride results in increased abundance of Aluminum] which results in decreased expression of CDH1 mRNA; [Aluminum Chloride results in increased abundance of Aluminum] which results in decreased expression of CDH1 protein CTD PMID:32437896 NCBI chr19:38,768,467...38,838,395
Ensembl chr19:38,768,467...38,838,395
JBrowse link
G Chat choline O-acetyltransferase decreases expression
multiple interactions
decreases activity
ISO Aluminum results in decreased expression of CHAT protein
APP protein promotes the reaction [Aluminum results in decreased activity of CHAT protein]; meloxicam inhibits the reaction [Aluminum results in decreased expression of CHAT protein]
CTD PMID:16724269, PMID:16928369 NCBI chr16:8,576,858...8,686,131
Ensembl chr16:8,577,840...8,686,131
JBrowse link
G Crp C-reactive protein multiple interactions ISO [Zinc co-treated with Aluminum] results in increased expression of CRP protein; [Zinc co-treated with Copper co-treated with Aluminum] results in increased expression of CRP protein CTD PMID:27816692 NCBI chr13:91,080,448...91,081,358
Ensembl chr13:91,054,974...91,093,713
JBrowse link
G Daxx death-domain associated protein increases expression ISO Aluminum results in increased expression of DAXX mRNA CTD PMID:16308480 NCBI chr20:5,480,103...5,485,962
Ensembl chr20:5,480,103...5,485,926
JBrowse link
G Drd1 dopamine receptor D1 multiple interactions EXP Aluminum inhibits the reaction [SCH 23390 binds to DRD1 protein] CTD PMID:9109525 NCBI chr17:11,099,736...11,104,352
Ensembl chr17:11,101,306...11,103,541
JBrowse link
G Drd2 dopamine receptor D2 multiple interactions EXP Aluminum inhibits the reaction [3-N-methylspiperone binds to DRD2 protein] CTD PMID:9109525 NCBI chr 8:53,678,777...53,743,643
Ensembl chr 8:53,678,777...53,743,642
JBrowse link
G Eno2 enolase 2 decreases activity ISO Aluminum results in decreased activity of ENO2 protein CTD PMID:11860913 NCBI chr 4:157,285,192...157,294,090
Ensembl chr 4:157,285,179...157,294,047
JBrowse link
G Epor erythropoietin receptor affects expression ISO Aluminum affects the expression of EPOR protein CTD PMID:15777837 NCBI chr 8:22,969,737...22,974,468
Ensembl chr 8:22,969,745...22,974,321
JBrowse link
G Esr1 estrogen receptor 1 multiple interactions ISO [aluminum chlorhydrate results in increased abundance of Aluminum] inhibits the reaction [Estradiol results in increased phosphorylation of ESR1 protein]; [aluminum chlorhydrate results in increased abundance of Aluminum] inhibits the reaction [NRG1 protein results in increased phosphorylation of ESR1 protein]; [aluminum chlorhydrate results in increased abundance of Aluminum] which results in increased expression of ESR1 protein; [Estradiol co-treated with [aluminum chlorhydrate results in increased abundance of Aluminum]] results in increased expression of ESR1 protein CTD PMID:31945389 NCBI chr 1:41,192,029...41,594,799
Ensembl chr 1:41,192,824...41,594,796
JBrowse link
G Esr2 estrogen receptor 2 multiple interactions ISO [[aluminum chlorhydrate results in increased abundance of Aluminum] co-treated with [Tretinoin co-treated with Estradiol]] affects the localization of ESR2 protein; [[aluminum chlorhydrate results in increased abundance of Aluminum] which co-treated with Tretinoin] results in decreased expression of and affects the localization of ESR2 protein; [aluminum chlorhydrate results in increased abundance of Aluminum] which results in decreased expression of and affects the localization of ESR2 protein; [Estradiol co-treated with [aluminum chlorhydrate results in increased abundance of Aluminum]] results in decreased expression of ESR2 protein CTD PMID:31945389 NCBI chr 6:99,163,953...99,214,711
Ensembl chr 6:99,164,357...99,214,251
JBrowse link
G F8 coagulation factor VIII affects folding
multiple interactions
ISO Aluminum affects the folding of F8 protein
[Aluminum promotes the reaction [F8 protein binds to F8 protein]] which results in decreased activity of F8 protein
CTD PMID:15349964 NCBI chr18:367,862...399,242
Ensembl chr18:367,862...399,242
JBrowse link
G Fh fumarate hydratase multiple interactions ISO Aluminum results in decreased expression of and results in decreased activity of FH protein CTD PMID:16906525 NCBI chr13:93,651,486...93,677,371
Ensembl chr13:93,651,484...93,677,377
JBrowse link
G Fos Fos proto-oncogene, AP-1 transcription factor subunit multiple interactions ISO [Aluminum co-treated with Copper] inhibits the reaction [lipopolysaccharide, Escherichia coli O111 B4 affects the localization of FOS protein] CTD PMID:23690655 NCBI chr 6:109,300,433...109,303,299
Ensembl chr 6:109,300,433...109,303,299
JBrowse link
G G6pd glucose-6-phosphate dehydrogenase increases activity ISO
EXP
Aluminum results in increased activity of G6PD protein CTD PMID:16572710, PMID:16979867 NCBI chr  X:156,274,800...156,293,935
Ensembl chr  X:156,274,800...156,293,926
JBrowse link
G Gfap glial fibrillary acidic protein increases expression
multiple interactions
EXP
ISO
Aluminum results in increased expression of GFAP protein
[Aluminum Chloride results in increased abundance of Aluminum] which results in increased expression of GFAP protein
Vitamin E inhibits the reaction [Aluminum results in increased expression of GFAP protein]
CTD PMID:16545059, PMID:31363819 NCBI chr10:90,990,762...90,999,435
Ensembl chr10:90,990,762...90,999,506
JBrowse link
G Gnai1 G protein subunit alpha i1 decreases expression EXP Aluminum results in decreased expression of GNAI1 protein CTD PMID:9626627 NCBI chr 4:13,405,136...13,486,866
Ensembl chr 4:13,405,136...13,485,883
JBrowse link
G Gnai2 G protein subunit alpha i2 decreases expression EXP Aluminum results in decreased expression of GNAI2 protein CTD PMID:9626627 NCBI chr 8:116,370,730...116,391,337
Ensembl chr 8:116,370,744...116,391,307
JBrowse link
G Gnaq G protein subunit alpha q increases response to substance ISO GNAQ protein results in increased susceptibility to Aluminum CTD PMID:15068510 NCBI chr 1:233,382,778...233,622,584
Ensembl chr 1:233,382,708...233,622,786
JBrowse link
G Gpd1 glycerol-3-phosphate dehydrogenase 1 multiple interactions ISO Aluminum results in increased expression of and results in increased activity of GPD1 protein CTD PMID:17762189 NCBI chr 7:141,368,928...141,377,931
Ensembl chr 7:141,370,491...141,377,928
JBrowse link
G Gpx1 glutathione peroxidase 1 decreases activity
multiple interactions
ISO Aluminum results in decreased activity of GPX1 protein
Vitamin E inhibits the reaction [Aluminum results in decreased activity of GPX1 protein]
CTD PMID:17709913 NCBI chr 8:117,117,430...117,118,528
Ensembl chr 8:117,117,430...117,118,522
JBrowse link
G Gsr glutathione-disulfide reductase decreases expression
multiple interactions
EXP Aluminum results in decreased expression of GSR protein
Plant Extracts inhibits the reaction [Aluminum results in decreased expression of GSR protein]
CTD PMID:24486960 NCBI chr16:62,197,617...62,239,987
Ensembl chr16:62,197,617...62,241,361
JBrowse link
G Hif1a hypoxia inducible factor 1 subunit alpha increases localization ISO Aluminum results in increased localization of HIF1A protein CTD PMID:16979867 NCBI chr 6:96,810,868...96,856,303
Ensembl chr 6:96,810,907...96,856,052
JBrowse link
G Hk1 hexokinase 1 multiple interactions
decreases activity
EXP Meclofenoxate inhibits the reaction [Aluminum results in decreased activity of HK1 protein] CTD PMID:16969689 NCBI chr20:31,911,460...31,979,780
Ensembl chr20:31,912,262...31,956,649
JBrowse link
G Idh1 isocitrate dehydrogenase (NADP(+)) 1 decreases activity EXP Aluminum results in decreased activity of IDH1 protein CTD PMID:15486972 NCBI chr 9:71,882,108...71,911,645
Ensembl chr 9:71,882,105...71,900,044
JBrowse link
G Idh2 isocitrate dehydrogenase (NADP(+)) 2 decreases activity EXP Aluminum results in decreased activity of IDH2 protein CTD PMID:15486972 NCBI chr 1:141,874,354...141,893,674
Ensembl chr 1:141,866,283...141,893,705
JBrowse link
G Ifnb1 interferon beta 1 multiple interactions ISO [Aluminum co-treated with Copper] inhibits the reaction [lipopolysaccharide, Escherichia coli O111 B4 results in increased expression of IFNB1 mRNA] CTD PMID:23690655 NCBI chr 5:106,865,192...106,865,746
Ensembl chr 5:106,865,192...106,865,746
JBrowse link
G Igf1 insulin-like growth factor 1 multiple interactions ISO Aluminum inhibits the reaction [IGF1 protein results in increased activity of MTR protein] CTD PMID:14745455 NCBI chr 7:28,412,123...28,491,815
Ensembl chr 7:28,412,198...28,486,609
JBrowse link
G Il12b interleukin 12B multiple interactions ISO [Aluminum co-treated with Copper] inhibits the reaction [lipopolysaccharide, Escherichia coli O111 B4 results in increased expression of IL12B mRNA] CTD PMID:23690655 NCBI chr10:30,034,447...30,048,774
Ensembl chr10:30,038,709...30,048,085
JBrowse link
G Il1b interleukin 1 beta multiple interactions
increases expression
EXP [Cadmium co-treated with Aluminum co-treated with Fluorides] results in increased expression of IL1B protein; Berberine inhibits the reaction [[Cadmium co-treated with Aluminum co-treated with Fluorides] results in increased expression of IL1B protein]; caffeic acid inhibits the reaction [Aluminum results in increased expression of IL1B protein]; Vitamin E inhibits the reaction [Aluminum results in increased expression of IL1B protein] CTD PMID:16545059, PMID:27368151, PMID:29170048 NCBI chr 3:121,876,256...121,882,637
Ensembl chr 3:121,876,263...121,882,726
JBrowse link
G Il4 interleukin 4 increases expression ISO Aluminum results in increased expression of IL4 mRNA CTD PMID:16630673 NCBI chr10:38,963,979...38,969,531
Ensembl chr10:38,963,979...38,969,531
JBrowse link
G Il6 interleukin 6 multiple interactions
increases expression
EXP
ISO
[Cadmium co-treated with Aluminum co-treated with Fluorides] results in increased expression of IL6 protein; Berberine inhibits the reaction [[Cadmium co-treated with Aluminum co-treated with Fluorides] results in increased expression of IL6 protein]; caffeic acid inhibits the reaction [Aluminum results in increased expression of IL6 protein]
[Zinc co-treated with Aluminum] results in increased expression of IL6 protein; [Zinc co-treated with Copper co-treated with Aluminum] results in increased expression of IL6 protein
CTD PMID:27368151, PMID:27816692, PMID:29170048 NCBI chr 4:3,043,231...3,047,807
Ensembl chr 4:3,043,231...3,047,807
JBrowse link
G Jun Jun proto-oncogene, AP-1 transcription factor subunit multiple interactions ISO [Aluminum co-treated with Copper] inhibits the reaction [lipopolysaccharide, Escherichia coli O111 B4 affects the localization of JUN protein] CTD PMID:23690655 NCBI chr 5:114,011,184...114,014,277
Ensembl chr 5:114,011,189...114,014,277
JBrowse link
G Klk1 kallikrein 1 multiple interactions ISO Aluminum binds to and results in decreased activity of KLK1 protein CTD PMID:15558947 NCBI chr 1:100,131,562...100,135,556
Ensembl chr 1:100,059,967...100,203,329
Ensembl chr 1:100,059,967...100,203,329
Ensembl chr 1:100,059,967...100,203,329
JBrowse link
G Litaf lipopolysaccharide-induced TNF factor multiple interactions ISO [Titanium co-treated with Vanadium co-treated with Aluminum] results in increased expression of LITAF mRNA CTD PMID:17408380 NCBI chr10:4,753,546...4,763,272
Ensembl chr10:4,719,713...4,763,510
JBrowse link
G LOC100360841 ribosomal protein L37-like decreases expression ISO Aluminum results in decreased expression of RPL37 mRNA; Aluminum results in decreased expression of RPL37 protein CTD PMID:27329587 NCBI chr 9:69,790,829...69,791,199
Ensembl chr 9:69,790,831...69,791,196
JBrowse link
G Lonrf2 LON peptidase N-terminal domain and ring finger 2 decreases expression EXP Aluminum results in decreased expression of LONRF2 mRNA CTD PMID:19010380 NCBI chr 9:45,468,001...45,506,448
Ensembl chr 9:45,466,688...45,505,767
JBrowse link
G Mapk3 mitogen activated protein kinase 3 multiple interactions EXP [Aluminum co-treated with Iron] results in increased phosphorylation of MAPK3 protein CTD PMID:16728372 NCBI chr 1:198,192,773...198,198,975
Ensembl chr 1:198,192,773...198,198,975
JBrowse link
G Mapt microtubule-associated protein tau increases phosphorylation
multiple interactions
EXP Aluminum results in increased phosphorylation of MAPT protein
[Cadmium co-treated with Aluminum co-treated with Fluorides] results in increased expression of MAPT mRNA; Berberine inhibits the reaction [[Cadmium co-treated with Aluminum co-treated with Fluorides] results in increased expression of MAPT mRNA]
CTD PMID:17662457, PMID:29170048 NCBI chr10:92,289,002...92,386,517
Ensembl chr10:92,288,910...92,386,517
JBrowse link
G Mir21 microRNA 21 multiple interactions ISO [Air Pollutants, Occupational results in increased abundance of Aluminum] which results in increased expression of MIR21 mRNA CTD PMID:27506416 NCBI chr10:73,902,210...73,902,301
Ensembl chr10:73,902,210...73,902,301
JBrowse link
G Mir30d microRNA 30d multiple interactions ISO [Air Pollutants, Occupational results in increased abundance of Aluminum] which results in increased expression of MIR30D mRNA CTD PMID:27506416 NCBI chr 7:109,286,463...109,286,544
Ensembl chr 7:109,286,463...109,286,544
JBrowse link
G Mir322 microRNA 322 multiple interactions ISO [Air Pollutants, Occupational results in increased abundance of Aluminum] which results in increased expression of MIR424 mRNA CTD PMID:27506416 NCBI chr  X:158,148,161...158,148,255
Ensembl chr  X:158,148,161...158,148,255
JBrowse link
G Mmp2 matrix metallopeptidase 2 increases expression EXP Aluminum results in increased expression of MMP2 protein CTD PMID:16052892 NCBI chr19:15,542,771...15,570,589
Ensembl chr19:15,542,765...15,570,611
JBrowse link
G Mmp7 matrix metallopeptidase 7 multiple interactions ISO [Aluminum Chloride results in increased abundance of Aluminum] which results in increased expression of MMP7 mRNA CTD PMID:32437896 NCBI chr 8:5,893,253...5,900,965
Ensembl chr 8:5,893,249...5,901,049
JBrowse link
G Mmp9 matrix metallopeptidase 9 increases expression
multiple interactions
EXP
ISO
Aluminum results in increased expression of MMP9 protein
[Aluminum Chloride results in increased abundance of Aluminum] which results in increased expression of MMP9 mRNA
CTD PMID:16052892, PMID:32437896 NCBI chr 3:161,413,410...161,421,473
Ensembl chr 3:161,413,298...161,421,520
JBrowse link
G Mpo myeloperoxidase increases expression ISO Aluminum results in increased expression of MPO protein CTD PMID:17402216 NCBI chr10:75,087,892...75,098,260
Ensembl chr10:75,087,892...75,098,260
JBrowse link
G Mtr 5-methyltetrahydrofolate-homocysteine methyltransferase multiple interactions ISO Aluminum inhibits the reaction [[Hydroxocobalamin co-treated with S-Adenosylmethionine] results in increased activity of MTR protein alternative form]; Aluminum inhibits the reaction [IGF1 protein results in increased activity of MTR protein]; Aluminum inhibits the reaction [mecobalamin results in increased activity of MTR protein alternative form] CTD PMID:14745455, PMID:26989453 NCBI chr17:66,210,444...66,295,014
Ensembl chr17:66,210,461...66,295,014
JBrowse link
G Nos2 nitric oxide synthase 2 multiple interactions EXP
ISO
[Aluminum co-treated with Iron] results in increased expression of NOS2 protein
[Aluminum co-treated with Copper] inhibits the reaction [lipopolysaccharide, Escherichia coli O111 B4 results in increased expression of NOS2 mRNA]
CTD PMID:16728372, PMID:23690655 NCBI chr10:66,188,290...66,221,621
Ensembl chr10:66,189,786...66,313,190
JBrowse link
G Nrg1 neuregulin 1 multiple interactions ISO [aluminum chlorhydrate results in increased abundance of Aluminum] inhibits the reaction [NRG1 protein results in increased phosphorylation of ESR1 protein] CTD PMID:31945389 NCBI chr16:62,969,573...64,065,063
Ensembl chr16:63,837,216...64,057,434
JBrowse link
G Ogdh oxoglutarate dehydrogenase multiple interactions
increases activity
ISO
EXP
Aluminum results in decreased expression of and results in decreased activity of OGDH protein
Aluminum results in increased activity of OGDH protein
CTD PMID:10806405, PMID:16906525 NCBI chr14:86,414,924...86,481,903
Ensembl chr14:86,414,949...86,613,327
JBrowse link
G Oprd1 opioid receptor, delta 1 multiple interactions EXP [Enkephalin, D-Penicillamine (2,5)- binds to and results in increased activity of OPRD1 protein] which results in decreased abundance of Aluminum CTD PMID:7477890 NCBI chr 5:150,288,126...150,323,063
Ensembl chr 5:150,288,126...150,323,063
JBrowse link
G Pck1 phosphoenolpyruvate carboxykinase 1 multiple interactions ISO [aluminum chlorhydrate results in increased abundance of Aluminum] which results in decreased expression of PCK1 protein CTD PMID:31945389 NCBI chr 3:171,213,936...171,219,885
Ensembl chr 3:171,213,936...171,219,871
JBrowse link
G Pcna proliferating cell nuclear antigen multiple interactions ISO [aluminum chloride results in increased abundance of Aluminum] which results in decreased expression of PCNA mRNA CTD PMID:29635646 NCBI chr 3:124,880,698...124,884,570
Ensembl chr 3:124,880,698...124,884,570
JBrowse link
G Pklr pyruvate kinase L/R increases activity ISO Aluminum results in increased activity of PKLR protein CTD PMID:16979867 NCBI chr 2:188,449,158...188,458,034
Ensembl chr 2:188,449,210...188,459,592
JBrowse link
G Plcd1 phospholipase C, delta 1 increases expression EXP Aluminum results in increased expression of PLCD1 protein CTD PMID:10814511 NCBI chr 8:127,753,514...127,782,070
Ensembl chr 8:127,753,539...127,782,070
JBrowse link
G Ptgs2 prostaglandin-endoperoxide synthase 2 increases expression
multiple interactions
ISO Aluminum results in increased expression of PTGS2 mRNA; Aluminum results in increased expression of PTGS2 protein
[Aluminum co-treated with Copper] inhibits the reaction [lipopolysaccharide, Escherichia coli O111 B4 results in increased expression of PTGS2 mRNA]; meloxicam inhibits the reaction [Aluminum results in increased expression of PTGS2 mRNA]; meloxicam inhibits the reaction [Aluminum results in increased expression of PTGS2 protein]
CTD PMID:16928369, PMID:23690655 NCBI chr13:67,351,230...67,356,920
Ensembl chr13:67,351,087...67,359,335
JBrowse link
G Pth parathyroid hormone multiple interactions ISO [TF protein binds to and results in increased uptake of Aluminum] which results in decreased secretion of PTH protein CTD PMID:10978387 NCBI chr 1:178,215,829...178,218,761
Ensembl chr 1:178,215,829...178,218,761
JBrowse link
G Rcvrn recoverin multiple interactions ISO [APP protein modified form binds to Aluminum] which results in increased expression of RCVRN mRNA CTD PMID:21298039 NCBI chr10:54,246,250...54,253,996
Ensembl chr10:54,246,250...54,253,996
JBrowse link
G Rela RELA proto-oncogene, NF-kB subunit multiple interactions ISO [Aluminum co-treated with Copper] inhibits the reaction [lipopolysaccharide, Escherichia coli O111 B4 affects the localization of RELA protein] CTD PMID:23690655 NCBI chr 1:220,992,770...221,003,249
Ensembl chr 1:220,992,770...221,003,249
JBrowse link
G S100b S100 calcium binding protein B increases expression
multiple interactions
EXP Aluminum results in increased expression of S100B protein
Vitamin E inhibits the reaction [Aluminum results in increased expression of S100B protein]
CTD PMID:16545059 NCBI chr20:13,130,633...13,142,856
Ensembl chr20:13,130,636...13,142,856
JBrowse link
G Scgb1a1 secretoglobin family 1A member 1 decreases expression EXP
ISO
Aluminum results in decreased expression of SCGB1A1 protein CTD PMID:16052892, PMID:16099050 NCBI chr 1:225,279,698...225,283,246
Ensembl chr 1:225,279,676...225,283,326
JBrowse link
G Slc2a1 solute carrier family 2 member 1 increases expression ISO Aluminum results in increased expression of SLC2A1 protein CTD PMID:16979867 NCBI chr 5:138,154,677...138,182,897
Ensembl chr 5:138,154,673...138,182,897
JBrowse link
G Snai1 snail family transcriptional repressor 1 multiple interactions ISO 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide inhibits the reaction [[Aluminum Chloride results in increased abundance of Aluminum] which results in increased expression of SNAI1 protein]; [Aluminum Chloride results in increased abundance of Aluminum] which results in increased expression of SNAI1 mRNA; [Aluminum Chloride results in increased abundance of Aluminum] which results in increased expression of SNAI1 protein CTD PMID:32437896 NCBI chr 3:164,274,710...164,279,199
Ensembl chr 3:164,274,710...164,279,378
JBrowse link
G Snca synuclein alpha affects response to substance ISO SNCA protein affects the susceptibility to Aluminum CTD PMID:23106139 NCBI chr 4:90,782,412...90,883,236
Ensembl chr 4:90,782,374...90,882,285
JBrowse link
G Sod2 superoxide dismutase 2 decreases activity EXP Aluminum results in decreased activity of SOD2 protein CTD PMID:19010380 NCBI chr 1:47,914,757...47,921,587
Ensembl chr 1:47,914,759...47,921,587
JBrowse link
G Tf transferrin multiple interactions
increases uptake
affects binding
ISO [Aluminum binds to TF protein] which results in decreased uptake of Iron; [Aluminum binds to TF protein] which results in decreased uptake of Manganese; [Aluminum binds to TF protein] which results in increased uptake of Aluminum; [TF protein binds to Aluminum] affects the activity of [TF protein binds to Iron]; [TF protein binds to Aluminum] which results in increased uptake of Aluminum; [TF protein binds to Aluminum] which results in increased uptake of Iron; [TF protein binds to and results in increased uptake of Aluminum] which results in decreased secretion of PTH protein; TF protein binds to [Aluminum co-treated with Iron]; TF protein binds to and results in increased uptake of Aluminum
TF protein results in increased uptake of Aluminum
Aluminum binds to TF protein; TF protein binds to Aluminum
TRF protein binds to Aluminum
CTD PMID:1375080, PMID:2039817, PMID:2308257, PMID:8782865, PMID:10978387, PMID:11193083, PMID:12627980, PMID:15149824, PMID:19859668, PMID:22873711 NCBI chr 8:111,694,570...111,721,275
Ensembl chr 8:111,673,547...111,721,333
JBrowse link
G Tfrc transferrin receptor decreases expression
affects uptake
EXP Aluminum results in decreased expression of TFRC mRNA
TFRC protein affects the uptake of Aluminum
CTD PMID:9630424, PMID:11068183 NCBI chr11:71,397,423...71,419,263
Ensembl chr11:71,397,383...71,419,223
JBrowse link
G Tgfb1 transforming growth factor, beta 1 multiple interactions ISO [Aluminum Chloride results in increased abundance of Aluminum] which results in increased expression of TGFB1 mRNA CTD PMID:32437896 NCBI chr 1:82,480,875...82,497,196
Ensembl chr 1:82,480,195...82,497,199
JBrowse link
G Tnf tumor necrosis factor increases expression
multiple interactions
EXP
ISO
Aluminum results in increased expression of TNF protein
[Aluminum co-treated with Copper] inhibits the reaction [lipopolysaccharide, Escherichia coli O111 B4 results in increased expression of TNF mRNA]
[Cadmium co-treated with Aluminum co-treated with Fluorides] results in increased expression of TNF mRNA; [Cadmium co-treated with Aluminum co-treated with Fluorides] results in increased expression of TNF protein; Berberine inhibits the reaction [[Cadmium co-treated with Aluminum co-treated with Fluorides] results in increased expression of TNF mRNA]; Berberine inhibits the reaction [[Cadmium co-treated with Aluminum co-treated with Fluorides] results in increased expression of TNF protein]; caffeic acid inhibits the reaction [Aluminum results in increased expression of TNF protein]; Vitamin E inhibits the reaction [Aluminum results in increased expression of TNF protein]
[Titanium co-treated with Vanadium co-treated with Aluminum] results in increased expression of TNF mRNA
CTD PMID:16545059, PMID:17408380, PMID:23690655, PMID:27368151, PMID:29170048 NCBI chr20:5,189,382...5,192,000
Ensembl chr20:5,189,390...5,192,000
JBrowse link
G Tubb3 tubulin, beta 3 class III multiple interactions ISO [Aluminum Chloride results in increased abundance of Aluminum] which results in decreased expression of TUBB3 protein CTD PMID:31363819 NCBI chr19:56,220,759...56,229,813
Ensembl chr19:56,220,755...56,229,813
JBrowse link
G Txn2 thioredoxin 2 multiple interactions ISO [aluminum chlorhydrate results in increased abundance of Aluminum] which results in decreased expression of TXN2 protein CTD PMID:31945389 NCBI chr 7:119,144,350...119,158,173
Ensembl chr 7:119,144,351...119,158,201
JBrowse link
G Uba52 ubiquitin A-52 residue ribosomal protein fusion product 1 decreases expression ISO Aluminum results in decreased expression of UBA52 mRNA; Aluminum results in decreased expression of UBA52 protein CTD PMID:27329587 NCBI chr16:20,668,925...20,671,127
Ensembl chr16:20,668,971...20,671,127
JBrowse link
G Vegfa vascular endothelial growth factor A multiple interactions ISO 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide inhibits the reaction [[Aluminum Chloride results in increased abundance of Aluminum] which results in increased expression of VEGFA protein]; [Aluminum Chloride results in increased abundance of Aluminum] which results in increased expression of and results in increased secretion of VEGFA protein; [Aluminum Chloride results in increased abundance of Aluminum] which results in increased secretion of VEGFA protein CTD PMID:32437896 NCBI chr 9:17,340,341...17,355,681
Ensembl chr 9:17,340,341...17,355,681
JBrowse link
G Vim vimentin multiple interactions ISO 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide inhibits the reaction [[Aluminum Chloride results in increased abundance of Aluminum] which results in increased expression of VIM protein]; [Aluminum Chloride results in increased abundance of Aluminum] which results in increased expression of VIM mRNA; [Aluminum Chloride results in increased abundance of Aluminum] which results in increased expression of VIM protein CTD PMID:32437896 NCBI chr17:80,882,715...80,891,200
Ensembl chr17:80,882,666...80,891,212
JBrowse link
G Xdh xanthine dehydrogenase increases activity EXP Aluminum results in increased activity of XDH protein CTD PMID:11787993 NCBI chr 6:25,149,570...25,211,273
Ensembl chr 6:25,149,235...25,211,494
JBrowse link
boric acid term browser
Symbol Object Name Qualifiers Evidence Notes Source PubMed Reference(s) RGD Reference(s) Position
G Ace angiotensin I converting enzyme multiple interactions ISO boric acid inhibits the reaction [epigallocatechin gallate results in decreased activity of ACE protein] CTD PMID:28544013 NCBI chr10:94,170,766...94,213,831
Ensembl chr10:94,170,766...94,187,822
JBrowse link
G Acta2 actin alpha 2, smooth muscle decreases expression ISO boric acid results in decreased expression of ACTA2 protein CTD PMID:25637568 NCBI chr 1:252,537,614...252,550,394
Ensembl chr 1:252,537,615...252,550,394
JBrowse link
G Adipoq adiponectin, C1Q and collagen domain containing multiple interactions ISO boric acid inhibits the reaction [[Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with INS protein] results in increased expression of ADIPOQ mRNA]; boric acid inhibits the reaction [[Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with INS protein] results in increased expression of and results in increased secretion of ADIPOQ protein] CTD PMID:28285642 NCBI chr11:81,330,845...81,344,488
Ensembl chr11:81,330,293...81,344,488
JBrowse link
G Agt angiotensinogen multiple interactions ISO boric acid inhibits the reaction [[Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with INS protein] results in increased expression of AGT mRNA] CTD PMID:28285642 NCBI chr19:57,321,594...57,333,460
Ensembl chr19:57,321,640...57,333,433
JBrowse link
G Akt1 AKT serine/threonine kinase 1 increases expression ISO boric acid results in increased expression of AKT1 mRNA CTD PMID:31368021 NCBI chr 6:137,218,398...137,239,970
Ensembl chr 6:137,218,376...137,236,258
JBrowse link
G Arg1 arginase 1 decreases activity ISO boric acid results in decreased activity of ARG1 protein CTD PMID:21232540 NCBI chr 1:21,525,421...21,537,872
Ensembl chr 1:21,525,421...21,537,863
JBrowse link
G Atf4 activating transcription factor 4 increases expression ISO boric acid results in increased expression of ATF4 mRNA; boric acid results in increased expression of ATF4 protein CTD PMID:25425213, PMID:27587023 NCBI chr 7:121,480,723...121,482,781
Ensembl chr 7:121,480,723...121,482,772
JBrowse link
G Atf6 activating transcription factor 6 multiple interactions ISO boric acid results in increased cleavage of and affects the localization of ATF6 protein CTD PMID:27587023 NCBI chr13:89,053,457...89,242,531
Ensembl chr13:89,055,983...89,242,443
JBrowse link
G Bax BCL2 associated X, apoptosis regulator decreases expression ISO boric acid results in decreased expression of BAX mRNA CTD PMID:31368021 NCBI chr 1:101,451,801...101,457,207
Ensembl chr 1:101,451,802...101,457,207
JBrowse link
G Bcl2 BCL2, apoptosis regulator increases expression ISO boric acid results in increased expression of BCL2 mRNA CTD PMID:31368021 NCBI chr13:26,605,426...26,769,374
Ensembl chr13:26,605,426...26,769,374
JBrowse link
G Calr calreticulin increases expression ISO boric acid results in increased expression of CALR mRNA CTD PMID:27587023 NCBI chr19:25,956,771...25,961,666
Ensembl chr19:25,956,771...25,961,666
JBrowse link
G Casp3 caspase 3 decreases expression
multiple interactions
ISO boric acid results in decreased expression of CASP3 mRNA
boric acid inhibits the reaction [Formaldehyde results in increased expression of CASP3 mRNA]
CTD PMID:31368021, PMID:31823256 NCBI chr16:48,845,011...48,863,249
Ensembl chr16:48,845,012...48,863,204
JBrowse link
G Cat catalase multiple interactions
decreases activity
EXP
ISO
[boric acid co-treated with Arsenic Trioxide] affects the activity of CAT protein; [boric acid results in increased abundance of Boron] inhibits the reaction [bisphenol A results in decreased activity of CAT protein]; boric acid inhibits the reaction [Acrylamide results in increased activity of CAT protein]
boric acid results in decreased activity of CAT protein
boric acid affects the reaction [Formaldehyde results in decreased activity of CAT protein]
CTD PMID:26184899, PMID:29913234, PMID:30997025, PMID:31823256 NCBI chr 3:93,379,872...93,412,058
Ensembl chr 3:93,379,874...93,412,058
JBrowse link
G Ccnd1 cyclin D1 multiple interactions
increases expression
ISO boric acid inhibits the reaction [[Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with INS protein] results in decreased expression of CCND1 protein]
boric acid results in increased expression of CCND1 mRNA
CTD PMID:28285642 NCBI chr 1:218,090,750...218,100,447
Ensembl chr 1:218,090,750...218,100,325
JBrowse link
G Cebpa CCAAT/enhancer binding protein alpha multiple interactions ISO boric acid inhibits the reaction [[Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with INS protein] results in increased expression of CEBPA mRNA]; boric acid inhibits the reaction [[Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with INS protein] results in increased expression of CEBPA protein]; CTNNB1 protein promotes the reaction [boric acid inhibits the reaction [[Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with INS protein] results in increased expression of CEBPA protein]] CTD PMID:28285642 NCBI chr 1:91,363,492...91,366,164
Ensembl chr 1:91,363,492...91,366,164
JBrowse link
G Cebpb CCAAT/enhancer binding protein beta multiple interactions ISO boric acid inhibits the reaction [[Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with INS protein] results in increased expression of CEBPB mRNA] CTD PMID:28285642 NCBI chr 3:164,424,502...164,425,933
Ensembl chr 3:164,424,515...164,425,910
JBrowse link
G Col1a2 collagen type I alpha 2 chain affects expression ISO boric acid affects the expression of COL1A2 mRNA CTD PMID:24704097 NCBI chr 4:31,534,225...31,569,152
Ensembl chr 4:31,534,225...31,569,151
JBrowse link
G Csf2 colony stimulating factor 2 increases expression ISO boric acid results in increased expression of CSF2 protein CTD PMID:27206737 NCBI chr10:39,602,089...39,604,070
Ensembl chr10:39,602,089...39,604,070
JBrowse link
G Csf3 colony stimulating factor 3 increases expression ISO boric acid results in increased expression of CSF3 protein CTD PMID:27206737 NCBI chr10:86,616,785...86,619,160
Ensembl chr10:86,616,785...86,619,157
JBrowse link
G Ctnnb1 catenin beta 1 multiple interactions ISO boric acid inhibits the reaction [[Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with INS protein] results in decreased expression of CTNNB1 protein]; CTNNB1 protein promotes the reaction [boric acid inhibits the reaction [[Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with INS protein] results in increased expression of CEBPA protein]]; CTNNB1 protein promotes the reaction [boric acid inhibits the reaction [[Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with INS protein] results in increased expression of FABP4 protein]]; CTNNB1 protein promotes the reaction [boric acid inhibits the reaction [[Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with INS protein] results in increased expression of PPARG protein]] CTD PMID:28285642 NCBI chr 8:129,601,511...129,628,378
Ensembl chr 8:129,617,812...129,627,372
JBrowse link
G Ddit3 DNA-damage inducible transcript 3 decreases expression ISO boric acid results in decreased expression of DDIT3 mRNA; boric acid results in decreased expression of DDIT3 protein CTD PMID:27587023 NCBI chr 7:70,578,564...70,585,074
Ensembl chr 7:70,580,198...70,585,084
JBrowse link
G Des desmin affects expression ISO boric acid affects the expression of DES mRNA CTD PMID:25637568 NCBI chr 9:82,556,574...82,564,288
Ensembl chr 9:82,556,573...82,564,294
JBrowse link
G Dvl2 dishevelled segment polarity protein 2 multiple interactions ISO boric acid inhibits the reaction [[Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with INS protein] results in decreased expression of DVL2 mRNA] CTD PMID:28285642 NCBI chr10:56,609,810...56,619,269
Ensembl chr10:56,610,051...56,619,269
JBrowse link
G Edem1 ER degradation enhancing alpha-mannosidase like protein 1 increases expression ISO boric acid results in increased expression of EDEM1 mRNA CTD PMID:27587023 NCBI chr 4:140,886,644...140,918,654
Ensembl chr 4:140,886,545...140,915,779
JBrowse link
G Eif2ak3 eukaryotic translation initiation factor 2 alpha kinase 3 multiple interactions ISO EIF2AK3 protein affects the reaction [boric acid affects the localization of NFE2L2 protein]; EIF2AK3 protein affects the reaction [boric acid results in increased expression of GCLC mRNA]; EIF2AK3 protein affects the reaction [boric acid results in increased phosphorylation of EIF2S1 protein] CTD PMID:30196486 NCBI chr 4:98,648,513...98,709,695
Ensembl chr 4:98,648,545...98,709,694
JBrowse link
G Eif2s1 eukaryotic translation initiation factor 2 subunit alpha increases phosphorylation
multiple interactions
ISO boric acid results in increased phosphorylation of EIF2S1 protein
EIF2AK3 protein affects the reaction [boric acid results in increased phosphorylation of EIF2S1 protein]
CTD PMID:25425213, PMID:27587023, PMID:30196486 NCBI chr 6:102,048,372...102,073,041
Ensembl chr 6:102,048,372...102,073,041
JBrowse link
G Fabp4 fatty acid binding protein 4 multiple interactions ISO boric acid inhibits the reaction [[Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with INS protein] results in increased expression of FABP4 mRNA]; boric acid inhibits the reaction [[Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with INS protein] results in increased expression of FABP4 protein]; CTNNB1 protein promotes the reaction [boric acid inhibits the reaction [[Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with INS protein] results in increased expression of FABP4 protein]] CTD PMID:28285642 NCBI chr 2:93,792,666...93,797,267
Ensembl chr 2:93,792,601...93,797,305
JBrowse link
G Fasn fatty acid synthase multiple interactions ISO boric acid inhibits the reaction [[Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with INS protein] results in increased expression of FASN mRNA] CTD PMID:28285642 NCBI chr10:109,987,735...110,005,901
Ensembl chr10:109,987,735...110,005,901
JBrowse link
G Fgf2 fibroblast growth factor 2 multiple interactions ISO boric acid promotes the reaction [[Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with INS protein] results in increased expression of FGF2 protein] CTD PMID:28285642 NCBI chr 2:124,081,072...124,134,133
Ensembl chr 2:124,081,072...124,134,681
JBrowse link
G Fgf7 fibroblast growth factor 7 increases expression ISO boric acid results in increased expression of FGF7 protein CTD PMID:27206737 NCBI chr 3:118,315,859...118,368,464
Ensembl chr 3:118,317,761...118,366,872
JBrowse link
G Fn1 fibronectin 1 increases expression
affects expression
ISO boric acid results in increased expression of FN1 mRNA
boric acid affects the expression of FN1 mRNA
CTD PMID:27206737 NCBI chr 9:78,900,111...78,969,018
Ensembl chr 9:78,900,103...78,969,078
JBrowse link
G Gapdh glyceraldehyde-3-phosphate dehydrogenase decreases expression ISO boric acid results in decreased expression of GAPDH protein CTD PMID:28285642 NCBI chr 4:157,676,336...157,680,322
Ensembl chr 4:157,676,595...157,679,962
JBrowse link
G Gas6 growth arrest specific 6 multiple interactions ISO boric acid inhibits the reaction [[Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with INS protein] results in increased expression of GAS6 protein] CTD PMID:28285642 NCBI chr16:81,213,364...81,243,824
Ensembl chr16:81,213,364...81,243,757
JBrowse link
G Gck glucokinase increases expression ISO boric acid results in increased expression of GCK mRNA CTD PMID:31368021 NCBI chr14:86,149,146...86,191,589
Ensembl chr14:86,148,928...86,190,659
JBrowse link
G Gclc glutamate-cysteine ligase, catalytic subunit multiple interactions
increases expression
ISO EIF2AK3 protein affects the reaction [boric acid results in increased expression of GCLC mRNA] CTD PMID:30196486 NCBI chr 8:85,059,051...85,097,471
Ensembl chr 8:85,059,051...85,097,468
JBrowse link
G Gpt glutamic--pyruvic transaminase multiple interactions EXP [boric acid results in increased abundance of Boron] inhibits the reaction [bisphenol A results in increased expression of GPT protein] CTD PMID:30997025 NCBI chr 7:117,759,083...117,761,932
Ensembl chr 7:117,759,083...117,761,931
JBrowse link
G Herpud1 homocysteine inducible ER protein with ubiquitin like domain 1 increases expression ISO boric acid results in increased expression of HERPUD1 mRNA CTD PMID:27587023 NCBI chr19:11,046,905...11,057,440
Ensembl chr19:11,046,909...11,057,254
JBrowse link
G Hmox1 heme oxygenase 1 increases expression ISO boric acid results in increased expression of HMOX1 mRNA CTD PMID:30196486 NCBI chr19:14,508,634...14,515,455
Ensembl chr19:14,508,616...14,515,456
JBrowse link
G Hoxa6 homeobox A6 affects expression EXP boric acid affects the expression of HOXA6 mRNA CTD PMID:12749385 NCBI chr 4:82,173,478...82,183,597
Ensembl chr 4:82,173,293...82,263,302
JBrowse link
G Hoxc6 homeo box C6 affects expression EXP boric acid affects the expression of HOXC6 mRNA CTD PMID:12749385 NCBI chr 7:144,612,230...144,626,036
Ensembl chr 7:144,623,555...144,625,516
JBrowse link
G Hspa5 heat shock protein family A (Hsp70) member 5 increases expression ISO boric acid results in increased expression of HSPA5 mRNA; boric acid results in increased expression of HSPA5 protein CTD PMID:25425213, PMID:27587023 NCBI chr 3:13,838,304...13,842,763
Ensembl chr 3:13,838,304...13,842,762
JBrowse link
G Ifng interferon gamma multiple interactions EXP boric acid inhibits the reaction [Acrylamide results in increased expression of IFNG mRNA]; boric acid inhibits the reaction [Arsenic Trioxide results in increased expression of IFNG mRNA]; boric acid inhibits the reaction [Arsenic Trioxide results in increased expression of IFNG protein] CTD PMID:29913234, PMID:30368975 NCBI chr 7:61,337,383...61,341,419
Ensembl chr 7:61,337,381...61,341,419
JBrowse link
G Il10 interleukin 10 multiple interactions EXP [boric acid results in increased abundance of Boron] inhibits the reaction [bisphenol A results in decreased expression of IL10 mRNA] CTD PMID:30997025 NCBI chr13:47,738,933...47,743,392
Ensembl chr13:47,739,526...47,743,392
JBrowse link
G Il1b interleukin 1 beta multiple interactions EXP [boric acid results in increased abundance of Boron] inhibits the reaction [bisphenol A results in increased expression of IL1B mRNA]; boric acid inhibits the reaction [Acrylamide results in increased expression of IL1B mRNA]; boric acid inhibits the reaction [Arsenic Trioxide results in increased expression of IL1B mRNA]; boric acid inhibits the reaction [Arsenic Trioxide results in increased expression of IL1B protein] CTD PMID:29913234, PMID:30368975, PMID:30997025 NCBI chr 3:121,876,256...121,882,637
Ensembl chr 3:121,876,263...121,882,726
JBrowse link
G Il4 interleukin 4 increases expression ISO boric acid results in increased expression of IL4 mRNA CTD PMID:31368021 NCBI chr10:38,963,979...38,969,531
Ensembl chr10:38,963,979...38,969,531
JBrowse link
G Il6 interleukin 6 multiple interactions ISO
EXP
boric acid promotes the reaction [[Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with INS protein] results in increased expression of IL6 mRNA]
[boric acid results in increased abundance of Boron] inhibits the reaction [bisphenol A results in increased expression of IL6 mRNA]
CTD PMID:28285642, PMID:30997025 NCBI chr 4:3,043,231...3,047,807
Ensembl chr 4:3,043,231...3,047,807
JBrowse link
G Ins2 insulin 2 multiple interactions
increases expression
ISO boric acid inhibits the reaction [[Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with INS protein] results in decreased expression of CCND1 protein]; boric acid inhibits the reaction [[Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with INS protein] results in decreased expression of CTNNB1 protein]; boric acid inhibits the reaction [[Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with INS protein] results in decreased expression of DVL2 mRNA]; boric acid inhibits the reaction [[Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with INS protein] results in increased expression of ADIPOQ mRNA]; boric acid inhibits the reaction [[Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with INS protein] results in increased expression of AGT mRNA]; boric acid inhibits the reaction [[Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with INS protein] results in increased expression of and results in increased secretion of ADIPOQ protein]; boric acid inhibits the reaction [[Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with INS protein] results in increased expression of CEBPA mRNA]; boric acid inhibits the reaction [[Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with INS protein] results in increased expression of CEBPA protein]; boric acid inhibits the reaction [[Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with INS protein] results in increased expression of CEBPB mRNA]; boric acid inhibits the reaction [[Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with INS protein] results in increased expression of FABP4 mRNA]; boric acid inhibits the reaction [[Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with INS protein] results in increased expression of FABP4 protein]; boric acid inhibits the reaction [[Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with INS protein] results in increased expression of FASN mRNA]; boric acid inhibits the reaction [[Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with INS protein] results in increased expression of GAS6 protein]; boric acid inhibits the reaction [[Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with INS protein] results in increased expression of KLF5 mRNA]; boric acid inhibits the reaction [[Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with INS protein] results in increased expression of LEP mRNA]; boric acid inhibits the reaction [[Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with INS protein] results in increased expression of LIPE mRNA]; boric acid inhibits the reaction [[Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with INS protein] results in increased expression of PPARG mRNA]; boric acid inhibits the reaction [[Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with INS protein] results in increased expression of PPARG protein]; boric acid inhibits the reaction [[Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with INS protein] results in increased expression of SLC2A4 mRNA]; boric acid inhibits the reaction [[Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with INS protein] results in increased expression of SLC2A4 protein]; boric acid inhibits the reaction [[Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with INS protein] results in increased expression of SREBF1 mRNA]; boric acid inhibits the reaction [[Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with INS protein] results in increased expression of TNFRSF1A protein]; boric acid inhibits the reaction [[Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with INS protein] results in increased phosphorylation of MAPK1 protein]; boric acid inhibits the reaction [[Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with INS protein] results in increased phosphorylation of MAPK3 protein]; boric acid promotes the reaction [[Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with INS protein] results in increased expression of FGF2 protein]; boric acid promotes the reaction [[Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with INS protein] results in increased expression of IL6 mRNA]; CTNNB1 protein promotes the reaction [boric acid inhibits the reaction [[Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with INS protein] results in increased expression of CEBPA protein]]; CTNNB1 protein promotes the reaction [boric acid inhibits the reaction [[Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with INS protein] results in increased expression of FABP4 protein]]; CTNNB1 protein promotes the reaction [boric acid inhibits the reaction [[Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with INS protein] results in increased expression of PPARG protein]]
boric acid results in increased expression of INS2 mRNA
CTD PMID:28285642, PMID:31368021 NCBI chr 1:215,856,967...215,858,034
Ensembl chr 1:215,856,971...215,858,034
JBrowse link
G Klf5 Kruppel-like factor 5 multiple interactions ISO boric acid inhibits the reaction [[Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with INS protein] results in increased expression of KLF5 mRNA] CTD PMID:28285642 NCBI chr15:83,703,796...83,722,921
Ensembl chr15:83,703,791...83,722,921
JBrowse link
G Lama5 laminin subunit alpha 5 increases expression ISO boric acid results in increased expression of LAMA5 mRNA CTD PMID:27206737 NCBI chr 3:175,553,042...175,601,112
Ensembl chr 3:175,553,045...175,601,127
JBrowse link
G Lep leptin multiple interactions ISO boric acid inhibits the reaction [[Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with INS protein] results in increased expression of LEP mRNA]; boric acid results in decreased expression of and results in decreased secretion of LEP protein CTD PMID:28285642 NCBI chr 4:56,337,695...56,351,818
Ensembl chr 4:56,337,695...56,351,818
JBrowse link
G Lipe lipase E, hormone sensitive type multiple interactions ISO boric acid inhibits the reaction [[Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with INS protein] results in increased expression of LIPE mRNA] CTD PMID:28285642 NCBI chr 1:82,248,031...82,266,727
Ensembl chr 1:82,248,046...82,266,727
JBrowse link
G Mapk1 mitogen activated protein kinase 1 multiple interactions ISO boric acid inhibits the reaction [[Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with INS protein] results in increased phosphorylation of MAPK1 protein] CTD PMID:28285642 NCBI chr11:88,203,863...88,273,301
Ensembl chr11:88,211,599...88,273,254
JBrowse link
G Mapk3 mitogen activated protein kinase 3 multiple interactions ISO boric acid inhibits the reaction [[Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with INS protein] results in increased phosphorylation of MAPK3 protein] CTD PMID:28285642 NCBI chr 1:198,192,773...198,198,975
Ensembl chr 1:198,192,773...198,198,975
JBrowse link
G Mmp2 matrix metallopeptidase 2 decreases expression ISO boric acid results in decreased expression of MMP2 protein CTD PMID:28285642 NCBI chr19:15,542,771...15,570,589
Ensembl chr19:15,542,765...15,570,611
JBrowse link
G Myh1 myosin heavy chain 1 affects expression ISO boric acid affects the expression of MYH1 mRNA CTD PMID:25637568 NCBI chr10:53,740,841...53,764,610
Ensembl chr10:53,713,938...53,848,347
JBrowse link
G Myod1 myogenic differentiation 1 affects expression
decreases expression
ISO boric acid affects the expression of MYOD1 mRNA
boric acid results in decreased expression of MYOD1 protein
CTD PMID:25637568 NCBI chr 1:102,396,538...102,399,248
Ensembl chr 1:102,396,538...102,399,248
JBrowse link
G Myog myogenin affects expression ISO boric acid affects the expression of MYOG mRNA CTD PMID:25637568 NCBI chr13:51,126,459...51,129,048
Ensembl chr13:51,126,459...51,129,048
JBrowse link
G Nfe2l2 nuclear factor, erythroid 2-like 2 affects localization
multiple interactions
ISO boric acid affects the localization of NFE2L2 protein
EIF2AK3 protein affects the reaction [boric acid affects the localization of NFE2L2 protein]
CTD PMID:30196486 NCBI chr 3:62,497,568...62,525,146
Ensembl chr 3:62,497,571...62,524,996
JBrowse link
G Nfkb1 nuclear factor kappa B subunit 1 multiple interactions
affects expression
ISO boric acid affects the reaction [Formaldehyde results in increased expression of NFKB1 mRNA]
boric acid affects the expression of NFKB1 mRNA
CTD PMID:31823256 NCBI chr 2:240,773,520...240,890,053
Ensembl chr 2:240,773,456...240,866,689
JBrowse link
G Nos2 nitric oxide synthase 2 multiple interactions ISO boric acid inhibits the reaction [Lipopolysaccharides results in increased expression of NOS2 mRNA] CTD PMID:27206737 NCBI chr10:66,188,290...66,221,621
Ensembl chr10:66,189,786...66,313,190
JBrowse link
G Nqo1 NAD(P)H quinone dehydrogenase 1 increases expression ISO boric acid results in increased expression of NQO1 mRNA CTD PMID:30196486 NCBI chr19:38,422,210...38,437,103
Ensembl chr19:38,422,164...38,437,180
JBrowse link
G Pcna proliferating cell nuclear antigen increases expression EXP boric acid results in increased expression of PCNA protein CTD PMID:17943231 NCBI chr 3:124,880,698...124,884,570
Ensembl chr 3:124,880,698...124,884,570
JBrowse link
G Pdx1 pancreatic and duodenal homeobox 1 increases expression ISO boric acid results in increased expression of PDX1 mRNA CTD PMID:31368021 NCBI chr12:9,496,044...9,501,211
Ensembl chr12:9,496,044...9,501,213
JBrowse link
G Pparg peroxisome proliferator-activated receptor gamma multiple interactions ISO boric acid inhibits the reaction [[Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with INS protein] results in increased expression of PPARG mRNA]; boric acid inhibits the reaction [[Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with INS protein] results in increased expression of PPARG protein]; CTNNB1 protein promotes the reaction [boric acid inhibits the reaction [[Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with INS protein] results in increased expression of PPARG protein]] CTD PMID:28285642 NCBI chr 4:147,274,055...147,399,383
Ensembl chr 4:147,274,107...147,399,380
JBrowse link
G Ppp1r15a protein phosphatase 1, regulatory subunit 15A increases expression ISO boric acid results in increased expression of PPP1R15A mRNA; boric acid results in increased expression of PPP1R15A protein CTD PMID:27587023 NCBI chr 1:101,511,899...101,515,043
Ensembl chr 1:101,511,901...101,514,974
JBrowse link
G Ptgs2 prostaglandin-endoperoxide synthase 2 multiple interactions ISO boric acid inhibits the reaction [Lipopolysaccharides results in increased expression of PTGS2 mRNA] CTD PMID:27206737 NCBI chr13:67,351,230...67,356,920
Ensembl chr13:67,351,087...67,359,335
JBrowse link
G Rela RELA proto-oncogene, NF-kB subunit multiple interactions EXP boric acid inhibits the reaction [Acrylamide results in increased expression of RELA mRNA]; boric acid inhibits the reaction [Arsenic Trioxide results in increased expression of RELA mRNA]; boric acid inhibits the reaction [Arsenic Trioxide results in increased expression of RELA protein] CTD PMID:29913234, PMID:30368975 NCBI chr 1:220,992,770...221,003,249
Ensembl chr 1:220,992,770...221,003,249
JBrowse link
G Runx2 RUNX family transcription factor 2 affects expression ISO boric acid affects the expression of RUNX2 mRNA CTD PMID:24704097 NCBI chr 9:18,564,743...18,773,092
Ensembl chr 9:18,564,927...18,773,092
JBrowse link
G Slc2a2 solute carrier family 2 member 2 increases expression ISO boric acid results in increased expression of SLC2A2 mRNA CTD PMID:31368021 NCBI chr 2:114,413,427...114,445,418
Ensembl chr 2:114,413,410...114,445,395
JBrowse link
G Slc2a4 solute carrier family 2 member 4 multiple interactions ISO boric acid inhibits the reaction [[Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with INS protein] results in increased expression of SLC2A4 mRNA]; boric acid inhibits the reaction [[Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with INS protein] results in increased expression of SLC2A4 protein] CTD PMID:28285642 NCBI chr10:56,552,921...56,558,562
Ensembl chr10:56,552,983...56,558,487
JBrowse link
G Slc4a2 solute carrier family 4 member 2 increases expression ISO boric acid results in increased expression of SLC4A2 mRNA CTD PMID:22576912 NCBI chr 4:7,264,677...7,282,355
Ensembl chr 4:7,264,683...7,281,223
JBrowse link
G Slc4a3 solute carrier family 4 member 3 increases expression ISO boric acid results in increased expression of SLC4A3 mRNA CTD PMID:22576912 NCBI chr 9:82,742,207...82,755,119
Ensembl chr 9:82,741,920...82,755,153
JBrowse link
G Sparc secreted protein acidic and cysteine rich affects expression ISO boric acid affects the expression of SPARC mRNA CTD PMID:24704097 NCBI chr10:40,742,390...40,764,232
Ensembl chr10:40,742,400...40,764,185
JBrowse link
G Srebf1 sterol regulatory element binding transcription factor 1 multiple interactions ISO boric acid inhibits the reaction [[Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with INS protein] results in increased expression of SREBF1 mRNA] CTD PMID:28285642 NCBI chr10:46,570,996...46,593,021
Ensembl chr10:46,570,996...46,593,009
JBrowse link
G Syvn1 synoviolin 1 decreases expression ISO boric acid results in decreased expression of SYVN1 mRNA CTD PMID:27587023 NCBI chr 1:221,409,281...221,416,229
Ensembl chr 1:221,409,271...221,417,886
JBrowse link
G Tgfb1 transforming growth factor, beta 1 increases expression ISO boric acid results in increased expression of TGFB1 protein
boric acid results in increased expression of TGFB1 mRNA
CTD PMID:27206737, PMID:31368021 NCBI chr 1:82,480,875...82,497,196
Ensembl chr 1:82,480,195...82,497,199
JBrowse link
G Tnf tumor necrosis factor multiple interactions
decreases expression
increases secretion
increases expression
ISO
EXP
boric acid inhibits the reaction [Formaldehyde results in increased expression of TNF mRNA]; boric acid inhibits the reaction [Lipopolysaccharides results in increased expression of TNF mRNA]; boric acid inhibits the reaction [Lipopolysaccharides results in increased secretion of TNF protein]
boric acid results in decreased expression of TNF mRNA
[boric acid results in increased abundance of Boron] inhibits the reaction [bisphenol A results in increased expression of TNF mRNA]; boric acid inhibits the reaction [Acrylamide results in increased expression of TNF mRNA]; boric acid inhibits the reaction [Arsenic Trioxide results in increased expression of TNF mRNA]; boric acid inhibits the reaction [Arsenic Trioxide results in increased expression of TNF protein]
boric acid results in increased secretion of TNF protein
boric acid results in increased expression of TNF mRNA
CTD PMID:9618283, PMID:18755394, PMID:29913234, PMID:30368975, PMID:30997025, PMID:31823256 NCBI chr20:5,189,382...5,192,000
Ensembl chr20:5,189,390...5,192,000
JBrowse link
G Tnfrsf1a TNF receptor superfamily member 1A multiple interactions ISO boric acid inhibits the reaction [[Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with INS protein] results in increased expression of TNFRSF1A protein] CTD PMID:28285642 NCBI chr 4:157,864,905...157,877,634
Ensembl chr 4:157,864,969...157,877,633
JBrowse link
G Tp53 tumor protein p53 decreases expression ISO boric acid results in decreased expression of TRP53 mRNA CTD PMID:31368021 NCBI chr10:56,186,299...56,198,449
Ensembl chr10:56,187,020...56,198,449
JBrowse link
G Xbp1 X-box binding protein 1 increases expression ISO boric acid results in increased expression of XBP1 mRNA CTD PMID:27587023 NCBI chr14:85,753,736...85,758,820
Ensembl chr14:85,753,760...85,758,145
JBrowse link
boric acids term browser
Symbol Object Name Qualifiers Evidence Notes Source PubMed Reference(s) RGD Reference(s) Position
G Ggt1 gamma-glutamyltransferase 1 decreases activity EXP Boric Acids analog results in decreased activity of GGT1 protein CTD PMID:6149445 NCBI chr20:14,019,723...14,045,781
Ensembl chr20:14,019,723...14,025,068
JBrowse link
G Muc1 mucin 1, cell surface associated decreases expression ISO Boric Acids results in decreased expression of MUC1 mRNA CTD PMID:21060261 NCBI chr 2:188,543,137...188,547,874
Ensembl chr 2:188,543,137...188,547,874
JBrowse link
G Muc16 mucin 16, cell surface associated decreases expression ISO Boric Acids results in decreased expression of MUC16 mRNA CTD PMID:21060261 NCBI chr 8:18,438,838...18,639,777 JBrowse link
boron atom term browser
Symbol Object Name Qualifiers Evidence Notes Source PubMed Reference(s) RGD Reference(s) Position
G Atrnl1 attractin like 1 increases expression ISO Boron results in increased expression of ATRNL1 mRNA CTD PMID:21625915 NCBI chr 1:278,546,113...279,098,977
Ensembl chr 1:278,557,792...278,815,473
JBrowse link
G Bglap bone gamma-carboxyglutamate protein increases expression ISO Boron results in increased expression of BGLAP mRNA CTD PMID:21625915 NCBI chr 2:187,741,770...187,748,445
Ensembl chr 2:187,741,770...187,742,747
JBrowse link
G Bmp7 bone morphogenetic protein 7 increases expression ISO Boron results in increased expression of BMP7 mRNA CTD PMID:21625915 NCBI chr 3:170,879,972...170,955,820
Ensembl chr 3:170,879,973...170,955,399
JBrowse link
G Casp3 caspase 3 increases expression ISO Boron results in increased expression of CASP3 protein modified form CTD PMID:23462526 NCBI chr16:48,845,011...48,863,249
Ensembl chr16:48,845,012...48,863,204
JBrowse link
G Cat catalase multiple interactions EXP [boric acid results in increased abundance of Boron] inhibits the reaction [bisphenol A results in decreased activity of CAT protein] CTD PMID:30997025 NCBI chr 3:93,379,872...93,412,058
Ensembl chr 3:93,379,874...93,412,058
JBrowse link
G Ccnd1 cyclin D1 decreases expression ISO Boron results in decreased expression of CCND1 protein CTD PMID:23462526 NCBI chr 1:218,090,750...218,100,447
Ensembl chr 1:218,090,750...218,100,325
JBrowse link
G Col1a1 collagen type I alpha 1 chain increases expression ISO Boron results in increased expression of COL1A1 mRNA CTD PMID:21625915 NCBI chr10:82,745,801...82,762,790
Ensembl chr10:82,745,801...82,762,789
JBrowse link
G Gpt glutamic--pyruvic transaminase multiple interactions EXP [boric acid results in increased abundance of Boron] inhibits the reaction [bisphenol A results in increased expression of GPT protein] CTD PMID:30997025 NCBI chr 7:117,759,083...117,761,932
Ensembl chr 7:117,759,083...117,761,931
JBrowse link
G Il10 interleukin 10 multiple interactions EXP [boric acid results in increased abundance of Boron] inhibits the reaction [bisphenol A results in decreased expression of IL10 mRNA] CTD PMID:30997025 NCBI chr13:47,738,933...47,743,392
Ensembl chr13:47,739,526...47,743,392
JBrowse link
G Il1b interleukin 1 beta multiple interactions EXP [boric acid results in increased abundance of Boron] inhibits the reaction [bisphenol A results in increased expression of IL1B mRNA] CTD PMID:30997025 NCBI chr 3:121,876,256...121,882,637
Ensembl chr 3:121,876,263...121,882,726
JBrowse link
G Il6 interleukin 6 multiple interactions EXP [boric acid results in increased abundance of Boron] inhibits the reaction [bisphenol A results in increased expression of IL6 mRNA] CTD PMID:30997025 NCBI chr 4:3,043,231...3,047,807
Ensembl chr 4:3,043,231...3,047,807
JBrowse link
G Tnf tumor necrosis factor multiple interactions EXP [boric acid results in increased abundance of Boron] inhibits the reaction [bisphenol A results in increased expression of TNF mRNA] CTD PMID:30997025 NCBI chr20:5,189,382...5,192,000
Ensembl chr20:5,189,390...5,192,000
JBrowse link
bortezomib term browser
Symbol Object Name Qualifiers Evidence Notes Source PubMed Reference(s) RGD Reference(s) Position
G Abca2 ATP binding cassette subfamily A member 2 decreases expression ISO Bortezomib results in decreased expression of ABCA2 mRNA CTD PMID:20977926 NCBI chr 3:2,648,787...2,668,770
Ensembl chr 3:2,648,885...2,668,809
JBrowse link
G Abcb1a ATP binding cassette subfamily B member 1A multiple interactions
decreases expression
decreases activity
ISO ATP2A1 protein affects the reaction [Bortezomib results in decreased expression of ABCB1]; Bortezomib promotes the reaction [Chloroquine results in decreased expression of ABCB1 mRNA]; Bortezomib promotes the reaction [Chloroquine results in decreased expression of and results in increased nitrosation of ABCB1 protein]; Bortezomib results in decreased expression of and results in increased nitrosation of ABCB1 protein; Chloroquine promotes the reaction [Bortezomib results in decreased expression of ABCB1 mRNA]; Chloroquine promotes the reaction [Bortezomib results in decreased expression of and results in increased nitrosation of ABCB1 protein]
[Chloroquine co-treated with Bortezomib] results in decreased expression of ABCB1A protein; Bortezomib promotes the reaction [Chloroquine results in decreased expression of ABCB1A mRNA]; Bortezomib promotes the reaction [Chloroquine results in decreased expression of and results in increased nitrosation of ABCB1A protein]; Bortezomib results in decreased expression of and results in increased nitrosation of ABCB1A protein; CEBPB protein alternative form promotes the reaction [[Chloroquine co-treated with Bortezomib] results in decreased expression of ABCB1A protein]; Chloroquine promotes the reaction [Bortezomib results in decreased expression of ABCB1A mRNA]; Chloroquine promotes the reaction [Bortezomib results in decreased expression of and results in increased nitrosation of ABCB1A protein]; Doxorubicin promotes the reaction [CEBPB protein alternative form promotes the reaction [[Chloroquine co-treated with Bortezomib] results in decreased expression of ABCB1A protein]]
Bortezomib results in decreased expression of ABCB1; Bortezomib results in decreased expression of ABCB1 mRNA
Bortezomib results in decreased activity of ABCB1 protein
CTD PMID:25576094, PMID:30482226 NCBI chr 4:22,339,829...22,517,642
Ensembl chr 4:22,133,521...22,425,515
JBrowse link
G Abcc1 ATP binding cassette subfamily C member 1 decreases expression ISO Bortezomib results in decreased expression of ABCC1 mRNA CTD PMID:20977926 NCBI chr10:549,537...672,235
Ensembl chr10:549,883...672,196
JBrowse link
G Abcc2 ATP binding cassette subfamily C member 2 increases expression ISO Bortezomib results in increased expression of ABCC2 mRNA CTD PMID:21215737 NCBI chr 1:263,554,426...263,612,556
Ensembl chr 1:263,554,453...263,613,252
JBrowse link
G Abcc4 ATP binding cassette subfamily C member 4 decreases expression ISO Bortezomib results in decreased expression of ABCC4 mRNA CTD PMID:20977926 NCBI chr15:103,695,415...103,927,980
Ensembl chr15:103,696,557...103,927,592
JBrowse link
G Abhd16a abhydrolase domain containing 16A, phospholipase increases expression ISO Bortezomib results in increased expression of ABHD16A mRNA CTD PMID:20977926 NCBI chr20:5,080,070...5,094,935
Ensembl chr20:5,080,070...5,094,935
JBrowse link
G Abhd2 abhydrolase domain containing 2, acylglycerol lipase increases expression ISO Bortezomib results in increased expression of ABHD2 mRNA CTD PMID:20977926 NCBI chr 1:140,998,240...141,087,405
Ensembl chr 1:140,998,240...141,087,405
JBrowse link
G Abi1 abl-interactor 1 increases expression ISO Bortezomib results in increased expression of ABI1 mRNA CTD PMID:20977926 NCBI chr17:89,951,662...90,033,334
Ensembl chr17:89,951,752...90,033,328
JBrowse link
G Abl1 ABL proto-oncogene 1, non-receptor tyrosine kinase multiple interactions ISO [alvocidib co-treated with Bortezomib co-treated with ABL1 protein] results in decreased phosphorylation of LYN protein; [alvocidib co-treated with Bortezomib co-treated with ABL1] results in decreased phosphorylation of CRKL protein; [alvocidib co-treated with Bortezomib] results in decreased expression of ABL1 protein; [Arsenic Trioxide co-treated with Bortezomib] results in decreased expression of ABL1 protein; [Bortezomib co-treated with N,N-dimethylsphingosine] results in decreased expression of ABL1 protein; Bortezomib promotes the reaction [Dichlororibofuranosylbenzimidazole results in decreased expression of ABL1 protein] CTD PMID:15039284, PMID:17495969, PMID:21195056 NCBI chr 3:10,041,820...10,145,076
Ensembl chr 3:10,041,826...10,144,388
JBrowse link
G Ace angiotensin I converting enzyme multiple interactions ISO [Butyrates co-treated with Bortezomib] results in increased activity of ACE protein mutant form CTD PMID:20454656 NCBI chr10:94,170,766...94,213,831
Ensembl chr10:94,170,766...94,187,822
JBrowse link
G Acot7 acyl-CoA thioesterase 7 decreases expression ISO Bortezomib results in decreased expression of ACOT7 mRNA CTD PMID:20977926 NCBI chr 5:169,357,582...169,450,215
Ensembl chr 5:169,357,517...169,450,219
JBrowse link
G Adam10 ADAM metallopeptidase domain 10 decreases expression ISO Bortezomib results in decreased expression of ADAM10 mRNA CTD PMID:20977926 NCBI chr 8:77,107,355...77,237,483
Ensembl chr 8:77,107,536...77,237,483
JBrowse link
G Adm adrenomedullin multiple interactions
decreases expression
ISO Bortezomib inhibits the reaction [arsenic trioxide results in decreased expression of ADM mRNA]
Bortezomib results in decreased expression of ADM mRNA
CTD PMID:20471514 NCBI chr 1:175,443,189...175,447,260
Ensembl chr 1:175,445,088...175,447,259
JBrowse link
G Aff1 AF4/FMR2 family, member 1 increases expression ISO Bortezomib results in increased expression of AFF1 mRNA CTD PMID:20977926 NCBI chr14:7,222,883...7,384,916
Ensembl chr14:7,226,586...7,384,876
JBrowse link
G Aff4 AF4/FMR2 family, member 4 increases expression ISO Bortezomib results in increased expression of AFF4 mRNA CTD PMID:20977926 NCBI chr10:38,692,167...38,773,021
Ensembl chr10:38,692,211...38,773,021
JBrowse link
G Agk acylglycerol kinase decreases expression ISO Bortezomib results in decreased expression of AGK mRNA CTD PMID:20977926 NCBI chr 4:68,483,345...68,561,518
Ensembl chr 4:68,483,320...68,560,801
JBrowse link
G Agrn agrin decreases expression ISO Bortezomib results in decreased expression of AGRN mRNA CTD PMID:20977926 NCBI chr 5:173,589,910...173,622,813
Ensembl chr 5:173,589,819...173,622,645
JBrowse link
G Agtpbp1 ATP/GTP binding protein 1 increases expression ISO Bortezomib results in increased expression of AGTPBP1 mRNA CTD PMID:20977926 NCBI chr17:5,510,009...5,614,416
Ensembl chr17:5,511,385...5,614,435
JBrowse link
G Agtrap angiotensin II receptor-associated protein decreases expression ISO Bortezomib results in decreased expression of AGTRAP mRNA CTD PMID:20977926 NCBI chr 5:164,888,069...164,898,387
Ensembl chr 5:164,886,813...164,898,420
JBrowse link
G Aifm1 apoptosis inducing factor, mitochondria associated 1 affects localization
multiple interactions
ISO Bortezomib affects the localization of AIFM1 protein
[Bortezomib co-treated with Butyrates] affects the localization of AIFM1 protein; [Bortezomib co-treated with vorinostat] affects the localization of AIFM1 protein
CTD PMID:12893773, PMID:16024631 NCBI chr  X:135,304,063...135,343,062
Ensembl chr  X:135,304,066...135,343,087
JBrowse link
G Aifm2 apoptosis inducing factor, mitochondria associated 2 increases expression ISO Bortezomib results in increased expression of AIFM2 mRNA CTD PMID:20977926 NCBI chr20:31,329,047...31,353,548
Ensembl chr20:31,339,787...31,352,906
JBrowse link
G Aim2 absent in melanoma 2 increases expression ISO Bortezomib results in increased expression of AIM2 mRNA CTD PMID:20977926 NCBI chr13:91,919,834...91,963,080
Ensembl chr13:91,954,138...91,962,588
JBrowse link
G Akr1b1 aldo-keto reductase family 1 member B increases expression ISO Bortezomib results in increased expression of AKR1B1 mRNA; Bortezomib results in increased expression of AKR1B1 protein CTD PMID:21215737 NCBI chr 4:61,706,866...61,720,959
Ensembl chr 4:61,706,864...61,720,956
JBrowse link
G Akr1b10 aldo-keto reductase family 1 member B10 increases expression ISO Bortezomib results in increased expression of AKR1B10 mRNA; Bortezomib results in increased expression of AKR1B10 protein CTD PMID:21215737 NCBI chr 4:61,813,265...61,830,371
Ensembl chr 4:61,771,970...61,828,657
JBrowse link
G Akr1b8 aldo-keto reductase family 1, member B8 increases expression EXP Bortezomib results in increased expression of AKR1B8 mRNA CTD PMID:20830808 NCBI chr 4:61,772,064...61,784,637
Ensembl chr 4:61,771,970...61,828,657
JBrowse link
G Akr1c2 aldo-keto reductase family 1, member C2 affects expression ISO Bortezomib affects the expression of AKR1C2 mRNA CTD PMID:21215737 NCBI chr17:69,388,337...69,435,160
Ensembl chr17:69,388,335...69,404,341
JBrowse link
G Akr1c3 aldo-keto reductase family 1, member C3 increases expression ISO Bortezomib results in increased expression of AKR1C3 mRNA CTD PMID:21215737 NCBI chr17:69,761,126...69,778,021
Ensembl chr17:69,761,118...69,778,021
JBrowse link
G Akr7a2 aldo-keto reductase family 7, member A2 multiple interactions ISO [BRCA1 mutant form results in increased susceptibility to Bortezomib] which results in decreased expression of AKR7A2 mRNA CTD PMID:25522274 NCBI chr 5:157,759,448...157,768,473
Ensembl chr 5:157,759,416...157,768,471
JBrowse link
G Akt1 AKT serine/threonine kinase 1 multiple interactions
decreases expression
decreases activity
ISO [alvocidib co-treated with Bortezomib] results in decreased expression of AKT1 protein modified form; [Bortezomib co-treated with lapatinib] results in decreased phosphorylation of AKT1 protein; [Bortezomib co-treated with lonafarnib] results in decreased expression of AKT1 protein; [Bortezomib co-treated with lonafarnib] results in decreased expression of AKT1 protein modified form; [Bortezomib co-treated with panobinostat] results in decreased activity of AKT1 protein; [Bortezomib co-treated with sorafenib] results in decreased phosphorylation of AKT1 protein; [Bortezomib results in decreased activity of CBL protein] promotes the reaction [arsenic trioxide results in increased activity of AKT1 protein]; [geldanamycin co-treated with Bortezomib] results in decreased expression of AKT1 protein; [vorinostat co-treated with Bortezomib] results in decreased phosphorylation of and results in decreased expression of AKT1 protein; AKT1 protein inhibits the reaction [[Bortezomib co-treated with sorafenib] results in increased cleavage of CASP3 protein]; AKT1 protein inhibits the reaction [[Bortezomib co-treated with sorafenib] results in increased cleavage of CASP9 protein]; AKT1 protein inhibits the reaction [[Bortezomib co-treated with sorafenib] results in increased cleavage of PARP1 protein]; AKT1 protein inhibits the reaction [[Bortezomib co-treated with TNFSF10 protein] results in increased activity of CASP8 protein]; AKT1 protein inhibits the reaction [[Bortezomib co-treated with TNFSF10 protein] results in increased cleavage of PARP1 protein]; AKT1 protein results in decreased susceptibility to [Bortezomib co-treated with sorafenib]; Bortezomib inhibits the reaction [TNFSF10 protein results in increased activity of AKT1 protein]; Okadaic Acid inhibits the reaction [Bortezomib results in decreased expression of AKT1 protein modified form]
Bortezomib results in decreased activity of AKT1 protein
CTD PMID:15039284, PMID:15781649, PMID:16118318, PMID:16985072, PMID:18445700, PMID:18701494, PMID:19261616, PMID:19457607, PMID:20701607, PMID:21472287 NCBI chr 6:137,218,398...137,239,970
Ensembl chr 6:137,218,376...137,236,258
JBrowse link
G Aldh18a1 aldehyde dehydrogenase 18 family, member A1 decreases expression ISO Bortezomib results in decreased expression of ALDH18A1 mRNA CTD PMID:20977926 NCBI chr 1:259,641,673...259,674,521
Ensembl chr 1:259,641,676...259,674,425
Ensembl chr 1:259,641,676...259,674,425
JBrowse link
G Aldh5a1 aldehyde dehydrogenase 5 family, member A1 decreases expression ISO Bortezomib results in decreased expression of ALDH5A1 mRNA CTD PMID:20977926 NCBI chr17:42,133,076...42,159,413
Ensembl chr17:42,133,076...42,159,413
JBrowse link
G Aldh6a1 aldehyde dehydrogenase 6 family, member A1 decreases expression ISO Bortezomib results in decreased expression of ALDH6A1 mRNA CTD PMID:20977926 NCBI chr 6:108,146,552...108,167,185
Ensembl chr 6:108,146,582...108,167,185
JBrowse link
G Alox12 arachidonate 12-lipoxygenase, 12S type increases response to substance ISO ALOX12 gene SNP results in increased susceptibility to Bortezomib CTD PMID:20864405 NCBI chr10:56,851,734...56,864,049
Ensembl chr10:56,851,734...56,864,005
JBrowse link
G Anapc11 anaphase promoting complex subunit 11 decreases expression ISO Bortezomib results in decreased expression of ANAPC11 mRNA CTD PMID:17659339 NCBI chr10:109,774,779...109,785,877
Ensembl chr10:109,774,878...109,785,877
JBrowse link
G Anapc5 anaphase-promoting complex subunit 5 decreases expression
increases expression
ISO Bortezomib results in decreased expression of ANAPC5 mRNA
Bortezomib results in increased expression of ANAPC5 mRNA
CTD PMID:17895889, PMID:20977926 NCBI chr12:39,209,134...39,242,696
Ensembl chr12:39,209,129...39,242,690
JBrowse link
G Ankrd9 ankyrin repeat domain 9 increases expression ISO Bortezomib results in increased expression of ANKRD9 mRNA CTD PMID:20977926 NCBI chr 6:135,409,698...135,412,552
Ensembl chr 6:135,410,030...135,412,312
JBrowse link
G Ano10 anoctamin 10 increases expression ISO Bortezomib results in increased expression of ANO10 mRNA CTD PMID:20977926 NCBI chr 8:130,812,941...130,931,021
Ensembl chr 8:130,813,214...130,930,990
JBrowse link
G Ap1s1 adaptor related protein complex 1 subunit sigma 1 decreases expression ISO Bortezomib results in decreased expression of AP1S1 mRNA CTD PMID:20977926 NCBI chr12:22,665,128...22,676,079
Ensembl chr12:22,665,112...22,676,075
JBrowse link
G Ap2a1 adaptor related protein complex 2 subunit alpha 1 decreases expression ISO Bortezomib results in decreased expression of AP2A1 mRNA CTD PMID:20977926 NCBI chr 1:100,896,582...100,926,443
Ensembl chr 1:100,896,947...100,926,335
JBrowse link
G Apobr apolipoprotein B receptor decreases expression ISO Bortezomib results in decreased expression of APOBR mRNA CTD PMID:20977926 NCBI chr 1:197,999,209...198,003,839
Ensembl chr 1:197,999,037...198,003,839
JBrowse link
G Apool apolipoprotein O-like increases expression ISO Bortezomib results in increased expression of APOOL mRNA CTD PMID:20977926 NCBI chr  X:83,678,269...83,750,550
Ensembl chr  X:83,678,339...83,750,549
JBrowse link
G Aqp3 aquaporin 3 (Gill blood group) increases expression ISO Bortezomib results in increased expression of AQP3 mRNA CTD PMID:20977926 NCBI chr 5:57,423,735...57,429,252
Ensembl chr 5:57,423,734...57,429,245
JBrowse link
G Ar androgen receptor multiple interactions ISO Bortezomib binds to and results in decreased activity of AR protein; Bortezomib inhibits the reaction [Metribolone results in increased activity of AR protein] CTD PMID:25752796, PMID:30818834 NCBI chr  X:67,656,253...67,828,998
Ensembl chr  X:67,656,253...67,829,026
JBrowse link
G Arf6 ADP-ribosylation factor 6 increases expression ISO Bortezomib results in increased expression of ARF6 mRNA CTD PMID:20977926 NCBI chr 6:91,697,109...91,698,257
Ensembl chr 6:91,697,109...91,698,255
JBrowse link
G Arfgap1 ADP-ribosylation factor GTPase activating protein 1 decreases expression ISO Bortezomib results in decreased expression of ARFGAP1 mRNA CTD PMID:20977926 NCBI chr 3:176,475,847...176,490,642
Ensembl chr 3:176,475,893...176,489,925
JBrowse link
G Arhgap1 Rho GTPase activating protein 1 decreases expression ISO Bortezomib results in decreased expression of ARHGAP1 mRNA CTD PMID:20977926 NCBI chr 3:80,555,196...80,576,881
Ensembl chr 3:80,555,196...80,576,856
JBrowse link
G Arhgdia Rho GDP dissociation inhibitor alpha decreases expression ISO Bortezomib results in decreased expression of ARHGDIA mRNA CTD PMID:20977926 NCBI chr10:109,754,012...109,757,506
Ensembl chr10:109,754,004...109,757,550
JBrowse link
G Arid3b AT-rich interaction domain 3B multiple interactions ISO [BRCA1 mutant form results in increased susceptibility to Bortezomib] which results in increased expression of ARID3B mRNA CTD PMID:25522274 NCBI chr 8:62,569,601...62,616,837
Ensembl chr 8:62,569,528...62,616,828
JBrowse link
G Arl4c ADP ribosylation factor like GTPase 4C decreases expression ISO Bortezomib results in decreased expression of ARL4C mRNA CTD PMID:20977926 NCBI chr 9:95,783,651...95,787,092
Ensembl chr 9:95,786,508...95,787,094
JBrowse link
G Arl8a ADP-ribosylation factor like GTPase 8A increases expression ISO Bortezomib results in increased expression of ARL8A mRNA CTD PMID:20977926 NCBI chr13:51,972,974...51,981,976
Ensembl chr13:51,972,974...51,981,976
JBrowse link
G Arrb1 arrestin, beta 1 decreases expression ISO Bortezomib results in decreased expression of ARRB1 mRNA CTD PMID:20977926 NCBI chr 1:164,502,099...164,573,947
Ensembl chr 1:164,502,389...164,593,139
JBrowse link
G Asap1 ArfGAP with SH3 domain, ankyrin repeat and PH domain 1 decreases expression ISO Bortezomib results in decreased expression of ASAP1 mRNA CTD PMID:20977926 NCBI chr 7:104,670,076...104,951,090
Ensembl chr 7:104,669,672...104,801,045
JBrowse link
G Ate1 arginyltransferase 1 increases expression ISO Bortezomib results in increased expression of ATE1 mRNA CTD PMID:20977926 NCBI chr 1:200,810,741...200,885,593
NCBI chr 1:200,958,564...201,082,100
Ensembl chr 1:200,810,771...201,082,727
JBrowse link
G Atf2 activating transcription factor 2 multiple interactions
increases phosphorylation
increases expression
ISO pyrazolanthrone inhibits the reaction [Bortezomib results in increased phosphorylation of ATF2 protein]
Bortezomib results in increased expression of ATF2 mRNA
CTD PMID:12393500, PMID:20977926 NCBI chr 3:60,721,137...60,795,951
Ensembl chr 3:60,721,135...60,795,951
JBrowse link
G Atf3 activating transcription factor 3 increases response to substance
increases expression
multiple interactions
ISO
EXP
ATF3 results in increased susceptibility to Bortezomib
Bortezomib results in increased expression of ATF3 mRNA; Bortezomib results in increased expression of ATF3 protein
Bortezomib results in increased expression of ATF3; Bortezomib results in increased expression of ATF3 mRNA; Bortezomib results in increased expression of ATF3 protein
[BRCA1 mutant form results in increased susceptibility to Bortezomib] which results in increased expression of ATF3 mRNA; ATF3 mutant form promotes the reaction [Bortezomib results in increased expression of PMAIP1 mRNA]
CTD PMID:17898295, PMID:20022965, PMID:20830808, PMID:21762082, PMID:25522274 NCBI chr13:109,817,892...109,849,632
Ensembl chr13:109,817,728...109,849,632
JBrowse link
G Atf4 activating transcription factor 4 multiple interactions
increases expression
decreases response to substance
ISO 1,2-Dihydroxybenzene-3,5-Disulfonic Acid Disodium Salt inhibits the reaction [Bortezomib results in increased expression of ATF4 protein]; ATF4 mutant form inhibits the reaction [Bortezomib results in increased expression of PMAIP1 mRNA]; ATF4 mutant form inhibits the reaction [Bortezomib results in increased expression of PMAIP1 protein]; Bortezomib promotes the reaction [ATF4 protein binds to PMAIP1 promoter]; Dactinomycin inhibits the reaction [Bortezomib results in increased expression of ATF4 mRNA]; Dactinomycin inhibits the reaction [Bortezomib results in increased expression of ATF4 protein]; NUPR1 mutant form promotes the reaction [Bortezomib results in increased expression of ATF4 mRNA]
Bortezomib results in increased expression of ATF4 mRNA; Bortezomib results in increased expression of ATF4 protein
ATF4 results in decreased susceptibility to Bortezomib
CTD PMID:15509775, PMID:16928686, PMID:20022965 NCBI chr 7:121,480,723...121,482,781
Ensembl chr 7:121,480,723...121,482,772
JBrowse link
G Atf5 activating transcription factor 5 increases expression ISO Bortezomib results in increased expression of ATF5 mRNA CTD PMID:17898295 NCBI chr 1:100,807,821...100,812,410
Ensembl chr 1:100,808,241...100,810,522
JBrowse link
G Atg5 autophagy related 5 multiple interactions ISO ATG5 gene mutant form inhibits the reaction [Bortezomib results in increased cleavage of and results in increased activity of CASP3 protein]; ATG5 gene mutant form inhibits the reaction [HRAS protein promotes the reaction [Bortezomib results in increased cleavage of and results in increased activity of CASP3 protein]] CTD PMID:22842577 NCBI chr20:49,301,783...49,393,147
Ensembl chr20:49,318,308...49,393,140
JBrowse link
G Atm ATM serine/threonine kinase multiple interactions
increases cleavage
ISO [CASP8 protein results in increased activity of CASP3 protein] affects the reaction [Bortezomib results in increased cleavage of ATM protein]; benzyloxycarbonyl-isoleucyl-glutamyl-threonyl-aspartic acid fluoromethyl ketone inhibits the reaction [Bortezomib results in increased cleavage of ATM protein] CTD PMID:12393500 NCBI chr 8:58,015,938...58,119,973
Ensembl chr 8:58,015,940...58,120,045
JBrowse link
G Atp1a3 ATPase Na+/K+ transporting subunit alpha 3 decreases expression ISO Bortezomib results in decreased expression of ATP1A3 mRNA CTD PMID:20977926 NCBI chr 1:81,852,423...81,881,565
Ensembl chr 1:81,852,429...81,881,549
JBrowse link
G Atp2a1 ATPase sarcoplasmic/endoplasmic reticulum Ca2+ transporting 1 multiple interactions
affects response to substance
ISO ATP2A1 protein affects the reaction [Bortezomib results in decreased expression of ABCB1]
ATP2A1 protein affects the susceptibility to Bortezomib
CTD PMID:25576094 NCBI chr 1:197,855,912...197,875,038 JBrowse link
G Atp6v0e1 ATPase H+ transporting V0 subunit e1 increases expression ISO Bortezomib results in increased expression of ATP6V0E1 mRNA CTD PMID:20977926 NCBI chr10:16,769,857...16,792,930
Ensembl chr10:16,769,666...16,792,909
JBrowse link
G B2m beta-2 microglobulin decreases expression ISO Bortezomib results in decreased expression of B2M protein CTD PMID:17204182 NCBI chr 3:114,087,287...114,093,311
Ensembl chr 3:114,087,287...114,093,309
JBrowse link
G B3gnt2 UDP-GlcNAc:betaGal beta-1,3-N-acetylglucosaminyltransferase 2 decreases expression ISO Bortezomib results in decreased expression of B3GNT2 mRNA CTD PMID:20977926 NCBI chr14:107,592,336...107,617,189
Ensembl chr14:107,592,336...107,617,161
JBrowse link
G B4galt6 beta-1,4-galactosyltransferase 6 increases expression ISO Bortezomib results in increased expression of B4GALT6 mRNA CTD PMID:20977926 NCBI chr18:15,462,913...15,525,584
Ensembl chr18:15,462,913...15,525,579
JBrowse link
G Bag3 BAG cochaperone 3 increases expression ISO Bortezomib results in increased expression of BAG3 mRNA CTD PMID:15509775, PMID:17659339, PMID:20471514 NCBI chr 1:199,941,258...199,965,191
Ensembl chr 1:199,941,161...199,965,191
JBrowse link
G Bak1 BCL2-antagonist/killer 1 multiple interactions
increases expression
ISO [nutlin 3 co-treated with Bortezomib] results in increased activity of BAK1 protein; BAK1 affects the reaction [Bortezomib results in increased susceptibility to and results in increased activity of TNFSF10 protein]
BAK1 protein results in increased susceptibility to [Bortezomib co-treated with TNFSF10 protein]
Bortezomib results in increased expression of BAK1 protein
CTD PMID:12902978, PMID:17326159, PMID:20850924 NCBI chr20:5,609,620...5,618,899
Ensembl chr20:5,609,625...5,618,260
JBrowse link
G Bard1 BRCA1 associated RING domain 1 increases response to substance ISO BARD1 mutant form results in increased susceptibility to Bortezomib CTD PMID:25522274 NCBI chr 9:78,297,723...78,368,777
Ensembl chr 9:78,294,834...78,369,031
JBrowse link
G Bax BCL2 associated X, apoptosis regulator multiple interactions
increases expression
ISO [Bortezomib co-treated with arsenic trioxide] affects the expression of BAX protein; [nutlin 3 co-treated with Bortezomib] results in increased activity of BAX protein; BAX results in increased susceptibility to [Bortezomib co-treated with panobinostat]; Bortezomib inhibits the reaction [BAX mutant form inhibits the reaction [TNFSF10 protein results in increased localization of DIABLO protein]]
Bortezomib results in increased expression of BAX protein
CTD PMID:12902978, PMID:18445700, PMID:18718063, PMID:20383943, PMID:20850924 NCBI chr 1:101,451,801...101,457,207
Ensembl chr 1:101,451,802...101,457,207
JBrowse link
G Bbc3 Bcl-2 binding component 3 increases expression ISO Bortezomib results in increased expression of BBC3 mRNA; Bortezomib results in increased expression of BBC3 protein CTD PMID:17898295, PMID:20051518 NCBI chr 1:78,261,491...78,267,802 JBrowse link
G Bcl2 BCL2, apoptosis regulator multiple interactions
increases expression
increases cleavage
decreases expression
ISO [arsenic trioxide co-treated with Bortezomib] results in decreased expression of BCL2 mRNA; [Bortezomib co-treated with arsenic trioxide] affects the expression of BCL2 protein; [Bortezomib co-treated with arsenic trioxide] results in decreased expression of BCL2 protein; [Bortezomib co-treated with Butyrates] results in increased cleavage of BCL2 protein; [Bortezomib co-treated with Daunorubicin] results in decreased expression of BCL2 mRNA; [Bortezomib co-treated with vorinostat] results in increased cleavage of BCL2 protein; [geldanamycin co-treated with Bortezomib] results in decreased expression of BCL2 protein; [vorinostat co-treated with Bortezomib] results in decreased expression of BCL2 protein; BCL2 affects the reaction [Bortezomib results in increased susceptibility to and results in increased activity of TNFSF10 protein]; lonafarnib promotes the reaction [Bortezomib results in increased cleavage of BCL2 protein modified form]
Bortezomib results in increased expression of BCL2 mRNA; Bortezomib results in increased expression of BCL2 protein
Bortezomib results in decreased expression of BCL2 mRNA; Bortezomib results in decreased expression of BCL2 protein
CTD PMID:15173093, PMID:15781649, PMID:16022909, PMID:16118318, PMID:16446371, PMID:17156654, PMID:17326159, PMID:17327374, PMID:17351739, PMID:17895889, PMID:18718063, PMID:18928586, PMID:20051518, PMID:20383943, PMID:20471514, PMID:21302442, PMID:24377552 NCBI chr13:26,605,426...26,769,374
Ensembl chr13:26,605,426...26,769,374
JBrowse link
G Bcl2a1 BCL2-related protein A1 multiple interactions
increases expression
ISO [romidepsin co-treated with Bortezomib] results in decreased expression of BCL2A1 protein
Bortezomib results in increased expression of BCL2A1A protein
CTD PMID:18223231, PMID:20051518 NCBI chr 8:96,551,424...96,559,527
Ensembl chr 8:96,551,245...96,559,483
JBrowse link
G Bcl2l1 Bcl2-like 1 multiple interactions
decreases expression
increases expression
increases cleavage
decreases response to substance
ISO [alvocidib co-treated with Bortezomib] results in decreased expression of BCL2L1 protein; [geldanamycin co-treated with Bortezomib] results in decreased expression of BCL2L1 protein; [romidepsin co-treated with Bortezomib] results in decreased expression of BCL2L1 protein; [vorinostat co-treated with Bortezomib] results in decreased expression of BCL2L1 protein alternative form; [vorinostat co-treated with Bortezomib] results in increased expression of BCL2L1 mRNA alternative form; [vorinostat co-treated with Bortezomib] results in increased expression of BCL2L1 protein alternative form; BCL2L1 affects the reaction [Bortezomib results in increased susceptibility to and results in increased activity of TNFSF10 protein]; BCL2L1 protein results in decreased susceptibility to [Bortezomib co-treated with trichostatin A]; lonafarnib promotes the reaction [Bortezomib results in increased cleavage of BCL2L1 protein]; SCIO-469 promotes the reaction [Bortezomib results in decreased expression of BCL2L1 protein]; trichostatin A promotes the reaction [Bortezomib results in decreased expression of BCL2L1 mRNA]; trichostatin A promotes the reaction [Bortezomib results in decreased expression of BCL2L1 protein]
Bortezomib results in decreased expression of BCL2L1 mRNA; Bortezomib results in decreased expression of BCL2L1 protein
Bortezomib results in increased expression of BCL2L1 protein
BCL2L1 protein results in decreased susceptibility to Bortezomib
CTD PMID:15039284, PMID:15543232, PMID:15781649, PMID:16118318, PMID:16446371, PMID:16617327, PMID:16904634, PMID:17326159, PMID:17327374, PMID:17351739, PMID:18223231, PMID:19100720, PMID:20051518 NCBI chr 3:148,259,594...148,314,191
Ensembl chr 3:148,259,596...148,313,810
JBrowse link
G Bcl2l11 BCL2 like 11 multiple interactions
increases expression
increases activity
increases response to substance
ISO [Bortezomib co-treated with romidepsin] results in increased expression of BCL2L11 protein; Acetylcysteine inhibits the reaction [[Bortezomib co-treated with romidepsin] results in increased expression of BCL2L11 protein]
Bortezomib results in increased expression of BCL2L11 protein
Bortezomib results in increased activity of BCL2L11 protein
BCL2L11 results in increased susceptibility to Bortezomib
CTD PMID:15173094, PMID:16024631, PMID:16446371, PMID:17326159, PMID:18566236 NCBI chr 3:120,726,906...120,764,192
Ensembl chr 3:120,726,906...120,764,192
JBrowse link
G Bcl2l2 Bcl2-like 2 increases expression ISO Bortezomib results in increased expression of BCL2L2 mRNA CTD PMID:18928586 NCBI chr15:33,543,774...33,549,165
Ensembl chr15:33,544,312...33,549,164
JBrowse link
G Bcl3 BCL3, transcription coactivator multiple interactions
decreases expression
ISO [arsenic trioxide co-treated with Bortezomib] results in decreased expression of BCL3 mRNA
Bortezomib results in decreased expression of BCL3 mRNA
CTD PMID:20471514, PMID:20977926 NCBI chr 1:80,730,758...80,745,273
Ensembl chr 1:80,730,499...80,744,831
JBrowse link
G Bcl6 BCL6, transcription repressor increases expression ISO Bortezomib results in increased expression of BCL6 mRNA CTD PMID:20977926 NCBI chr11:80,255,790...80,279,075
Ensembl chr11:80,255,790...80,279,075
JBrowse link
G Bcl7a BAF chromatin remodeling complex subunit BCL7A decreases expression ISO Bortezomib results in decreased expression of BCL7A mRNA CTD PMID:20977926 NCBI chr12:38,659,294...38,691,191
Ensembl chr12:38,662,303...38,691,075
JBrowse link
G Bcr BCR activator of RhoGEF and GTPase decreases expression ISO Bortezomib results in decreased expression of BCR mRNA CTD PMID:20977926 NCBI chr20:14,421,250...14,546,406
Ensembl chr20:14,421,141...14,545,772
JBrowse link
G Becn1 beclin 1 multiple interactions
decreases response to substance
ISO BECN1 mutant form promotes the reaction [Bortezomib results in increased cleavage of and results in increased activity of CASP3 protein]
BECN1 protein results in decreased susceptibility to Bortezomib
CTD PMID:22842577 NCBI chr10:89,209,944...89,225,297
Ensembl chr10:89,209,940...89,225,297
JBrowse link
G Bid BH3 interacting domain death agonist increases cleavage
multiple interactions
ISO Bortezomib results in increased cleavage of BID protein
[Bortezomib co-treated with Butyrates] results in decreased expression of BID protein; [Bortezomib co-treated with TNFSF10 protein] results in increased cleavage of BID protein; [Bortezomib co-treated with vorinostat] results in decreased expression of BID protein; [Bortezomib results in increased susceptibility to and results in increased activity of TNFSF10 protein] which results in increased cleavage of BID protein; [TNFSF10 protein co-treated with Bortezomib] results in increased cleavage of BID protein; [vorinostat co-treated with Bortezomib] results in increased cleavage of BID protein; Bortezomib promotes the reaction [TNFSF10 protein results in increased cleavage of BID protein]
CTD PMID:12893773, PMID:12902978, PMID:15930312, PMID:17326159, PMID:17351739, PMID:17898295, PMID:19261616 NCBI chr 4:153,439,812...153,465,247
Ensembl chr 4:153,442,218...153,465,203
JBrowse link
G Bik BCL2-interacting killer increases response to substance
increases expression
increases activity
ISO BIK results in increased susceptibility to Bortezomib
Bortezomib results in increased expression of BIK protein
Bortezomib results in increased activity of BIK protein
CTD PMID:16446371, PMID:18566236 NCBI chr 7:124,390,924...124,410,449
Ensembl chr 7:124,391,432...124,410,447
JBrowse link
G Bin1 bridging integrator 1 increases expression ISO Bortezomib results in increased expression of BIN1 mRNA CTD PMID:17659339 NCBI chr18:25,163,575...25,222,139
Ensembl chr18:25,163,561...25,222,135
JBrowse link
G Birc2 baculoviral IAP repeat-containing 2 decreases expression
multiple interactions
ISO Bortezomib results in decreased expression of BIRC2 protein
[geldanamycin co-treated with Bortezomib] results in decreased expression of BIRC2 protein; [romidepsin co-treated with Bortezomib] results in decreased expression of BIRC2 protein
CTD PMID:15543232, PMID:15781649, PMID:17626072, PMID:18223231 NCBI chr 8:6,014,014...6,036,668
Ensembl chr 8:6,013,207...6,034,142
JBrowse link
G Birc3 baculoviral IAP repeat-containing 3 decreases expression
increases expression
multiple interactions
ISO Bortezomib results in decreased expression of BIRC3 protein
Bortezomib results in increased expression of BIRC3 mRNA; Bortezomib results in increased expression of BIRC3 protein
[BRCA1 mutant form results in increased susceptibility to Bortezomib] which results in increased expression of BIRC3 mRNA
CTD PMID:17626072, PMID:24085292, PMID:25522274 NCBI chr 8:6,048,590...6,076,828
Ensembl chr 8:6,048,969...6,076,598
JBrowse link
G Birc5 baculoviral IAP repeat-containing 5 decreases expression
multiple interactions
increases expression
ISO Bortezomib results in decreased expression of BIRC5 mRNA; Bortezomib results in decreased expression of BIRC5 protein
[irinotecan co-treated with Bortezomib] results in decreased expression of BIRC5 protein; [romidepsin co-treated with Bortezomib] results in increased cleavage of BIRC5 protein
Bortezomib results in increased expression of BIRC5 protein
CTD PMID:16373703, PMID:17510429, PMID:17898295, PMID:18223231, PMID:18850583, PMID:19636294, PMID:20977926 NCBI chr10:106,856,097...106,864,419
Ensembl chr10:106,856,097...106,864,413
JBrowse link
G Birc7 baculoviral IAP repeat-containing 7 multiple interactions
decreases expression
ISO arsenic trioxide promotes the reaction [Bortezomib results in decreased expression of BIRC7 mRNA] CTD PMID:21867610 NCBI chr 3:176,438,335...176,443,864
Ensembl chr 3:176,439,199...176,443,195
JBrowse link
G Bles03 basophilic leukemia expressed protein BLES03 decreases expression ISO Bortezomib results in decreased expression of C11ORF68 mRNA CTD PMID:20977926 NCBI chr 1:220,806,563...220,808,817
Ensembl chr 1:220,806,473...220,808,804
JBrowse link
G Blk BLK proto-oncogene, Src family tyrosine kinase decreases expression ISO Bortezomib results in decreased expression of BLK mRNA CTD PMID:20977926 NCBI chr15:46,555,552...46,593,778
Ensembl chr15:46,555,188...46,593,653
JBrowse link
G Blvrb biliverdin reductase B increases expression ISO Bortezomib results in increased expression of BLVRB mRNA CTD PMID:20977926 NCBI chr 1:84,256,063...84,273,726
Ensembl chr 1:84,256,159...84,274,075
JBrowse link
G Bnip3 BCL2 interacting protein 3 increases expression ISO Bortezomib results in increased expression of BNIP3 protein CTD PMID:20110775 NCBI chr 1:211,248,098...211,265,282
Ensembl chr 1:211,248,098...211,265,282
JBrowse link
G Brca1 BRCA1, DNA repair associated decreases expression
multiple interactions
increases response to substance
decreases ubiquitination
ISO Bortezomib results in decreased expression of BRCA1 mRNA
BRCA1 protein inhibits the reaction [BRCA1 gene mutant form results in increased susceptibility to Bortezomib]
[BRCA1 mutant form results in increased susceptibility to Bortezomib] which results in decreased expression of AKR7A2 mRNA; [BRCA1 mutant form results in increased susceptibility to Bortezomib] which results in decreased expression of CCNF mRNA; [BRCA1 mutant form results in increased susceptibility to Bortezomib] which results in decreased expression of CCNG2 mRNA; [BRCA1 mutant form results in increased susceptibility to Bortezomib] which results in decreased expression of CRYGEP mRNA; [BRCA1 mutant form results in increased susceptibility to Bortezomib] which results in decreased expression of DAPK2 mRNA; [BRCA1 mutant form results in increased susceptibility to Bortezomib] which results in decreased expression of DLGAP5 mRNA; [BRCA1 mutant form results in increased susceptibility to Bortezomib] which results in decreased expression of EGLN3 mRNA; [BRCA1 mutant form results in increased susceptibility to Bortezomib] which results in decreased expression of FZD2 mRNA; [BRCA1 mutant form results in increased susceptibility to Bortezomib] which results in decreased expression of H3C6 mRNA; [BRCA1 mutant form results in increased susceptibility to Bortezomib] which results in decreased expression of LGR4 mRNA; [BRCA1 mutant form results in increased susceptibility to Bortezomib] which results in decreased expression of RPS7P5 mRNA; [BRCA1 mutant form results in increased susceptibility to Bortezomib] which results in decreased expression of THRA mRNA; [BRCA1 mutant form results in increased susceptibility to Bortezomib] which results in decreased expression of TNFAIP8L1 mRNA; [BRCA1 mutant form results in increased susceptibility to Bortezomib] which results in decreased expression of TNKS mRNA; [BRCA1 mutant form results in increased susceptibility to Bortezomib] which results in increased activity of E2F1 protein; [BRCA1 mutant form results in increased susceptibility to Bortezomib] which results in increased cleavage of PARP1 protein; [BRCA1 mutant form results in increased susceptibility to Bortezomib] which results in increased expression of ARID3B mRNA; [BRCA1 mutant form results in increased susceptibility to Bortezomib] which results in increased expression of ATF3 mRNA; [BRCA1 mutant form results in increased susceptibility to Bortezomib] which results in increased expression of BIRC3 mRNA; [BRCA1 mutant form results in increased susceptibility to Bortezomib] which results in increased expression of CCNB1 protein; [BRCA1 mutant form results in increased susceptibility to Bortezomib] which results in increased expression of CRYAB mRNA; [BRCA1 mutant form results in increased susceptibility to Bortezomib] which results in increased expression of CTH mRNA; [BRCA1 mutant form results in increased susceptibility to Bortezomib] which results in increased expression of DUSP5 mRNA; [BRCA1 mutant form results in increased susceptibility to Bortezomib] which results in increased expression of ERN1 mRNA; [BRCA1 mutant form results in increased susceptibility to Bortezomib] which results in increased expression of FGF21 mRNA; [BRCA1 mutant form results in increased susceptibility to Bortezomib] which results in increased expression of GADD45A mRNA; [BRCA1 mutant form results in increased susceptibility to Bortezomib] which results in increased expression of GDF15 mRNA; [BRCA1 mutant form results in increased susceptibility to Bortezomib] which results in increased expression of HECW1 mRNA; [BRCA1 mutant form results in increased susceptibility to Bortezomib] which results in increased expression of HIKESHI mRNA; [BRCA1 mutant form results in increased susceptibility to Bortezomib] which results in increased expression of IL7R mRNA; [BRCA1 mutant form results in increased susceptibility to Bortezomib] which results in increased expression of KRTAP21-1 mRNA; [BRCA1 mutant form results in increased susceptibility to Bortezomib] which results in increased expression of MIR568 mRNA; [BRCA1 mutant form results in increased susceptibility to Bortezomib] which results in increased expression of PAWR mRNA; [BRCA1 mutant form results in increased susceptibility to Bortezomib] which results in increased expression of PCYT1A mRNA; [BRCA1 mutant form results in increased susceptibility to Bortezomib] which results in increased expression of RND3 mRNA; [BRCA1 mutant form results in increased susceptibility to Bortezomib] which results in increased expression of TNFAIP3 mRNA; [BRCA1 mutant form results in increased susceptibility to Bortezomib] which results in increased expression of TNFRSF9 mRNA; [BRCA1 mutant form results in increased susceptibility to Bortezomib] which results in increased expression of TRIB3 mRNA; [BRCA1 mutant form results in increased susceptibility to Bortezomib] which results in increased expression of TRIML2 mRNA; [BRCA1 mutant form results in increased susceptibility to Bortezomib] which results in increased expression of ZNF613 mRNA; [BRCA1 mutant form results in increased susceptibility to Bortezomib] which results in increased phosphorylation of RB1 protein; TP53BP1 protein affects the reaction [[BRCA1 mutant form results in increased susceptibility to Bortezomib] which results in increased cleavage of PARP1 protein]; TP53BP1 protein affects the reaction [[BRCA1 mutant form results in increased susceptibility to Bortezomib] which results in increased phosphorylation of RB1 protein]
Bortezomib results in decreased ubiquitination of BRCA1 protein
CTD PMID:21917757, PMID:25522274 NCBI chr10:89,394,821...89,455,093
Ensembl chr10:89,394,803...89,454,681
JBrowse link
G Brca2 BRCA2, DNA repair associated decreases expression
multiple interactions
ISO Bortezomib results in decreased expression of BRCA2 mRNA
[arsenic trioxide co-treated with Bortezomib] results in increased expression of BRCA2 mRNA
CTD PMID:21917757, PMID:25913414 NCBI chr12:503,660...544,754
Ensembl chr12:504,007...544,748
JBrowse link
G Brcc3 BRCA1/BRCA2-containing complex, subunit 3 decreases expression ISO Bortezomib results in decreased expression of BRCC3 mRNA CTD PMID:20977926 NCBI chr 9:9,863,380...9,865,920
Ensembl chr 9:9,863,404...9,865,920
JBrowse link
G Brf2 BRF2, RNA polymerase III transcription initiation factor subunit increases expression ISO Bortezomib results in increased expression of BRF2 mRNA CTD PMID:20977926 NCBI chr16:69,089,955...69,094,678
Ensembl chr16:69,089,955...69,094,680
JBrowse link
G Bsdc1 BSD domain containing 1 increases expression ISO Bortezomib results in increased expression of BSDC1 mRNA CTD PMID:20977926 NCBI chr 5:147,661,618...147,689,766
Ensembl chr 5:147,661,618...147,689,759
JBrowse link
G Ca9 carbonic anhydrase 9 decreases expression ISO Bortezomib results in decreased expression of CA9 protein CTD PMID:16061869 NCBI chr 5:59,008,277...59,015,535
Ensembl chr 5:59,008,933...59,015,528
JBrowse link
G Caap1 caspase activity and apoptosis inhibitor 1 increases expression ISO Bortezomib results in increased expression of CAAP1 mRNA CTD PMID:20977926 NCBI chr 5:113,479,416...113,532,961
Ensembl chr 5:113,480,547...113,532,878
JBrowse link
G Cacna1h calcium voltage-gated channel subunit alpha1 H decreases degradation ISO Bortezomib results in decreased degradation of CACNA1H protein CTD PMID:30552955 NCBI chr10:14,730,932...14,789,201
Ensembl chr10:14,730,941...14,788,617
JBrowse link
G Calr calreticulin multiple interactions
increases expression
ISO [CEBPB protein alternative form results in increased susceptibility to Doxorubicin] promotes the reaction [[Bortezomib co-treated with Chloroquine] results in increased expression of and affects the localization of CALR protein]; [CEBPB protein alternative form results in increased susceptibility to Doxorubicin] promotes the reaction [[Bortezomib co-treated with Chloroquine] results in increased expression of CALR mRNA]; [CEBPB protein alternative form results in increased susceptibility to Doxorubicin] promotes the reaction [Bortezomib results in increased expression of and affects the localization of CALR protein]; [CEBPB protein alternative form results in increased susceptibility to Doxorubicin] promotes the reaction [Bortezomib results in increased expression of CALR mRNA]; [Chloroquine co-treated with Bortezomib] promotes the reaction [CEBPB protein alternative form binds to CALR promoter]; [Chloroquine co-treated with Bortezomib] results in increased expression of and affects the localization of CALR protein; [Chloroquine co-treated with Bortezomib] results in increased expression of CALR mRNA; Bortezomib promotes the reaction [CEBPB protein alternative form binds to CALR promoter]; Bortezomib results in increased expression of and affects the localization of CALR protein; CEBPB protein alternative form promotes the reaction [[Chloroquine co-treated with Bortezomib] results in increased expression of and affects the localization of CALR protein]; CEBPB protein alternative form promotes the reaction [[Chloroquine co-treated with Bortezomib] results in increased expression of CALR mRNA]; CEBPB protein alternative form promotes the reaction [Bortezomib results in increased expression of and affects the localization of CALR protein]; CEBPB protein alternative form promotes the reaction [Bortezomib results in increased expression of CALR mRNA]; DDIT3 protein affects the reaction [[Chloroquine co-treated with Bortezomib] affects the localization of CALR protein]; DDIT3 protein affects the reaction [Bortezomib affects the localization of CALR protein]; Doxorubicin promotes the reaction [[Chloroquine co-treated with Bortezomib] affects the localization of CALR protein]; Doxorubicin promotes the reaction [Bortezomib affects the localization of CALR protein]
[Chloroquine co-treated with Bortezomib] results in increased expression of CALR protein; CEBPB protein alternative form promotes the reaction [[Chloroquine co-treated with Bortezomib] results in increased expression of CALR protein]; Doxorubicin promotes the reaction [CEBPB protein alternative form promotes the reaction [[Chloroquine co-treated with Bortezomib] results in increased expression of CALR protein]]
CTD PMID:30482226 NCBI chr19:25,956,771...25,961,666
Ensembl chr19:25,956,771...25,961,666
JBrowse link
G Capn15 calpain 15 decreases expression ISO Bortezomib results in decreased expression of CAPN15 mRNA CTD PMID:20977926 NCBI chr10:15,319,772...15,346,607
Ensembl chr10:15,319,774...15,346,374
JBrowse link
G Card9 caspase recruitment domain family, member 9 multiple interactions ISO [arsenic trioxide co-treated with Bortezomib] results in increased expression of CARD9 mRNA CTD PMID:20471514 NCBI chr 3:3,798,346...3,806,841
Ensembl chr 3:3,798,347...3,806,713
JBrowse link
G Casp12 caspase 12 increases cleavage ISO Bortezomib results in increased cleavage of CASP12 protein CTD PMID:15509775, PMID:16357177 NCBI chr 8:2,658,892...2,686,160
Ensembl chr 8:2,659,865...2,686,160
JBrowse link
G Casp2 caspase 2 multiple interactions
increases response to substance
increases cleavage
ISO benzoylcarbonyl-valyl-aspartyl-valyl-alanyl-aspartyl-fluoromethyl ketone inhibits the reaction [Bortezomib results in increased cleavage of and results in increased activity of CASP2 protein]; Bortezomib promotes the reaction [Brefeldin A results in increased cleavage of and results in increased activity of CASP2 protein]; Bortezomib results in increased cleavage of and results in increased activity of CASP2 protein; Brefeldin A promotes the reaction [Bortezomib results in increased cleavage of and results in increased activity of CASP2 protein]; CASP2 protein affects the reaction [Bortezomib results in increased cleavage of and results in increased activity of CASP9 protein]
CASP2 results in increased susceptibility to Bortezomib
Bortezomib results in increased cleavage of CASP2 protein
CTD PMID:15509775, PMID:16446371, PMID:18723477 NCBI chr 4:71,652,358...71,670,228
Ensembl chr 4:71,652,354...71,670,239
JBrowse link
G Casp3 caspase 3 increases activity
increases cleavage
multiple interactions
increases expression
ISO Bortezomib results in increased activity of CASP3 protein
Bortezomib results in increased cleavage of CASP3 protein
1,3-dihydroxy-4,4,5,5-tetramethyl-2-(4-carboxyphenyl)tetrahydroimidazole inhibits the reaction [[Chloroquine co-treated with Bortezomib] results in increased cleavage of CASP3 protein]; 1,3-dihydroxy-4,4,5,5-tetramethyl-2-(4-carboxyphenyl)tetrahydroimidazole inhibits the reaction [Bortezomib results in increased cleavage of CASP3 protein]; 1-(4-(4-propionylpiperazin-1-yl)-3-(trifluoromethyl)phenyl)-9-(quinolin-3-yl)benzo(h)(1,6)naphthyridin-2(1H)-one inhibits the reaction [[Bortezomib co-treated with Chloroquine] results in increased cleavage of CASP3 protein]; [Bortezomib co-treated with Chloroquine] results in increased cleavage of CASP3 protein; [Chloroquine co-treated with Bortezomib] results in increased cleavage of CASP3 protein; [SCIO-469 co-treated with Bortezomib] results in increased activity of CASP3 protein; ATG5 gene mutant form inhibits the reaction [Bortezomib results in increased cleavage of and results in increased activity of CASP3 protein]; ATG5 gene mutant form inhibits the reaction [HRAS protein promotes the reaction [Bortezomib results in increased cleavage of and results in increased activity of CASP3 protein]]; betulinic acid inhibits the reaction [[Chloroquine co-treated with Bortezomib] results in increased cleavage of CASP3 protein]; betulinic acid inhibits the reaction [Bortezomib results in increased cleavage of CASP3 protein]; Bortezomib results in increased cleavage of and results in increased activity of CASP3 protein; CEBPB protein alternative form promotes the reaction [[Chloroquine co-treated with Bortezomib] results in increased cleavage of CASP3 protein]; Doxorubicin promotes the reaction [[Bortezomib co-treated with Chloroquine] results in increased cleavage of CASP3 protein]; Doxorubicin promotes the reaction [Bortezomib results in increased cleavage of CASP3 protein]; Doxorubicin promotes the reaction [CEBPB protein alternative form promotes the reaction [[Chloroquine co-treated with Bortezomib] results in increased cleavage of CASP3 protein]]; HRAS protein promotes the reaction [Bortezomib results in increased cleavage of and results in increased activity of CASP3 protein]; Nitroprusside promotes the reaction [[Chloroquine co-treated with Bortezomib] results in increased cleavage of CASP3 protein]; Nitroprusside promotes the reaction [Bortezomib results in increased cleavage of CASP3 protein]
1,2-Dihydroxybenzene-3,5-Disulfonic Acid Disodium Salt affects the reaction [Bortezomib results in increased cleavage of CASP3 protein]; 1,3-dihydroxy-4,4,5,5-tetramethyl-2-(4-carboxyphenyl)tetrahydroimidazole inhibits the reaction [[Chloroquine co-treated with Bortezomib] results in increased cleavage of CASP3 protein]; 1,3-dihydroxy-4,4,5,5-tetramethyl-2-(4-carboxyphenyl)tetrahydroimidazole inhibits the reaction [Bortezomib results in increased cleavage of CASP3 protein]; 1-(4-(4-propionylpiperazin-1-yl)-3-(trifluoromethyl)phenyl)-9-(quinolin-3-yl)benzo(h)(1,6)naphthyridin-2(1H)-one inhibits the reaction [[Bortezomib co-treated with Chloroquine] results in increased cleavage of CASP3 protein]; [Arsenic Trioxide co-treated with Bortezomib] results in increased activity of CASP3 protein; [Arsenic Trioxide co-treated with Bortezomib] results in increased cleavage of CASP3 protein; [Bortezomib co-treated with 1-(2-cyano-3,12-dioxooleana-1,9-dien-28-oyl) imidazole] results in increased activity of CASP3 protein; [Bortezomib co-treated with abexinostat] results in increased activity of CASP3 protein; [Bortezomib co-treated with Arsenic Trioxide] affects the expression of CASP3 protein; [Bortezomib co-treated with Arsenic Trioxide] results in increased activity of CASP3 protein; [Bortezomib co-treated with Arsenic Trioxide] results in increased expression of CASP3 protein; [Bortezomib co-treated with Butyrates] results in increased cleavage of and results in increased activity of CASP3 protein; [Bortezomib co-treated with Chloroquine] results in increased cleavage of CASP3 protein; [Bortezomib co-treated with N,N-dimethylsphingosine] results in increased cleavage of and results in increased activity of CASP3 protein; [Bortezomib co-treated with oblimersen co-treated with Cyclophosphamide] results in increased activity of CASP3 protein; [Bortezomib co-treated with Sorafenib] results in increased cleavage of CASP3 protein; [Bortezomib co-treated with TNFSF10 protein] results in increased cleavage of CASP3 protein; [Bortezomib co-treated with trichostatin A] results in increased cleavage of and results in increased activity of CASP3 protein; [Bortezomib co-treated with Vorinostat] results in increased activity of CASP3 protein; [Bortezomib co-treated with Vorinostat] results in increased cleavage of and results in increased activity of CASP3 protein; [Bortezomib results in increased susceptibility to and results in increased activity of TNFSF10 protein] which results in increased cleavage of CASP3 protein; [CASP8 protein results in increased activity of CASP3 protein] affects the reaction [Bortezomib results in increased cleavage of ATM protein]; [CASP8 protein results in increased activity of CASP3 protein] affects the reaction [Bortezomib results in increased cleavage of MDM2 protein]; [CASP8 protein results in increased activity of CASP3 protein] affects the reaction [Bortezomib results in increased cleavage of PRKDC protein]; [CASP8 protein results in increased activity of CASP3 protein] affects the reaction [Bortezomib results in increased phosphorylation of TP53 protein]; [Cisplatin co-treated with Bortezomib] results in increased activity of CASP3 protein; [Dexamethasone co-treated with Bortezomib] results in increased activity of CASP3 protein; [gambogic acid co-treated with Bortezomib] results in increased activity of CASP3 protein; [lonafarnib co-treated with Bortezomib] results in increased cleavage of CASP3 protein; [nutlin 3 co-treated with Bortezomib] results in increased activity of CASP3 protein; [TNFSF10 protein co-treated with Bortezomib] results in increased activity of CASP3 protein; [trichostatin A co-treated with Bortezomib] results in increased cleavage of CASP3 protein; [Vorinostat co-treated with Bortezomib] results in increased activity of CASP3 protein; [Vorinostat co-treated with Bortezomib] results in increased cleavage of CASP3 protein; AKT1 protein inhibits the reaction [[Bortezomib co-treated with Sorafenib] results in increased cleavage of CASP3 protein]; BECN1 mutant form promotes the reaction [Bortezomib results in increased cleavage of and results in increased activity of CASP3 protein]; benzyloxycarbonyl-valyl-alanyl-aspartic acid analog inhibits the reaction [[gambogic acid co-treated with Bortezomib] results in increased activity of CASP3 protein]; betulinic acid inhibits the reaction [[Chloroquine co-treated with Bortezomib] results in increased cleavage of CASP3 protein]; betulinic acid inhibits the reaction [Bortezomib results in increased cleavage of CASP3 protein]; Boc-D-FMK inhibits the reaction [[Bortezomib co-treated with Sorafenib] results in increased cleavage of CASP3 protein]; Bortezomib promotes the reaction [belinostat results in increased cleavage of CASP3 protein]; Bortezomib promotes the reaction [Butyrates results in increased activity of CASP3 protein]; Bortezomib promotes the reaction [gallium nitrate results in increased activity of CASP3 protein]; Bortezomib promotes the reaction [NSC606985 results in increased activity of CASP3 protein]; Bortezomib promotes the reaction [romidepsin results in increased cleavage of CASP3 protein]; Bortezomib promotes the reaction [Thapsigargin results in increased activity of CASP3 protein]; Bortezomib promotes the reaction [TNFSF10 protein results in increased activity of CASP3 protein]; Bortezomib promotes the reaction [Tunicamycin results in increased activity of CASP3 protein]; Bortezomib promotes the reaction [Vorinostat results in increased activity of CASP3 protein]; Bortezomib results in increased cleavage of and results in increased activity of CASP3 protein; DDIT3 protein affects the reaction [[Chloroquine co-treated with Bortezomib] results in increased cleavage of CASP3 protein]; DDIT3 protein affects the reaction [Bortezomib results in increased cleavage of CASP3 protein]; Doxorubicin promotes the reaction [[Chloroquine co-treated with Bortezomib] results in increased cleavage of CASP3 protein]; Doxorubicin promotes the reaction [Bortezomib results in increased cleavage of CASP3 protein]; MAPK14 mutant form inhibits the reaction [Bortezomib results in increased cleavage of CASP3 protein]; Nitroprusside promotes the reaction [[Chloroquine co-treated with Bortezomib] results in increased cleavage of CASP3 protein]; Nitroprusside promotes the reaction [Bortezomib results in increased cleavage of CASP3 protein]; PMAIP1 protein promotes the reaction [[Bortezomib co-treated with Arsenic Trioxide] results in increased activity of CASP3 protein]; pyrazolanthrone inhibits the reaction [Bortezomib results in increased activity of CASP3 protein]; pyrazolanthrone inhibits the reaction [Bortezomib results in increased cleavage of CASP3 protein]; SCIO-469 promotes the reaction [Bortezomib results in increased cleavage of CASP3 protein]; STK4 mutant form inhibits the reaction [Bortezomib results in increased activity of CASP3 protein]; TNFRSF10B mutant form inhibits the reaction [[Bortezomib co-treated with TNFSF10 protein] results in increased cleavage of CASP3 protein]; TNFRSF10B mutant form inhibits the reaction [Bortezomib results in increased cleavage of CASP3 protein]; TNFSF10 protein promotes the reaction [Bortezomib results in increased activity of CASP3 protein]
Bortezomib results in increased expression of CASP3 protein
CTD PMID:12393500, PMID:12893773, PMID:15070698, PMID:15173093, PMID:15509775, PMID:15514602, PMID:15930312, PMID:16024631, PMID:16118318, PMID:16357177, PMID:16617327, PMID:16675587, PMID:16778179, PMID:16904634, PMID:16985072, PMID:17121930, PMID:17156654, PMID:17326159, PMID:17351739, PMID:17495969, PMID:17510429, PMID:17898295, PMID:17898787, PMID:18005386, PMID:18223231, PMID:18223318, PMID:18342500, PMID:18534018, PMID:18641367, PMID:18718063, PMID:18790767, PMID:19100720, PMID:19261616, PMID:19417023, PMID:19662097, PMID:20022965, PMID:20051518, PMID:20150630, PMID:20383943, PMID:20471514, PMID:20524303, PMID:20850924, PMID:21195056, PMID:21345073, PMID:21472287, PMID:21518486, PMID:22842577, PMID:23063726, PMID:23300809, PMID:24291039, PMID:24377552, PMID:29384525, PMID:30482226 NCBI chr16:48,845,011...48,863,249
Ensembl chr16:48,845,012...48,863,204
JBrowse link
G Casp4 caspase 4 multiple interactions
increases response to substance
increases cleavage
increases activity
ISO [Bortezomib co-treated with vorinostat] results in increased activity of CASP4 protein; CASP4 protein results in increased susceptibility to [Cisplatin co-treated with Bortezomib]; PMAIP1 protein promotes the reaction [[Bortezomib co-treated with vorinostat] results in increased activity of CASP4 protein]; pyrazolanthrone inhibits the reaction [Bortezomib results in increased cleavage of CASP4 protein]
CASP4 protein results in increased susceptibility to Bortezomib
Bortezomib results in increased activity of CASP4 protein
CTD PMID:16357177, PMID:18641367 NCBI chr 8:2,616,391...2,651,682
Ensembl chr 8:2,635,851...2,651,652
JBrowse link
G Casp6 caspase 6 multiple interactions
increases cleavage
ISO Bortezomib promotes the reaction [TNFSF10 protein results in increased cleavage of CASP6 protein]; SCIO-469 promotes the reaction [Bortezomib results in increased cleavage of CASP6 protein] CTD PMID:16617327, PMID:17510429 NCBI chr 2:235,341,326...235,353,715
Ensembl chr 2:235,341,365...235,353,967
Ensembl chr 2:235,341,365...235,353,967
JBrowse link
G Casp7 caspase 7 multiple interactions
increases cleavage
increases activity
ISO [Bortezomib co-treated with trichostatin A] results in increased cleavage of and results in increased activity of CASP7 protein; Bortezomib results in increased cleavage of and results in increased activity of CASP7 protein; SCIO-469 promotes the reaction [Bortezomib results in increased cleavage of CASP7 protein]
Bortezomib results in increased activity of CASP7 protein
CTD PMID:16024631, PMID:16617327, PMID:16904634, PMID:18342500, PMID:18534018, PMID:20022965, PMID:20524303, PMID:23300809 NCBI chr 1:277,190,557...277,242,779
Ensembl chr 1:277,190,964...277,242,774
JBrowse link
G Casp8 caspase 8 multiple interactions
increases cleavage
ISO [arsenic trioxide co-treated with Bortezomib] results in decreased expression of CASP8 mRNA; [Bortezomib co-treated with 1-(2-cyano-3,12-dioxooleana-1,9-dien-28-oyl) imidazole] results in increased activity of CASP8 protein; [Bortezomib co-treated with arsenic trioxide] results in increased expression of CASP8 protein; [Bortezomib co-treated with Butyrates] results in increased cleavage of and results in increased activity of CASP8 protein; [Bortezomib co-treated with TNFSF10 protein] results in increased activity of CASP8 protein; [Bortezomib co-treated with TNFSF10 protein] results in increased cleavage of CASP8 protein; [Bortezomib co-treated with trichostatin A] results in increased cleavage of and results in increased activity of CASP8 protein; [Bortezomib co-treated with vorinostat] results in increased activity of CASP8 protein; [Bortezomib co-treated with vorinostat] results in increased cleavage of and results in increased activity of CASP8 protein; [Bortezomib results in increased susceptibility to and results in increased activity of TNFSF10 protein] which results in increased cleavage of CASP8 protein; [CASP8 protein results in increased activity of CASP3 protein] affects the reaction [Bortezomib results in increased cleavage of ATM protein]; [CASP8 protein results in increased activity of CASP3 protein] affects the reaction [Bortezomib results in increased cleavage of MDM2 protein]; [CASP8 protein results in increased activity of CASP3 protein] affects the reaction [Bortezomib results in increased cleavage of PRKDC protein]; [CASP8 protein results in increased activity of CASP3 protein] affects the reaction [Bortezomib results in increased phosphorylation of TP53 protein]; [gambogic acid co-treated with Bortezomib] results in increased activity of CASP8 protein; [IFNA2 protein co-treated with Bortezomib] results in increased activity of CASP8 protein; [lonafarnib co-treated with Bortezomib] results in increased cleavage of CASP8 protein; [TNFSF10 protein co-treated with Bortezomib] results in increased cleavage of CASP8 protein; [trichostatin A co-treated with Bortezomib] results in increased cleavage of CASP8 protein; [vorinostat co-treated with Bortezomib] results in increased cleavage of CASP8 protein; AKT1 protein inhibits the reaction [[Bortezomib co-treated with TNFSF10 protein] results in increased activity of CASP8 protein]; Bortezomib promotes the reaction [abexinostat results in increased cleavage of CASP8 protein]; Bortezomib promotes the reaction [arsenic trioxide results in increased activity of CASP8 protein]; Bortezomib promotes the reaction [Butyrates results in increased activity of CASP8 protein]; Bortezomib promotes the reaction [TNFSF10 protein results in increased activity of CASP8 protein]; Bortezomib promotes the reaction [TNFSF10 protein results in increased cleavage of CASP8 protein]; Bortezomib promotes the reaction [vorinostat results in increased activity of CASP8 protein]; Bortezomib results in increased cleavage of and results in increased activity of CASP8 protein; CDKN1A protein affects the reaction [[TNFSF10 protein co-treated with Bortezomib] results in increased cleavage of CASP8 protein]; SCIO-469 promotes the reaction [Bortezomib results in increased cleavage of CASP8 protein]; TNFRSF10B mutant form inhibits the reaction [[Bortezomib co-treated with TNFSF10 protein] results in increased cleavage of CASP8 protein]; TNFRSF10B mutant form inhibits the reaction [Bortezomib results in increased cleavage of CASP8 protein] CTD PMID:12393500, PMID:12893773, PMID:12902978, PMID:15070698, PMID:15173093, PMID:15930312, PMID:16024631, PMID:16118318, PMID:16617327, PMID:16778179, PMID:16904634, PMID:17172406, PMID:17326159, PMID:17351739, PMID:17510429, PMID:17620439, PMID:17626072, PMID:17659339, PMID:17898787, PMID:18005386, PMID:18641367, PMID:19100720, PMID:19261616, PMID:19417023, PMID:20051518, PMID:20442297, PMID:20471514, PMID:21345073, PMID:24291039, PMID:24377552 NCBI chr 9:65,614,142...65,662,624
Ensembl chr 9:65,614,142...65,662,106
JBrowse link
G Casp9 caspase 9 multiple interactions
increases expression
increases response to substance
increases cleavage
ISO 1,2-Dihydroxybenzene-3,5-Disulfonic Acid Disodium Salt affects the reaction [Bortezomib results in increased cleavage of CASP9 protein]; [Bortezomib co-treated with 1-(2-cyano-3,12-dioxooleana-1,9-dien-28-oyl) imidazole] results in increased activity of CASP9 protein; [Bortezomib co-treated with arsenic trioxide] results in increased activity of CASP9 protein; [Bortezomib co-treated with arsenic trioxide] results in increased expression of CASP9 protein; [Bortezomib co-treated with Butyrates] results in increased cleavage of and results in increased activity of CASP9 protein; [Bortezomib co-treated with sorafenib] results in increased cleavage of CASP9 protein; [Bortezomib co-treated with TNFSF10 protein] results in increased cleavage of CASP9 protein; [Bortezomib co-treated with trichostatin A] results in increased cleavage of and results in increased activity of CASP9 protein; [Bortezomib co-treated with vorinostat] results in increased activity of CASP9 protein; [Bortezomib co-treated with vorinostat] results in increased cleavage of and results in increased activity of CASP9 protein; [Bortezomib results in increased susceptibility to and results in increased activity of TNFSF10 protein] which results in increased cleavage of CASP9 protein; [gambogic acid co-treated with Bortezomib] results in increased activity of CASP9 protein; [lonafarnib co-treated with Bortezomib] results in increased cleavage of CASP9 protein; [nutlin 3 co-treated with Bortezomib] results in increased activity of CASP9 protein; [trichostatin A co-treated with Bortezomib] results in increased cleavage of CASP9 protein; AKT1 protein inhibits the reaction [[Bortezomib co-treated with sorafenib] results in increased cleavage of CASP9 protein]; benzoylcarbonyl-valyl-aspartyl-valyl-alanyl-aspartyl-fluoromethyl ketone inhibits the reaction [Bortezomib results in increased cleavage of and results in increased activity of CASP9 protein]; benzyloxycarbonyl-leucyl-glutamyl-histidyl-aspartic acid fluoromethyl ketone inhibits the reaction [Bortezomib results in increased cleavage of and results in increased activity of CASP9 protein]; benzyloxycarbonyl-valyl-alanyl-aspartic acid analog inhibits the reaction [[gambogic acid co-treated with Bortezomib] results in increased activity of CASP9 protein]; Bortezomib promotes the reaction [abexinostat results in increased cleavage of CASP9 protein]; Bortezomib promotes the reaction [arsenic trioxide results in increased activity of CASP9 protein]; Bortezomib promotes the reaction [belinostat results in increased cleavage of CASP9 protein]; Bortezomib promotes the reaction [Butyrates results in increased activity of CASP9 protein]; Bortezomib promotes the reaction [romidepsin results in increased cleavage of CASP9 protein]; Bortezomib promotes the reaction [vorinostat results in increased activity of CASP9 protein]; Bortezomib results in increased cleavage of and results in increased activity of CASP9 protein; CASP2 protein affects the reaction [Bortezomib results in increased cleavage of and results in increased activity of CASP9 protein]; SCIO-469 promotes the reaction [Bortezomib results in increased cleavage of CASP9 protein]; TNFSF10 protein promotes the reaction [Bortezomib results in increased cleavage of CASP9 protein]
Bortezomib results in increased expression of CASP9 protein
CASP9 gene SNP results in increased susceptibility to Bortezomib; CASP9 results in increased susceptibility to Bortezomib
CTD PMID:12893773, PMID:15070698, PMID:15173093, PMID:15509775, PMID:16024631, PMID:16118318, PMID:16617327, PMID:16778179, PMID:16904634, PMID:16985072, PMID:17156654, PMID:17326159, PMID:17510429, PMID:17620439, PMID:17626072, PMID:17898295, PMID:17898787, PMID:18005386, PMID:18223231, PMID:18641367, PMID:18723477, PMID:19261616, PMID:19417023, PMID:20051518, PMID:20471514, PMID:20850924, PMID:20864405, PMID:21345073, PMID:21518486, PMID:24291039, PMID:24377552 NCBI chr 5:160,356,211...160,373,774
Ensembl chr 5:160,355,833...160,373,778
JBrowse link
G Cbl Cbl proto-oncogene multiple interactions ISO [Bortezomib results in decreased activity of CBL protein] promotes the reaction [arsenic trioxide results in increased activity of AKT1 protein] CTD PMID:19457607 NCBI chr 8:48,481,256...48,564,775
Ensembl chr 8:48,489,036...48,564,722
JBrowse link
G Cbr3 carbonyl reductase 3 increases expression ISO [Bortezomib results in increased expression of NFE2L2 protein] which results in increased expression of CBR3 mRNA; Bortezomib results in increased expression of CBR3 mRNA CTD PMID:20806931, PMID:20977926 NCBI chr11:33,909,417...33,917,674
Ensembl chr11:33,909,439...33,917,674
JBrowse link
G Cbx3 chromobox 3 increases expression ISO Bortezomib results in increased expression of CBX3 mRNA CTD PMID:20977926 NCBI chr 4:81,243,809...81,257,898
Ensembl chr 4:81,244,469...81,257,897
JBrowse link
G Ccar1 cell division cycle and apoptosis regulator 1 increases expression ISO Bortezomib results in increased expression of CCAR1 protein CTD PMID:21594647, PMID:21903591 NCBI chr20:32,373,443...32,416,044
Ensembl chr20:32,373,443...32,416,044
JBrowse link
G Ccdc186 coiled-coil domain containing 186 increases expression ISO Bortezomib results in increased expression of CCDC186 mRNA CTD PMID:20977926 NCBI chr 1:277,603,601...277,635,379
Ensembl chr 1:277,606,995...277,629,196
JBrowse link
G Ccdc32 coiled-coil domain containing 32 increases expression ISO Bortezomib results in increased expression of CCDC32 mRNA CTD PMID:20977926 NCBI chr 3:110,816,327...110,828,824
Ensembl chr 3:110,816,337...110,828,879
JBrowse link
G Ccdc6 coiled-coil domain containing 6 decreases expression ISO Bortezomib results in decreased expression of CCDC6 mRNA CTD PMID:20977926 NCBI chr20:19,729,005...19,825,219
Ensembl chr20:19,732,894...19,825,150
JBrowse link
G Ccdc82 coiled-coil domain containing 82 increases expression ISO Bortezomib results in increased expression of CCDC82 mRNA CTD PMID:20977926 NCBI chr 8:11,888,460...11,927,920
Ensembl chr 8:11,888,591...11,927,919
JBrowse link
G Ccl2 C-C motif chemokine ligand 2 decreases expression ISO Bortezomib results in decreased expression of CCL2 mRNA CTD PMID:20471514 NCBI chr10:69,412,065...69,413,863
Ensembl chr10:69,412,017...69,413,870
JBrowse link
G Ccl3 C-C motif chemokine ligand 3 increases expression
decreases expression
EXP
ISO
Bortezomib results in increased expression of CCL3 mRNA; Bortezomib results in increased expression of CCL3 protein
Bortezomib results in decreased expression of CCL3 mRNA
CTD PMID:18089816, PMID:20830808 NCBI chr10:70,869,516...70,871,066
Ensembl chr10:70,869,513...70,871,066
JBrowse link
G Ccnb1 cyclin B1 multiple interactions
increases expression
ISO [BRCA1 mutant form results in increased susceptibility to Bortezomib] which results in increased expression of CCNB1 protein; Bortezomib results in increased ubiquitination of and results in increased expression of CCNB1 protein
Bortezomib results in increased expression of CCNB1 protein
CTD PMID:19074855, PMID:20367638, PMID:25522274 NCBI chr 2:30,782,133...30,791,106
Ensembl chr 2:30,783,915...30,791,221
JBrowse link
G Ccnd1 cyclin D1 multiple interactions ISO [[Bortezomib co-treated with Butyrates] results in increased abundance of Reactive Oxygen Species] which results in decreased expression of CCND1 protein; [[Bortezomib co-treated with vorinostat] results in increased abundance of Reactive Oxygen Species] which results in decreased expression of CCND1 protein; [Bortezomib co-treated with Butyrates] results in decreased expression of CCND1 protein; [Bortezomib co-treated with vorinostat] results in decreased expression of CCND1 protein; [geldanamycin co-treated with Bortezomib] results in decreased expression of CCND1 protein; Acetylcysteine inhibits the reaction [[Bortezomib co-treated with Butyrates] results in decreased expression of CCND1 protein]; Boc-D-FMK inhibits the reaction [[Bortezomib co-treated with Butyrates] results in decreased expression of CCND1 protein]; Boc-D-FMK inhibits the reaction [[Bortezomib co-treated with vorinostat] results in decreased expression of CCND1 protein] CTD PMID:12893773, PMID:15173093, PMID:15781649 NCBI chr 1:218,090,750...218,100,447
Ensembl chr 1:218,090,750...218,100,325
JBrowse link
G Ccnd2 cyclin D2 decreases expression ISO Bortezomib results in decreased expression of CCND2 mRNA CTD PMID:20977926 NCBI chr 4:159,674,885...159,697,207
Ensembl chr 4:159,674,885...159,697,207
JBrowse link
G Ccnf cyclin F multiple interactions ISO [BRCA1 mutant form results in increased susceptibility to Bortezomib] which results in decreased expression of CCNF mRNA CTD PMID:25522274 NCBI chr10:13,594,687...13,619,935
Ensembl chr10:13,594,687...13,619,935
JBrowse link
G Ccng2 cyclin G2 multiple interactions ISO [BRCA1 mutant form results in increased susceptibility to Bortezomib] which results in decreased expression of CCNG2 mRNA CTD PMID:25522274 NCBI chr14:16,267,572...16,276,068
Ensembl chr14:16,267,573...16,276,068
JBrowse link
G Ccpg1 cell cycle progression 1 increases expression ISO Bortezomib results in increased expression of CCPG1 mRNA CTD PMID:20471514, PMID:20977926 NCBI chr 8:79,660,634...79,692,044
Ensembl chr 8:79,660,657...79,692,039
JBrowse link
G Cd27 CD27 molecule increases expression ISO Bortezomib results in increased expression of CD27 mRNA CTD PMID:17895889 NCBI chr 4:157,744,881...157,751,609
Ensembl chr 4:157,744,882...157,750,088
JBrowse link
G Cd38 CD38 molecule decreases expression ISO Bortezomib results in decreased expression of CD38 mRNA CTD PMID:20977926 NCBI chr14:71,714,768...71,754,990
Ensembl chr14:71,715,269...71,754,672
JBrowse link
G Cd5 Cd5 molecule decreases expression ISO Bortezomib results in decreased expression of CD5 mRNA CTD PMID:20977926 NCBI chr 1:226,770,912...226,791,861
Ensembl chr 1:226,770,744...226,791,879
JBrowse link
G Cd69 Cd69 molecule increases expression ISO Bortezomib results in increased expression of CD69 mRNA CTD PMID:20977926 NCBI chr 4:163,041,147...163,049,065
Ensembl chr 4:163,041,141...163,049,084
JBrowse link
G Cd79a CD79a molecule decreases expression ISO Bortezomib results in decreased expression of CD79A mRNA CTD PMID:20977926 NCBI chr 1:81,763,609...81,768,039
Ensembl chr 1:81,763,614...81,767,980
JBrowse link
G Cd82 Cd82 molecule decreases expression ISO Bortezomib results in decreased expression of CD82 mRNA CTD PMID:20977926 NCBI chr 3:82,324,344...82,368,846
Ensembl chr 3:82,324,354...82,368,357
JBrowse link
G Cd9 CD9 molecule increases expression ISO Bortezomib results in increased expression of CD9 mRNA CTD PMID:20977926 NCBI chr 4:157,977,163...158,010,091
Ensembl chr 4:157,977,162...158,010,166
JBrowse link
G Cdc23 cell division cycle 23 increases expression ISO Bortezomib results in increased expression of CDC23 mRNA CTD PMID:20977926 NCBI chr18:27,430,924...27,452,569
Ensembl chr18:27,430,905...27,452,420
JBrowse link
G Cdc34 cell division cycle 34, ubiqiutin conjugating enzyme increases expression ISO Bortezomib results in increased expression of CDC34 mRNA CTD PMID:20977926 NCBI chr 7:12,899,957...12,905,339
Ensembl chr 7:12,899,958...12,905,339
JBrowse link
G Cdc37 cell division cycle 37, HSP90 cochaperone increases expression ISO Bortezomib results in increased expression of CDC37 mRNA CTD PMID:17895889 NCBI chr 8:22,160,922...22,173,797
Ensembl chr 8:22,154,067...22,173,804
JBrowse link
G Cdc42 cell division cycle 42 decreases expression ISO Bortezomib results in decreased expression of CDC42 mRNA CTD PMID:20977926 NCBI chr 5:155,690,267...155,728,385
Ensembl chr 5:155,691,390...155,728,300
JBrowse link
G Cdc42se2 CDC42 small effector 2 decreases expression ISO Bortezomib results in decreased expression of CDC42SE2 mRNA CTD PMID:20977926 NCBI chr10:40,054,393...40,122,915
Ensembl chr10:40,054,400...40,122,915
JBrowse link
G Cdk1 cyclin-dependent kinase 1 multiple interactions
increases phosphorylation
increases activity
decreases activity
ISO Bortezomib inhibits the reaction [docetaxel results in increased activity of CDK1 protein]
Bortezomib results in increased phosphorylation of CDK1 protein
Bortezomib results in increased activity of CDK1 protein
Bortezomib results in decreased activity of CDK1 protein
CTD PMID:14749476, PMID:16928825, PMID:19074855, PMID:20367638 NCBI chr20:20,576,341...20,591,510
Ensembl chr20:20,576,377...20,591,549
JBrowse link
G Cdk2 cyclin dependent kinase 2 multiple interactions
decreases activity
ISO Bortezomib inhibits the reaction [docetaxel results in increased activity of CDK2 protein]
Bortezomib results in decreased activity of CDK2 protein
CTD PMID:14749476 NCBI chr 7:3,124,953...3,132,533
Ensembl chr 7:3,124,954...3,132,457
JBrowse link
G Cdkn1a cyclin-dependent kinase inhibitor 1A increases stability
multiple interactions
decreases response to substance
increases expression
ISO Bortezomib results in increased stability of CDKN1A protein
[Bortezomib co-treated with Butyrates] results in increased cleavage of CDKN1A protein; [Bortezomib co-treated with Butyrates] results in increased expression of and results in increased cleavage of CDKN1A protein; [Bortezomib co-treated with vorinostat] results in increased cleavage of CDKN1A protein; [Bortezomib co-treated with vorinostat] results in increased expression of and results in increased cleavage of CDKN1A protein; [TNFSF10 protein co-treated with Bortezomib] results in increased expression of CDKN1A protein; [trichostatin A co-treated with Bortezomib] results in increased expression of CDKN1A mRNA; [trichostatin A co-treated with Bortezomib] results in increased expression of CDKN1A protein; [vorinostat co-treated with Bortezomib] results in increased expression of CDKN1A protein; Bortezomib promotes the reaction [abexinostat results in increased expression of CDKN1A protein]; CDKN1A protein affects the reaction [[TNFSF10 protein co-treated with Bortezomib] results in increased cleavage of CASP8 protein]; CDKN1A results in decreased susceptibility to [Bortezomib co-treated with docetaxel]
CDKN1A results in decreased susceptibility to Bortezomib
Bortezomib results in increased expression of CDKN1A mRNA; Bortezomib results in increased expression of CDKN1A protein
CTD PMID:12893773, PMID:12902978, PMID:14749476, PMID:15173093, PMID:15543232, PMID:15930312, PMID:16928825, PMID:17327374, PMID:17898295, PMID:18223318, PMID:18445700, PMID:18790767, PMID:19220424, PMID:19417023, PMID:20383943, PMID:20977926, PMID:21345073 NCBI chr20:6,348,422...6,358,864
Ensembl chr20:6,351,458...6,358,864
JBrowse link
G Cdkn1b cyclin-dependent kinase inhibitor 1B multiple interactions
increases stability
increases expression
ISO [Bortezomib co-treated with Butyrates] results in increased cleavage of CDKN1B protein; [Bortezomib co-treated with Vorinostat] results in increased cleavage of CDKN1B protein; [Vorinostat co-treated with Bortezomib] results in increased expression of CDKN1B protein; Bortezomib promotes the reaction [Lapatinib results in increased expression of CDKN1B protein]; Cisplatin promotes the reaction [Bortezomib results in increased expression of CDKN1B protein]; Lapatinib promotes the reaction [Bortezomib results in increased expression of CDKN1B protein]
Bortezomib results in increased stability of CDKN1B protein
CTD PMID:14749476, PMID:15173093, PMID:15543232, PMID:18223318, PMID:18445700, PMID:18850583, PMID:19220424, PMID:19636294, PMID:20701607 NCBI chr 4:168,689,043...168,694,159
Ensembl chr 4:168,689,163...168,693,964
JBrowse link
G Cdt1 chromatin licensing and DNA replication factor 1 decreases expression ISO Bortezomib results in decreased expression of CDT1 mRNA CTD PMID:17659339 NCBI chr19:55,381,565...55,386,511
Ensembl chr19:55,381,565...55,386,511
JBrowse link
G Cebpa CCAAT/enhancer binding protein alpha multiple interactions ISO Bortezomib inhibits the reaction [NSC606985 results in decreased expression of CEBPA protein] CTD PMID:19662097 NCBI chr 1:91,363,492...91,366,164
Ensembl chr 1:91,363,492...91,366,164
JBrowse link
G Cebpb CCAAT/enhancer binding protein beta multiple interactions
increases expression
decreases expression
ISO
EXP
1,3-dihydroxy-4,4,5,5-tetramethyl-2-(4-carboxyphenyl)tetrahydroimidazole inhibits the reaction [[Bortezomib co-treated with Chloroquine] results in increased expression of CEBPB protein alternative form]; 1-(4-(4-propionylpiperazin-1-yl)-3-(trifluoromethyl)phenyl)-9-(quinolin-3-yl)benzo(h)(1,6)naphthyridin-2(1H)-one inhibits the reaction [[Bortezomib co-treated with Chloroquine] results in increased expression of CEBPB protein alternative form]; [CEBPB protein alternative form results in increased susceptibility to Doxorubicin] promotes the reaction [[Bortezomib co-treated with Chloroquine] results in increased expression of and affects the localization of CALR protein]; [CEBPB protein alternative form results in increased susceptibility to Doxorubicin] promotes the reaction [[Bortezomib co-treated with Chloroquine] results in increased expression of CALR mRNA]; [CEBPB protein alternative form results in increased susceptibility to Doxorubicin] promotes the reaction [Bortezomib results in increased expression of and affects the localization of CALR protein]; [CEBPB protein alternative form results in increased susceptibility to Doxorubicin] promotes the reaction [Bortezomib results in increased expression of CALR mRNA]; [Chloroquine co-treated with Bortezomib] promotes the reaction [CEBPB protein alternative form binds to CALR promoter]; [Chloroquine co-treated with Bortezomib] results in increased expression of CEBPB protein alternative form; betulinic acid inhibits the reaction [[Chloroquine co-treated with Bortezomib] results in increased expression of CEBPB protein alternative form]; betulinic acid inhibits the reaction [Bortezomib results in increased expression of CEBPB protein alternative form]; Bortezomib inhibits the reaction [Arsenic Trioxide results in decreased expression of CEBPB mRNA]; Bortezomib promotes the reaction [CEBPB protein alternative form binds to CALR promoter]; CEBPB protein alternative form promotes the reaction [[Chloroquine co-treated with Bortezomib] results in increased expression of and affects the localization of CALR protein]; CEBPB protein alternative form promotes the reaction [[Chloroquine co-treated with Bortezomib] results in increased expression of CALR mRNA]; CEBPB protein alternative form promotes the reaction [Bortezomib results in increased expression of and affects the localization of CALR protein]; CEBPB protein alternative form promotes the reaction [Bortezomib results in increased expression of CALR mRNA]; Doxorubicin promotes the reaction [[Chloroquine co-treated with Bortezomib] results in increased expression of CEBPB protein alternative form]; Doxorubicin promotes the reaction [Bortezomib results in increased expression of CEBPB protein alternative form]
1,3-dihydroxy-4,4,5,5-tetramethyl-2-(4-carboxyphenyl)tetrahydroimidazole inhibits the reaction [[Chloroquine co-treated with Bortezomib] results in increased expression of CEBPB protein alternative form]; 1-(4-(4-propionylpiperazin-1-yl)-3-(trifluoromethyl)phenyl)-9-(quinolin-3-yl)benzo(h)(1,6)naphthyridin-2(1H)-one inhibits the reaction [[Bortezomib co-treated with Chloroquine] results in increased expression of CEBPB protein alternative form]; [Chloroquine co-treated with Bortezomib] results in increased expression of CEBPB protein alternative form; betulinic acid inhibits the reaction [[Chloroquine co-treated with Bortezomib] results in increased expression of CEBPB protein alternative form]; betulinic acid inhibits the reaction [Bortezomib results in increased expression of CEBPB protein alternative form]; CEBPB protein alternative form promotes the reaction [[Chloroquine co-treated with Bortezomib] results in decreased expression of ABCB1A protein]; CEBPB protein alternative form promotes the reaction [[Chloroquine co-treated with Bortezomib] results in increased cleavage of CASP3 protein]; CEBPB protein alternative form promotes the reaction [[Chloroquine co-treated with Bortezomib] results in increased expression of CALR protein]; CEBPB protein alternative form promotes the reaction [[Chloroquine co-treated with Bortezomib] results in increased expression of DDIT3 protein]; CEBPB protein alternative form promotes the reaction [[Chloroquine co-treated with Bortezomib] results in increased expression of IFNG protein]; CEBPB protein alternative form promotes the reaction [[Chloroquine co-treated with Bortezomib] results in increased expression of MKI67 protein]; Doxorubicin promotes the reaction [[Chloroquine co-treated with Bortezomib] results in increased expression of CEBPB protein alternative form]; Doxorubicin promotes the reaction [Bortezomib results in increased expression of CEBPB protein alternative form]; Doxorubicin promotes the reaction [CEBPB protein alternative form promotes the reaction [[Chloroquine co-treated with Bortezomib] results in decreased expression of ABCB1A protein]]; Doxorubicin promotes the reaction [CEBPB protein alternative form promotes the reaction [[Chloroquine co-treated with Bortezomib] results in increased cleavage of CASP3 protein]]; Doxorubicin promotes the reaction [CEBPB protein alternative form promotes the reaction [[Chloroquine co-treated with Bortezomib] results in increased expression of CALR protein]]; Doxorubicin promotes the reaction [CEBPB protein alternative form promotes the reaction [[Chloroquine co-treated with Bortezomib] results in increased expression of DDIT3 protein]]; Doxorubicin promotes the reaction [CEBPB protein alternative form promotes the reaction [[Chloroquine co-treated with Bortezomib] results in increased expression of IFNG protein]]; Doxorubicin promotes the reaction [CEBPB protein alternative form promotes the reaction [[Chloroquine co-treated with Bortezomib] results in increased expression of MKI67 protein]]
Bortezomib results in decreased expression of CEBPB mRNA
CTD PMID:20471514, PMID:20830808, PMID:30482226 NCBI chr 3:164,424,502...164,425,933
Ensembl chr 3:164,424,515...164,425,910
JBrowse link
G Cenpc centromere protein C increases expression ISO Bortezomib results in increased expression of CENPC mRNA CTD PMID:20977926 NCBI chr14:23,611,909...23,670,314
Ensembl chr14:23,611,735...23,670,475
JBrowse link
G Cep290 centrosomal protein 290 increases expression ISO Bortezomib results in increased expression of CEP290 mRNA CTD PMID:20977926 NCBI chr 7:40,217,269...40,306,327
Ensembl chr 7:40,217,269...40,306,327
JBrowse link
G Cflar CASP8 and FADD-like apoptosis regulator affects expression
multiple interactions
decreases response to substance
decreases expression
increases expression
ISO Bortezomib affects the expression of CFLAR protein
[Bortezomib co-treated with TNFSF10 protein] results in decreased expression of CFLAR protein; [romidepsin co-treated with Bortezomib] results in decreased expression of CFLAR protein; TNFSF10 protein promotes the reaction [Bortezomib results in decreased expression of CFLAR protein]
CFLAR protein alternative form results in decreased susceptibility to Bortezomib; CFLAR results in decreased susceptibility to Bortezomib
Bortezomib results in decreased expression of CFLAR mRNA; Bortezomib results in decreased expression of CFLAR protein
Bortezomib results in increased expression of CFLAR protein; Bortezomib results in increased expression of CFLAR protein alternative form; Bortezomib results in increased expression of CFLAR protein modified form
CTD PMID:17326159, PMID:17327374, PMID:17351739, PMID:17510429, PMID:17659339, PMID:18223231, PMID:19100720, PMID:19922463, PMID:20515944, PMID:20876774 NCBI chr 9:65,534,608...65,586,395
Ensembl chr 9:65,534,704...65,587,251
JBrowse link
G Cgref1 cell growth regulator with EF hand domain 1 increases expression ISO Bortezomib results in increased expression of CGREF1 mRNA CTD PMID:17895889 NCBI chr 6:26,797,126...26,809,132
Ensembl chr 6:26,797,126...26,809,129
JBrowse link
G Chac1 ChaC glutathione-specific gamma-glutamylcyclotransferase 1 increases expression ISO Bortezomib results in increased expression of CHAC1 mRNA CTD PMID:15509775 NCBI chr 3:111,160,205...111,163,425
Ensembl chr 3:111,160,205...111,163,425
JBrowse link
G Chaf1a chromatin assembly factor 1 subunit A decreases expression ISO Bortezomib results in decreased expression of CHAF1A mRNA CTD PMID:17659339 NCBI chr 9:11,000,869...11,027,631
Ensembl chr 9:11,001,129...11,027,506
JBrowse link
G Chd2 chromodomain helicase DNA binding protein 2 increases expression ISO Bortezomib results in increased expression of CHD2 mRNA CTD PMID:20977926 NCBI chr 1:134,757,934...134,873,053
Ensembl chr 1:134,757,934...134,871,167
JBrowse link
G Chfr checkpoint with forkhead and ring finger domains decreases expression ISO Bortezomib results in decreased expression of CHFR mRNA CTD PMID:20977926 NCBI chr12:52,562,594...52,596,162
Ensembl chr12:52,562,597...52,596,076
JBrowse link
G Chst11 carbohydrate sulfotransferase 11 decreases expression ISO Bortezomib results in decreased expression of CHST11 mRNA CTD PMID:20977926 NCBI chr 7:26,641,856...26,890,503
Ensembl chr 7:26,645,422...26,859,716
JBrowse link
G Chst2 carbohydrate sulfotransferase 2 decreases expression ISO Bortezomib results in decreased expression of CHST2 mRNA CTD PMID:20977926 NCBI chr 8:103,186,759...103,190,612
Ensembl chr 8:103,188,651...103,190,243
JBrowse link
G Chuk component of inhibitor of nuclear factor kappa B kinase complex increases expression
increases activity
ISO Bortezomib results in increased expression of CHUK mRNA
Bortezomib results in increased activity of CHUK protein
CTD PMID:20471514, PMID:24085292 NCBI chr 1:263,848,829...263,884,354
Ensembl chr 1:263,848,884...263,885,169
JBrowse link
G Cideb cell death-inducing DFFA-like effector b decreases expression ISO Bortezomib results in decreased expression of CIDEB mRNA CTD PMID:17659339 NCBI chr15:34,439,844...34,444,244
Ensembl chr15:34,439,876...34,444,244
JBrowse link
G Cilk1 ciliogenesis associated kinase 1 increases expression ISO Bortezomib results in increased expression of CILK1 mRNA CTD PMID:20977926 NCBI chr 8:85,413,998...85,473,374
Ensembl chr 8:85,413,537...85,472,694
JBrowse link
G Clec7a C-type lectin domain containing 7A increases expression ISO Bortezomib results in increased expression of CLEC7A mRNA CTD PMID:20977926 NCBI chr 4:163,216,152...163,227,367
Ensembl chr 4:163,216,163...163,227,334
JBrowse link
G Clip4 CAP-GLY domain containing linker protein family, member 4 increases expression ISO Bortezomib results in increased expression of CLIP4 mRNA CTD PMID:20977926 NCBI chr 6:23,222,020...23,316,962
Ensembl chr 6:23,222,021...23,316,962
JBrowse link
G Cln6 CLN6, transmembrane ER protein decreases expression ISO Bortezomib results in decreased expression of CLN6 mRNA CTD PMID:20977926 NCBI chr 8:67,733,215...67,748,170
Ensembl chr 8:67,733,215...67,748,172
JBrowse link
G Clptm1 CLPTM1 regulator of GABA type A receptor forward trafficking decreases expression ISO Bortezomib results in decreased expression of CLPTM1 mRNA CTD PMID:20977926 NCBI chr 1:80,549,051...80,580,665
Ensembl chr 1:80,549,043...80,580,662
JBrowse link
G Clu clusterin increases expression ISO Bortezomib results in increased expression of CLU mRNA CTD PMID:20977926 NCBI chr15:42,626,612...42,665,858
Ensembl chr15:42,640,146...42,665,857
JBrowse link
G Cox8a cytochrome c oxidase subunit 8A decreases expression ISO Bortezomib results in decreased expression of COX8A mRNA CTD